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ABSTRACT 
Canada has the highest rate of Inflammatory Bowel Disease (IBD) in the world with 
approximately 0.67%. One of the primary nutritional health issues faced by Crohn’s disease 
(CD) patients is vitamin D deficiency, which can subsequently lead to more serious health 
complications. Vitamin D is shown to act as a modulator for the autoimmune system among 
CD patients.  
Phase I study aimed to determine vitamin D concentrations and disease activity 
among CD cases in Canada and Saudi Arabia, and evaluate the impact of higher doses of 
vitamin D compared to EAR on disease activity among CD patients. This pilot study was a 
double blind, randomized, control trial involving approximately 60 recent, active CD patients 
engaged in induction therapy. The sample size includes patients in Saskatoon, Saskatchewan, 
Canada (n=30) and Riyadh, Saudi Arabia (n=30). The patients have been divided into three 
groups to receive different oral doses of vitamin D including: 1: 400 IU/day (Control group, 
EAR level) 2: 2,000 IU/day 3: 10,000 IU/day. Data were collected at baseline (0), end of 9 
weeks (end of intervention), and at 2 months follow-up. Along with anthropometric 
measurements participants undergo laboratory examinations such as, WBC, HGB, Hct, 
platelets, ferritin, vitamin D, hsCRP and calprotection, undertake the Health related quality of 
life (HRQOL), and fill out socio-demographic and physical activity questionnaires. We also 
assessed their dietary intake at the baseline and Week 9 using two sets of three 24-hour 
dietary recalls. Due to a small sample size (n=9 cases) we have recruited, we presented Phase 
I as a case series. 
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Phase II study determined the association between vitamin D concentrations and 
disease activity among CD cohort in Saskatoon, Canada. In a retrospective cohort design, we 
studied 201 CD patients; 116 participants had vitamin D data. We extracted data from 
medical records over three years at IBD clinic, Royal University Hospital, Saskatoon, 
Canada. I evaluated the association between vitamin D status (serum 25OHD) and indicator 
of disease activity (hsCRP) as well as Harvey-Bradshaw index (HBI) in CD patients. The 
analyses conducted in the presence of other potential factors in three-time points (baseline, 
midpoint, last visit) using generalized estimating equation (GEE).  
Vitamin D concentrations was improved significantly from baseline to the last visit 
(p=0.005). At the baseline, mean 25OHD was 58.2±30.0 nmol/L; 26% of patients had 
optimal, 30% had adequate, 26% had insufficient, and 18% patients had deficient vitamin D 
levels. At the midpoint, mean serum vitamin D concentrations was 60.1±31.2 nmol/L; 31.3% 
had optimal level, 31,3% patients had insufficient level, 22.1% patients had adequate level, 
and 15.2% patients were vitamin D deficient. At final visit, mean vitamin D was 74.5±42.6 
nmol/L; 43.9% patients had optimal and 24.2% patients had adequate levels of vitamin D, 
while 18.1% patients were vitamin D insufficient and 13.6% patients had vitamin D 
deficiency. Vitamin D concentrations showed significant inverse association with hsCRP 
level over 15 months. Compared to vitamin D deficient category, patients in other categories 
(including insufficient, adequate and optimal levels of vitamin) had significantly lower 
hsCRP level over time (p <0.05). 
Vitamin D deficiency was associated with higher disease activity in Crohn’s disease 
patients. Higher vitamin D (25OHD) concentrations was associated with lower D disease 
activity levels in Crohn’s patients over 15 months.  
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CHAPTER 1 
1. INTRODUCTION 
1.1 Rationale 
The prevalence of autoimmune diseases is rapidly increasing around the globe 
(Economou & Pappas, 2008). Inflammatory bowel diseases (IBDs), including ulcerative colitis 
(UC) and Crohn’s disease (CD), are among the fastest growing autoimmune diseases in 
developing and developed countries (Economou & Pappas, 2008). Canada has one of the highest 
rates of IBD in the world (0.67% of Canadian population), and Saudi Arabia, a developing 
country, is facing an increasing number of incidents every year (Benchimol et al., 2009; Fadda et 
al., 2012). The role of nutrition in preventing disease activity in IBD, as well as the impact of 
IBD on the nutritional health of patients, has been documented in recent literature (Cantorna, 
2006; Graham & Kandil, 2002; Kamen & Tangpricha, 2010). In addition to its many health 
benefits, vitamin D has an impact on the modulation of the autoimmune system by development 
and function T cells (Cantorna, 2006). However, vitamin D insufficiency is a pandemic in 
seemingly healthy people, particularly those diagnosed with IBD (Holick & Chen, 2008; 
Langlois, Greene-Finestone, Little, Hidiroglou, & Whiting, 2010). One of the primary nutritional 
health issues faced by patients with CD is vitamin D deficiency (25(OH)D <20 ng/ml), which can 
lead to more serious health complications such as increasing disease activity (Joseph, George, 
Pulimood, Seshadri, & Chacko, 2009; Narula & Marshall, 2012). Studies suggest that vitamin D 
supplements are beneficial in treating CD because higher levels of vitamin D supplementation 
can significantly decrease disease activity (Ananthakrishnan et al., 2012). Jorgensen et al. (2010) 
stated that a daily vitamin D3 supplement of 1200 IU/d will significantly increase serum vitamin 
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D and therefore will decrease the risk of disease activity in cases of CD. However, the optimal 
dose by which disease activity can be controlled is not well known. 
The purpose of this study is to evaluate the impact of vitamin D supplementation on the 
disease activity among CD cases in Canada and Saudi Arabia. Many gaps exist in the literature 
on this topic. The majority of studies have focused on providing normal (600 IU) or high doses of 
vitamin D supplements (up to 5000 IU) to patients with CD. To our knowledge, only one 
unpublished study has been conducted in the United States to determine the effect of high doses 
(1,000 and 10,000 IU/ d) of vitamin D on CD. Only a few published studies measured vitamin D 
levels in patients with CD in Canada (Leslie, Miller, Rogala, & Bernstein, 2008a). However, thus 
far there has been no clinical trial in Saudi Arabia that explores the relationship between CD and 
a high dose of vitamin D supplements.  
In a pilot clinical trial (Phase I), we planned to evaluate the impact of different doses of 
vitamin D (400, 2000, 10,000 IU) on disease activity. We collected data on nutritional status and 
assess other factors that may have an impact on disease activity, including physical activity and 
socio-economic status. Similar research was completed by Dustin Boothe at Weill-Cornell 
Medical College in the United States, and he presented it at the American College of 
Gastroenterology (ACG) Annual Scientific Meeting 2011. However, there remains a need for 
research in this area to evaluate the effect of high doses of vitamin D supplementation in 
populations with different ethnic backgrounds and in other geographic areas with diverse 
environmental factors. 
 In a retrospective cohort (Phase II) study, we aimed to determine the association between 
vitamin D status and disease activity among CD cohort in Saskatoon, Canada. We evaluated the 
association between vitamin D status (serum 25OHD) and indicator of disease activity (hsCRP) 
as well as Harvey-Bradshaw index (HBI) in CD patients. Different study designs were conducted 
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to examine the association between vitamin D status, disease activity and other predictors. 
However, we conducted this study to address the research question.   
1.2 Study Objective 
1.2.1 Study phase I (Clinical trial) objective: to determine the effect of vitamin D 
supplementation on disease activity in patients with Crohn’s disease in Canada and Saudi Arabia.  
Specific objective and hypothesis 1.  
Objective 1. To determine vitamin D levels and disease activity in cases of Crohn’s 
disease in Canada and Saudi Arabia. 
Hypothesis 1: Patients who are suffering from Crohn’s disease are at risk of vitamin D 
deficiency / insufficiency.  
Specific objective and hypothesis 2. 
Objective 2. To evaluate the impact of vitamin D in doses higher than the Recommended 
Dietary Allowance (RDA) (>600 IU) on disease activity in patients with Crohn’s disease  
 Hypothesis 2: Providing vitamin D in doses higher than the RDA reduces disease activity 
in cases of Crohn’s disease. 
1.2.2 Study Phase II (Retrospective cohort) objective: To determine the association 
between vitamin D concentrations and disease activity in a cohort of patients with CD over three 
years. 
1.3 Significance  
The majority of studies regarding Crohn’s disease and vitamin D are focused on normal 
doses of vitamin D supplementation. To our knowledge, there is only one unpublished study that 
investigates the effect of a high dose of vitamin D (10,000 IU) on CD (Boothe, Lakehomer, 
Jacob, Scherl, & Bosworth, 2011). Another study focused on the effect of 5000 IU/d of vitamin 
D3 supplementation on disease activity in CD (Yang et al., 2013a). It is therefore imperative to 
 4 
investigate how high doses of vitamin D supplementation affect disease activity in patients with 
Crohn’s disease. In addition, the association of vitamin D concentration and disease activity in 
CD patients who were taking vitamin D supplements in natural setting. The results from this 
study will be beneficial to patients and researchers by contributing to their understanding of the 
role of vitamin D supplementation in disease activity in patients with CD. 
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CHAPTER 2 
2. LITERATURE REVIEW 
2.1 Crohn’s Disease 
2.1.1 Introduction to IBDs 
Dr. Burrill Bernard Crohn and his two colleagues, Dr. Gordon Oppenheimer and Dr. Leon 
Ginzburg, discovered Crohn’s disease in 1932 (Crohn, Ginzburg, & Oppenheimer, 1952). 
Inflammatory bowel diseases (IBDs) are diseases that refer to two distinct disorders: Crohn’s 
disease (CD) and ulcerative colitis (UC). These diseases are characterized by chronic 
inflammation and idiopathic relapsing disorders (Frank et al., 2007).  Although the symptoms can 
be quite similar, the areas affected in the digestive tract are different (Nabalamba, Bernstein, & 
Seko, 2004). Ulcerative colitis affects the rectum and colon (lining of the large intestine), 
whereas Crohn’s disease affects the digestive tract from the mouth, which is the beginning of the 
digestive tract,  to the terminal ileum (all the layers of the small intestine) or the colon, or both. 
Ulcerative colitis and Crohn’s disease can cause ulceration, which is often present in serious 
cases of these diseases. Additionally, inflammation (redness and swelling) occurs in the intestine; 
whereas CD occurs in patches of healthy tissue that can then expand into the intestinal wall 
(CCFC, 2008, 2012; Cohen, 1995; Head, Jurenka, & Ascp, 2004; Nabalamba et al., 2004). These 
diseases occur in people of any age; CD usually begins in youths and young adults between the 
ages of 15 and 35. Instances of UC increase at ages 15–30 and then at ages 50–70, with 25% of 
cases starting in childhood before the age of 18 (CCFC, 2012; Nabalamba et al., 2004; Sands and 
Siegel  2010). 
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2.1.2 Epidemiology of IBDs in Canada and Saudi Arabia  
A number of epidemiological studies discuss the prevalence and incidence of IBDs in the 
world. Worldwide, there are fewer than one to 15 new incidences of CD per 100,000 persons 
yearly; whereas the incidence of ulcerative colitis (UC) ranges from two to more than 20 per 
100,000 persons yearly (Herrinton et al., 2007; Loftus et al., 2007). The disease prevalence has 
increased dramatically in the developed countries of Northern Europe and North America (Loftus 
et al., 2007). The highest incidence rates of IBD are in Canada (UC: 248 per 100,000 persons; 
CD: 319 per 100,000 persons) and Europe (322 per 100,000 persons for CD in Italy; 505 per 
100,000 persons for UC in Norway; Bengtson et al., 2009; Bernstein et al., 2006; Cottone et al., 
2006).  
According to a 2008 report from the Crohn’s and Colitis Foundation of Canada, Canada 
has the highest rate of IBD in the world. The greatest estimate of the prevalence of IBDs in 2012 
was approximately 0.67% of the Canadian population; in other words, there were 233,000 
patients with IBD (129,000 with CD and 104,000 with UC) in Canada (CCFC, 2008, 2012). In 
1998–2000, there were 16.3 new incidences of CD and 12.9 of UC per 100,000 patients in 
Canada. New cases of IBDs are likely to reach 10,200 every year, with 5,700 cases having CD 
and 4,500 with UC. There are more diagnosed cases of CD than UC in Canada. Across Canada, 
Ontario has the highest provincial estimate rate of IBD, with approximately 55,000 per 100,000 
Canadians living with CD and 40,200 Canadians with UC. The province with the second highest 
estimate rate in Canada is Quebec, with a rate of 20,900 of CD and 20,500 per 100,000 with UC 
in 2012. The prevalence in Saskatchewan is approximately 5,000 per 100,000 living with CD and 
4,000 with UC (CCFC, 2012). In the United States, only two epidemiological studies have been 
conducted: one in California and one in Minnesota. The incidence of CD was between six and 
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eight per 100,000 cases, with a prevalence of UC between nine and 12 per 100,000 cases 
(Herrinton et al., 2007; C. Loftus et al., 2007). 
The prevalence of IBDs in Saudi Arabia has increased over the years. Fadda et al. (2012) 
conducted a retrospective study in Riyadh, the capital city of Saudi Arabia, from 1970 to 2008 in 
which researchers collected data from 312 patients with IBDs. The researchers found a 
significant increase in the number of incidences of CD and UC in the last 10 years when 
comparing 1970 to 1990. The study found 63% of participants with CD and 37% with UC; 48.7% 
were men and 51.3% were women. The majority of cases (56%) occurred in the central region 
(167 out of 312 patients). The researchers concluded that there was a gradual increase in the 
incidence of IBDs in Saudi Arabia throughout the years of the study. Another study demonstrated 
an increase in the number of CD cases (77 CD cases) at King Khalid University Hospital in 
Riyadh, Saudi Arabia, from 1994 to 2004 (Al-ghamdi et al., 2004). Aljebreen et al. (2014) 
recently studied the clinical epidemiology and phenotypic characteristics of CD in Riyadh, Saudi 
Arabia, among 497 CD patients from 2009 to 2013. The study showed that the majority of the 
patients are men (58.6%)—young adults between 15 to 30 years of age. According to the 
Montréal classification, most CD patients (48.8%) had ileocolonic involvement, 43.5% had 
involvement in terminal ileum, and 7.7% had colon involvement (Aljebreen et al., 2014). Some 
possible reasons for this increase include diet, environmental factors, and modernization (Fadda 
et al., 2012; Goh & Xiao, 2009). 
2.1.3 Clinical Presentation of CD 
Signs and symptoms of CD depend on the location of the disease. It is difficult to 
diagnose CD in the beginning, and it usually takes 3 years to confirm that the disease is present. 
In general, gastrointestinal symptoms include persistent diarrhea (loose, watery), abdominal 
cramps and pain (in the right lower quadrant), rectal bleeding, constipation, incomplete 
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evacuation, and stomatitis are more common in CD. Some patients may also experience perianal 
fistula, which can cause pain and bleeding. Other common symptoms found in CD patients 
include fever (in more than 50% of patients), fatigue, loss of appetite, and arthritis. Many patients 
have nutritional deficiency and malabsorption of nutrients, leading to more than 80% of CD 
patients experiencing weight loss (CCFC, 2008; DiPiro et al., 2005; Herfindal & Gourley, 2003). 
In addition, intestinal obstruction is a common complication that increases the risk of small 
intestine and colon cancer in CD patients (CCFC, 2008). The symptoms correlate well with the 
severity of the disease activity (CCFA, 2014d; Sands, 2010). Table 2.1 presents Clinical Features 
of Crohn’s Disease. Table 2.2 Types of Crohn’s Disease with Associated Symptoms. 
Table 2.1 Clinical Features of Crohn’s Disease 
Clinical features Signs and Symptoms 
Common symptoms 
Abdominal pain, diarrhea, fever, fatigue, anorexia, 
weight loss, rectal bleeding, nausea 
Common clinical signs 
Palpable mass in the right lower quarter, abdominal 
tenderness, guaiac positive stool 
Common laboratory and 
radiographic finding 
Mild leukocytosis and anemia, elevated ESR or CRP, 
strictures, fistulas, small involvement 
Extra-intestinal 
magnification 
a) 25 % Joint manifestations (arthralgia- arthritis) 
b) 15 % Mucocutaneous manifestations (erythema 
nodosum- aphthous ulcers of mouth-pyoderma 
gangrenosum). 
c) 5 % Ocular manifestations (recurrent iritis- 
episcleritis- uveitis). 
Note. Adapted from Inflammatory Bowel Disease translating basic science into clinical practice: 
Crohn's disease clinical course and complication, (p. 228-244), by Sands Bruce, 2010, West 
Sussex, UK : Wiley-Blackwell.  
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Table 2.2 Types of Crohn’s Disease with Associated Symptoms 
Type of 
CD 
Ileocolitis Ileitis 
Gastroduodenal 
CD 
Jejunoileitis Crohn’s colitis  
Area 
affected 
Ileum 
Colon 
Ileum 
Stomach 
The duodenum 
(beginning of the 
small intestine) 
Jejunum  Colon 
Symptoms 
Diarrhea, 
Cramping in the 
right middle or 
lower part of the 
abdomen, weight 
loss 
 
In sever ileitis 
cases: fistulas or 
abscess in the 
lower right of 
abdomen. 
Loss of appetite 
Weight loss 
Nausea 
Vomiting 
 
Pain and 
cramps after 
meals 
Diarrhea 
Fistulas  
(in severe 
cases) 
Diarrhea 
Abscess 
Fistulas 
ulcers around the 
anus 
Rectal bleeding 
Skin lesions 
Joint pains 
Note. Adapted from “Types of Crohn’s Disease with Associated Symptoms,” by Crohn's and 
Colitis foundation of America, accessed in 2014. 
 
2.1.4 Etiology and Pathogenesis 
 The exact cause of Crohn’s disease is unknown, but scientists have demonstrated that it 
may be caused by genetic, immunologic, infectious, or environmental factors (Pavli, Cavanaugh, 
& Grimm, 1996). To date, no evidence has been suggested to demonstrate the contributing 
factors with the risk of developing CD (UNC, 2014). CD has several gene components in its 
etiology. The most important genes that significantly increase an individual’s risk of developing 
CD are susceptibility mutations gene NOD2/ CARD15, which is located on chromosome 16 
(Hampe et al., 2001; Ogura et al., 2001). The exact mechanism of this gene is unclear, but gene 
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changes (mutations) disrupt the mucosa of the intestine so that the immune system is then 
influenced by the bacterial milieu in the digestive tract (Hisamatsu et al., 2003; Ogura et al., 
2001; Rosenstiel et al., 2003). The changes appear in approximately 20% of CD cases; however, 
4% of the people did not develop CD. In such cases, this gene requires action of unidentified 
factors such as viruses, bacteria, food additives, nutritional behavior, a weakened immune 
system, or an intestinal barrier to develop the disease (UNC, 2014). Incidence does increase in 
the relatives of persons who suffer from IBDs; around 5% to 20% of the people who have CD 
have at least one family member suffering from the disease. The risk of developing CD increases 
30 times when a parents and a siblings have the disease, and 50% of identical twins (Halfvarson, 
Bodin, Tysk, Lindberg, & Järnerot, 2003; Loftus et al., 2007; Loftus, 2004; Orholm, Binder, 
Sørensen, Rasmussen, & Kyvik, 2000; Russell & Satsangi, 2008). In addition, Ashkenazi Jewish 
populations and those of Caucasian origin are more likely to have IBD because of genetic factors 
(Herrinton et al., 2007).  
The prevailing view on inflammation and immune response is that these diseases reflect a 
primary T cell immune disorder. Another theory has suggested that CD is affected by the 
distribution of innate immunity (Marks & Segal, 2008). Imbalanced cytokine secretion also 
works to impair innate immunity, and the response of a sustained microbial resulting in 
inflammation in the colon can be due to its high bacterial load (Dessein, Chamaillard, & Danese, 
2008; Marks et al., 2006). Other causes that may contribute to CD are microorganisms such as 
Mycobacterium avium subspecies paratuberculosis (Eckburg & Relman, 2007). Current research 
has suggested that microorganisms might contribute to reduce the mucus layer and thus its 
inability to eliminate bacteria in the intestinal walls (Sartor, 2006).  
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Environmental factors may also contribute to Crohn’s disease, such as from a substance 
that an individual has eaten or microbes that are affected by the virus or the bacteria. Children 
who have been less exposed to infections in modern environments have high hygiene levels that 
contribute to the risk of CD (Koloski, Bret, & Radford-Smith, 2008). The disease is more likely 
to develop in Western industrialized nations than in other regions of the world (UNC, 2014). 
Smokers are more likely to develop the disease than people who do not smoke. In contrast, the 
risk of developing UC is lower in smokers than people who do not smoke. Researchers do not 
know how smoking affect CD, however there is a theory, smoking may cause change in the 
immune system lead to inflammation (Bernstein et al., 2006; Calkins, 1989; CCUK, 2014). Some 
studies have demonstrated that there is a correlation between a child’s exposure to secondhand 
smoke and an increased risk of CD ( Lashner, Shaheen, Hanauer, & Kirschner, 1993; Mahid, 
Minor, Stromberg, & Galandiuk, 2007; Persson, Ahlbom, & Hellers, 1990). Furthermore, the 
etiology of nutrition-related disease may contribute positively to developing CD. Positive 
associations have been reported between the increase of animal protein, omega-6, and milk 
protein intakes and an increased risk of developing CD (Hou, Abraham, & El-Serag, 2011; 
Shoda, Matsueda, Yamato, & Umeda, 1996). 
2.1.5 Diagnostic Evaluation in CD 
Diagnosis of Crohn’s disease is often challenging, It is primarily based on medical history 
and physical examination and supported by a combination of laboratory, radiographic, and 
endoscopic tests (Baumgart & Sandborn, 2012; Joseph et al., 2009; Pimentel et al., 2000). 
Diagnostic tests for CD provide accurate evidence to confirm the disease is present and to rule 
out other gastrointestinal conditions.  
Laboratory examinations, diagnostic imaging and endoscopic examination are critical for 
exploring the involvement extension and lesion type via colonoscopy, barium enema, and a 
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small-bowel series (Lashner, 2013). Crohn’s disease cannot be diagnosed through blood tests. To 
monitor the disease activity, routine laboratory investigations should include a complete blood 
count (CBC), blood chemistry (e.g., electrolytes, albumin, and liver enzymes), inflammatory 
markers (erythrocyte sedimentation rate [ESR]), C-reactive protein (CRP), and IgG/IgA antibody 
levels (Jørgensen et al., 2010; Miheller et al., 2009; Shafran et al., 2002). Liver function tests are 
used to determine liver problems. In addition, electrolytes panel are used to determine potassium 
levels; lower than normal levels (hypokalemia) occur when diarrhea is present. A stool test (e.g., 
calprotectin) is a useful tool for predicting a relapse (CCFA, 2014a). C-reactive protein and 
calprotectin are considered the best biomarkers and correlate well with endoscopic, radiologic, 
and clinical measurements (Loftus et al., 2007). 
Endoscopy is indicated for all CD patients; biopsy specimens are recommended to be 
taken from different parts of the GI tract to improve diagnostic accuracy (Laass, Roggenbuck, & 
Conrad, 2014). There are several types of endoscopy (e.g., sigmoidoscopy, colonoscopy, EGD, 
and capsule endoscopy) that may be utilized based on which part of the GI track needs to be 
examined (CCFA, 2014a). Doctors use imaging techniques to diagnose CD. One of the most 
frequently used techniques is small bowel enteroclysis (SBE) (Benevento et al., 2010). 
Computerized tomography (CT) and magnetic resonance imaging (MRI) scans are helpful to 
detect signs and complications in the small bowel (e.g., abscesses, intestinal blockages, and 
fistulas; Rajesh & Maglinte, 2006; Zissin, Hertz, Osadchy, Novis, & Gayer, 2009). 
2.1.6 Measurements of Disease Activity in CD 
2.1.6.1   Biomarker indicators 
C-reactive protein (CRP). C-reactive protein (CRP) is an acute-phase protein that 
functions in the innate immune system; it is one of the most important proteins produced by the 
liver at the site of inflammation. CRP levels increase rapidly upon stimulation by TNF-a, IL-1-b, 
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and IL-6 (Vermeire, Assche, & Rutgeerts, 2004). Crohn’s disease is associated with extremely 
high levels of CRP; however, UC has a moderate-to-absent level. CRP levels correlate well with 
disease activity; severe CD has higher CRP than does moderate CD, which is higher than mild 
disease (Vermeire et al., 2004). This protein can be measured through a blood sample and a high 
sensitivity CRP test assay (Clyne, 1999; Pepys & Hirschfield, 2003; Ridker & Libby, 2007).  
Fecal calprotectin. Calprotectin is a calcium and zinc binding protein present in 
neutrophils’ cytosol, where it accounts for 60% of the total cytosol proteins. Fecal calprotectin is 
strongly correlated with several conditions, including CD and colonic cancer, and the use of 
nonsteroidal anti-inflammatory drugs (NSAID; Chen, Huang, Chang, & Kong, 2012; Costa et al., 
2003; Joshi, Lewis, Creanor, & Ayling, 2010; Tibble et al., 2000). Calprotectin levels may be 
high in those newly diagnosed with IBD; a moderate concentration indicates inflammation is 
present or that the disease is becoming worse, whereas a low level excludes IBD (Lab test online, 
2013). The test is analyzed using the calprotectin ELISA test (Lab test online, 2013). ALPCO’s 
(2013) calprotectin ELISA assay is used to determine the quantity of human calprotectin in a 
stool sample. This assay includes two ranges, standard dynamic range (10–600 µg/g or 0.01-0.6 
mg), which is the optimal range, and extended dynamic range (30–1,800 µg/g or 0.03-1.8 mg), 
which is a marker to check the disease activity and mucosal inflammation in IBD patients 
(ALPCO, 2013). 
2.1.6.2 Subjective assessment 
Crohn’s disease activity index (CDAI). The Crohn’s disease activity index (CDAI) is the 
most widely tool used to measure disease severity and activity in adults. Investigators from the 
Illinois Midwest Regional Health Center in the United States developed the index in the 1970s. 
This index has a long history of use and is considered as the gold standard. This index consists of 
eight clinical variables, including general well-being, abdominal pain and mass, number of liquid 
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stools, opiates for diarrhea, and presence of complications. A weighting factor is adjusted before 
each factor is summed (Best, Becktel, Singleton, & Kern, 1976). The three variables, which 
include number of liquid stools, abdominal pain, and general well-being, are based on a patient’s 
diary for 7 days. A patient with a score of more than 450 points is associated with severe disease, 
and a score from 220 to 450 indicates moderate disease. Mild disease and response have scores 
from 150 to 220 and greater than 70 points, respectively; less than 150 points indicates a 
remission (Best et al., 1976; Hyams et al., 1991; Joseph et al., 2009; Miheller et al., 2009). 
Modigliani et al. (1989) demonstrated that CDAI is not associated with the extent and severity of 
ileocolonic CD inflammation. To illustrate, a patient might be in remission with a score of less 
than 150; however, the endoscopy might show significant colonic inflammation (Modigliani et 
al., 1990). Table 2.3 presents Crohn’s Disease Activity Index. 
  Pediatric Crohn’s disease activity index (PCDAI) is used to assess the disease activity in 
children. This index measures the same variables used in CDAI. The score ranges from 0 to 100; 
a score greater than 30 points defines a moderate to severe disease, scores between 11–30 define 
a mild disease, and a score less than 10 defines a disease that is in remission (Hyams et al., 1991).  
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Table 2.3 Crohn’s Disease Activity Index (CDAI) 
Variable Score Descriptor Factors 
Liquid stools  Sum of 7 days Sum × 2 
Abdominal 
pain 
None = 0 
Mild = 1 
Moderate =2 
Severe =3 
Sum of 7 days Sum × 5 
General well 
being 
Well = 0 
Slightly under par =1 
Poor =2 
Very poor =3 
Terrible = 4 
Sum of 7 days Sum ×7 
Extra-
intestinal  
Arthritis/arthralgia, Iritis/uveitis, 
erythema nodusum, pyoderma, 
gangrenosum, aphthous stomatitis, 
anal fistula/ fistula/ abscess, fever > 
37.8°C 
Number of listed 
complication 
Sum × 
20 
Antidiarrheal  No= 0 
Yes = 1 
Use in previous 7 
days 
Sum ×30 
Abdominal 
mass 
No = 0 
Questionable = 1 
Definite = 5 
 Sum × 
10 
Hematocrit For males, (47 – observed) 
For females (42 – observed) 
Expected - 
observed 
Sum × 6 
Weight Current body weight (kg) standard 
body weight (kg) 
100 x (1 -
(current/standard)) 
 
Note. Adopted from “Development of a Crohn's disease activity index. National Cooperative 
Crohn's Disease Study” by Best, et al., 1976, Gastroenterology, 70(3):439-44. 
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Table 2.4 Pediatric Crohn’s Disease Activity Index (PCDAI) 
Variable Score 
History over 1 week 
Abdominal pain 
Number of liquid stools 
General well being 
 
0-10 
0-10 
0-10 
Examination 
Weight 
Height 
Abdomen 
Perirectal disease 
 
0-10 
0-10 
0-10 
0-10 
Extra-intestinal manifestations 0-10 
Laboratory test: HCT , ESR 
 Albumin  
0-5 
0-10 
Note. Adopted from “Development and validation of a pediatric Crohn's disease activity index” 
by Hyams et al., 1991, Journal of pediatric gastroenterology and nutrition, 12(4)449. 
 
The Harvey-Bradshaw index (HBI). The Harvey-Bradshaw index was developed in 1980 
to simplify the CDAI and does not require biochemical tests. The Harvey-Bradshaw Index is a 
simple tool use for long-term clinical trials (Vermeire, Schreiber, Sandborn, Dubois, & Rutgeerts, 
2010). This index excludes some variables from CDAI (e.g., weight, hematocrit, and use of 
antidiarrheal). Table 2.5 provides the variables in HBI, and the total score equals the sum of the 
variables. The index utilizes 1-day measurements and consists of clinical parameters. The score 
ranges from 0 to 19; an HBI score of less than 5 is defined as remission, 5–7 indicates mild 
disease, 8–16 indicates moderately active disease, and more than 16 indicates severe disease. HBI 
is used for retrospective studies; however, CDAI requires prospective data (Best, 2006; Harvey & 
Bradshaw, 1980).  
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Table 2.5 The Harvey-Bradshaw index (HBI) 
Variable Score 
General well-being 
very well = 0 
slightly below par = 1 
poor =2  
very poor = 3 
terrible = 4 
Abdominal pain 
none = 0 
mild = 1 
moderate = 2 
severe = 3 
Number of liquid stools per day N 
Abdominal mass 
none = 0 
dubious = 1 
definite = 2 
definite and tender = 3 
Complications 
1 point for each item 
Arthralgia, uveitis, erythema nodosum, , aphthous 
ulcers, pyoderma gangrenosum, anal fissure, new 
fistula, abscess 
Note. Reprinted from “A simple index of Crohn's disease activity” by Harvey J. and Bradshaw J., 
1980, Lancet, 514. 
 
Health-related quality of life (HRQOL). Health-related quality of life (HRQOL) is a 
subjective evaluation of the overall quality of life that affects physical or mental health. The 
inflammatory bowel disease questionnaire (IBDQ) is a validated tool and the most commonly 
used in IBD to assess health-related quality of life. It is a physician or self-administrated version 
and consists of 32 questions classified into four dimensions: bowel (10 questions), social (5 
questions), systemic (5 questions), and emotional (12 questions). Scores for each question ranged 
from 1 to 7 points, with 1 (poor) to 7 (best). The total score ranges from 32 to 224 points, and the 
highest score indicates a better quality of life. This questionnaire significantly demonstrated the 
impact of quality of life on a patient’s health (Desalvo, Bloser, Reynolds, He, & Muntner, 2005; 
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Dominick, Ahern, Gold, & Heller, 2002; Metelko et al., 1995; Selim et al., 2009). The 
questionnaire is provide in the appendix baseline form. 
2.1.7 Dietary Factors in IBD 
2.1.7.1 Nutritional assessment in IBD. Malnutrition is well documented in many chronic 
disease studies that include CD. Malnutrition has been reported in 70% to 80% of hospitalized 
active IBD patients (Hartman, 2009; Head et al., 2004; Leiper, Rushworth, & Rhodes, 2010). 
Most IBD patients suffer from nutritional deficiencies (75%) and weight loss (20 to 75%), which 
are the main symptoms of CD. Several factors may combine and contribute to cause 
undernutrition, such as a decrease in calorie intake (vomiting, anorexia), loss of calories 
(malabsorption, diarrhea), drug interactions, an imbalance of electrolyte and fluid and gut blood 
loss (Ferguson, Shelling, Browning, Huebner, & Petermann, 2007; Hartman, 2009; Head et al., 
2004; Hébuterne, Filippi, Al-Jaouni, & Schneider, 2009; Leiper et al., 2010; Schneeweiss et al., 
1999).   
Nutritional deficiencies in vitamins, protein, and micronutrients have been found in most 
studies examining nutritional consequences in CD (Ferguson et al., 2007; Hébuterne et al., 2009). 
Low energy intake has been reported in about 40% of CD patients (Hartman, 2009; Sousa 
Guerreiro et al., 2007). Iron deficiency anemia due to blood loss was occurring in about 39.2% of 
CD patients (Vagianos, Bector, McConnell, & Bernstein, 2007). Vitamin D and C deficiency 
occurring from low serum levels of these nutrients were seen in 22% to 70% and 84% of CD 
patients, respectively (Filippi, Al-jaouni, Wiroth, & He, 2006; Vagianos et al., 2007). More than 
50% of patients had vitamin C, zinc, and niacin deficiencies (Filippi et al., 2006). 
A Canadian study conducted at the University of Manitoba in 2007 evaluated the 
nutritional assessment of IBD patients (Vagianos et al., 2007). Anthropometric measures, 
biochemical markers of nutrition, and food record assessment were recorded over 4 days. The 
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study found a high prevalence of inadequate vitamin E (63%), vitamin B6 (29%), carotene 
(23.4%), vitamin B12 (18.4%), vitamin D (18%), albumin (17.6%), and 15.% of zinc (Vagianos et 
al., 2007). Vitamin D and iron supplements were recommended to avoid the complications from 
these nutritional deficiencies (Battat et al., 2014; Vagianos et al., 2007). Drug interactions are 
associated with nutritional deficiencies, steroids suppress calcium absorption in the intestine, and 
sulfasalazine reduces folate absorption (Alemzadeh et al., 2002). 
2.1.7.2 Dietary intake and risk of CD. Research has demonstrated that a diet high in vitamins 
and minerals might play an important role in disease activity. Certain foods have shown to 
increase CD disease symptoms. A diet low in vegetables and fruits may increase the risk of 
Crohn’s disease. An increased risk of developing CD was associated with increased consumption 
of sugar, sweeteners, sweets, fat, and red meat (Chapman-Kiddell, Davies, Gillen, & Radford-
Smith, 2010; Hébuterne et al., 2009; Reif et al., 1997; Sakamoto et al., 1995). However, 
vegetables, fruits, fish, nuts, grains, and olive oil are inversely associated with CD (D’Souza et 
al., 2008).  
Recent studies have used nutritional supplementation to control disease activity and 
nutritional deficiencies. Low serum concentrations in several nutrients indicate a need for 
micronutrient dietary supplements as a recommended daily intake for vitamins and minerals in 
addition to calories (Buchman, 2005; Head et al., 2004). Antioxidant treatment such as vitamin E 
(800 IU/d) and C supplements (1,000 IU/d) were found to decrease oxidative stress significantly 
in CD patients (Aghdassi, 2003). Moreover, high consumption of omega-3 fatty acids intake 
reduces CRP, IL-1, and TNF synthesis (Endres, 1996; Tsujikawa et al., 2000). 
 Regardless, patients still have a serious disease that affects their colons. Patients often 
need folate supplements to protect against colon cancer. Other patients may need calcium and 
vitamin D supplements to avoid bone problems (Arden & Cooper, 2002; Ba Lashner, Provencher, 
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Seidner, Knesebeck, & Brzezinski, 1997). The prevalence of vitamin D deficiency was 
significant in CD patients; however, the impact of vitamin D in regulating autoimmune system in 
CD is less understood. 
2.1.8 Management of Crohn’s Disease 
2.1.8.1 Clinical medical management of Crohn’s disease in adults. There is no cure for 
Crohn’s disease, but a short-term goal is to provide medical treatment to control the symptoms by 
repressing inflammation and reaching remission. The long-term treatment goal is maintaining 
remission (CCFC, 2008). Medical therapy is determined by assessment of several points: 
severity, disease location, and the complications that the patient experiences. Each point is 
important to determine the type of medication to be used; some drugs work in a specific location 
in the bowel (e.g., aminosalicylate relives symptoms and inflammation in the left colon and 
rectum only). Other drugs such as budesonide affect ascending colon and ileum. In addition, 
severity is important because patients with severe disease may respond to a greater agent and vice 
versa (Bousvaros & Leichtner, 2012; Head et al., 2004).  
Several groups of drugs are used to treat CD. Aminosalicylate (5-ASA) drugs are used to 
treat mild to moderate disease, and it can decrease the inflammation on the lining of the digestive 
tract  (Bousvaros & Leichtner, 2012; CCFA, 2014b; CCFC, 2008). Corticosteroid drugs such as 
prednisone and methylprednisolone are used to treat moderate to severe CD disease by 
suppressing the entire immune system. Antibiotics can be used to treat infections such as 
abscesses and anal canal/vagina fistulas. In addition, immunmodulators medication such as 
azathioprine, methotrexate, and mercaptopurine can suppress or weaken the immune response. 
Biologic therapies such as TNF-agents consider the latest class of therapy used for CD patients 
who did not response well to the pervious medication. These drugs can lead to certain 
complications and side effects (Bousvaros & Leichtner, 2012; CCFA, 2014b; CCFC, 2008; Head 
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et al., 2004; Lichtenstein, Hanauer, & Sandborn, 2009). Mild to moderately active disease is 
typically treated with oral mesalamine or sulfasalazine. Moderate to severe diseases are treated 
with prednisone and infliximab (Lichtenstein et al., 2009).  
Surgery is required for some CD patients when the medications fail or the patients have 
serious complications and are no longer responding to the medication (Jewell, 1998). Some 
patients may require resection surgery for a part of the intestine. Other patients consider 
removing all diseased sections if they experiences stricture, abscess, or obstruction (CCFC, 
2008). 
2.1.8.2 Current nutrition management of Crohn’s disease. Nutrition therapy is an adjunctive 
part of the medical management of CD in adults. The goal of nutrition therapy is meeting 
patients’ nutritional needs to restore nutritional deficiencies and to reduce symptoms (Beyer, 
2008). Nutrition therapies consist of three applications. The first application is called exclusive 
enteral nutrition, which provides all nutritional needs through liquid formulas. This therapy 
promotes mucosal healing and suppresses inflammation in the intestine. The second application 
is called supplemental enteral nutrition, and it provides a supplement to a regular diet to increase 
nutrient and energy intake for maintaining remission. The third therapy focuses on micronutrient 
supplements to correct the deficiency e.g., vitamin D and calcium (Bousvaros & Leichtner, 
2012). 
Multivitamins supplementations are recommended along with folate (1–2 mg daily) and 
iron (10-15 mg) supplementations (Buchman, 2005; Eiden, 2003). The Recommended Dietary 
Allowance (RDA) recommend vitamin D 800 IU per day for CD patients with active disease 
especially in non-sunny cities (CCFA, 2014c). For CD patients suffering from severe 
malabsorption, a daily vitamin D supplement of up to 2,000–4,000 IU per day may be needed to 
correct the level of serum vitamin D (Eiden, 2003; Jeejeebhoy, 2002). The RDA for healthy 
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people for protein is 0.8 g/kg actual weight, whereas Crohn’s patients who are free from renal 
disease require 1.0–1.5 g/kg body weight. Calcium supplements of 1,000–1,500 mg divided by 
thirds over the day are suggested (Eiden, 2003). Nutrition support has a significant impact in 
increasing patients’ intakes to meet their daily nutrients requirements.  
Dietary recommendations are important for CD patients; however, there is no specific 
recommendation to manage the disease activity in CD. Individuals must have a dietary 
recommendation prescribed to them depending on which part of the intestine is affected. 
Physicians instruct patients to avoid the foods that increase digestive problems. Low-fiber diets 
and adequate omega-3 fatty acids are suggested for active CD patients. Maintaining good health 
by having adequate intake of protein, nutrients, and calories is critical to managing CD symptoms 
(Beyer, 2008; Buchman, 2005; CCFA, 2014c; Eiden, 2003; Head et al., 2004). 
2.2 Vitamin D 
2.2.1 Vitamin D Background 
Vitamin D is one of the first discovered fat-soluble vitamins (Holick, 2003; Institute of 
Medicine, 2010). Vitamin D (calcitriol) is considered a steroid hormone and is involved in 
regulating not only calcium and phosphorus concentrations and ensuring adequate bone 
mineralization, but also regulating immune system (Cranney et al., 2007; Institute of Medicine, 
2010). The active form (1,25-dihydroxyvitamin D) synthesized not only in the kidneys but in 
other cells such as immune cells (Glerup et al., 2000; NHMRC, 2012). 
2.2.2 Vitamin D Sources  
Vitamin D exists as cholecalciferol (vitamin D3), which is produced by skin cells or food 
of animal origin, and ergocalciferol (vitamin D2), which is provided through plant (fungus) 
dietary sources (Brannon, Yetley, Bailey, & Picciano, 2008; NHMRC, 2012). The metabolite, 
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25(OH)D coverts calcitriol (1.25-dihydroxyvitamin D or 1,25(OH)2D) which is the biologically 
active hormone that engages in physiological actions (NHMRC, 2012). The richest natural source 
of vitamin D is the sun. Dietary sources primarily include liver, egg yolks, veal, and fatty fish 
such as salmon, mackerel, tuna, and herring (Gropper, Smith, & Groff, 2009; Holick, 2004, 2008; 
Reichrath, 2008). Table 2.6 presents vitamin D content in some foods. 
Food fortification with vitamin D helps people meet their daily nutritional requirements. In 
the United States, for example, juices, breakfast cereals, breads, milk, and cheese are fortified 
with vitamin D (Gropper et al., 2009; Holick, 2008). The extent of fortification in Canada is not 
as diverse as in the United States. Only milk and margarine have been considered for mandatory 
fortification in Canada in the amount of 400 IU per 250mL and 530 IU/100g, respectively. Other 
food items such as yoghurt, orange juice, and some meal replacement items are fortified in 
Canada; however, the amount of vitamin D is not considerable (Calvo, Whiting, & Barton, 2004; 
Calvo & Whiting, 2013; Health Canada, 2012). 
Table 2.6 Vitamin D Content in Some Foods 
Food Serving size Vitamin D µg/serving 
Egg yolk, cooked 1 0.8 
Tuna, Bluefin, cooked 75g 5.5 
Canned tuna in water 75g 0.9 
Beef liver, fried 75g 0.9 
Salmon Sockeye, canned/bone 75g 13.9 
Salmon Atlantic, baked/broiled 75g 5.1 
Fortified milk 250 mL 2.5 
Fortified margarine 10 g 2.5 
Fortified  orange juice 250 mL 1.3 
Note. Derived from (Canadian Nutrient File, 2010). 
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2.2.3 Vitamin D Metabolism 
 Adequate exposure to solar ultraviolet radiation (295–300nm) can penetrate the skin 
when ultraviolet radiation is converted by 7-dehydrocholesterol to pre-vitamin D3 (Holick, 1994; 
Reichrath, 2008). A biologically inert form of pre-vitamin D3 stores in the epidermis and dermis 
undergoes isomerization reaction to convert pre-vitamin D3 to cholecalciferol (M. Holick, 2004). 
After being synthesized in the skin, cholecalciferol and vitamin D acquired from the diet are 
joined to a vitamin D-binding protein (DBP) for transport to the liver. In the liver, 25(OH)D3 is 
the form that is enzymatically hydroxylated on carbon 25. Then, 25(OH)D3 is transported in 
blood. In the kidneys, vitamin D links to vitamin D receptor (VDR) and retinoid X receptor 
(RXR) heterodimers and transformed to become the active metabolite form 1, 25(OH)2D3 when 
needed, which undergoes a second hydroxylation reaction on carbon 1. Vitamin D  remain stored 
in adipose tissue for months and is released when needed (Brannon et al., 2008; Combs Jr, 2012; 
DeLuca, 2004; Holick, 1994, 1996, 2004; Jones, Strugnell, & Deluca, 1998; McCary & Deluca, 
1999; Reichrath, 2008). 
The active form of vitamin D has a separate pathway; it is play a role in involving 
immune system cells and links to VDR and RXR. The VDR and RXR then bind to the vitamin D 
response elements (VDRE) in the nucleus to function in the immune system (Veldhoen & 
Brucklacher-Waldert, 2012).  
2.2.4 Physiological Actions of 1α, 25-dihydroxyvitamin D3 
2.2.4.1 Calcium and phosphate homeostasis and bone health. Vitamin D has a calciotropic 
function: controlling the homeostasis of calcium, phosphate, and bone mineralization. The 
essential role of vitamin D is to maintain and regulate calcium concentration in the plasma and to 
increase the level of serum Ca and phosphorus. When calcidiol is converted by the kidneys into 
the active form calcitriol (1,25-dihydroxycholecalciferol), the active form acts with PTH or alone 
 25 
on three different target tissues: intestine, kidney, and bone (Combs Jr, 2012; DeLuca, 2004; 
Whiting & Calvo, 2005).  
In the intestine, there is increased absorption of Ca
2 
and Po4-; however, in the kidney, 
there is increased reabsorption of Ca
2+
 only, which results in an increased level of Ca
2+
 in the 
plasma. Then, the 1,25(OH)2D3 decreases the PTH level, which excretes and activates Po4- 
reabsorption. Once in the bone, 1,25(OH)2D3 stimulates PTH, which leads to an increased level 
of bone calcium (Brannon et al., 2008; Combs Jr, 2012; Deluca, 2004; Gropper et al., 2009; 
McCary & Deluca, 1999; Reichrath, 2008; Sauberlich & Machlin, 1992). Adequate level of 
calcium and vitamin D can protect children from developing osteomalacia and older adults from 
developing osteoporosis (Cranney et al., 2007; Institute of Medicine, 2010). 
2.2.4.2  Vitamin D, the immune system, and diseases. Vitamin D has non-calciotropic 
functions in neuromuscular, cardiovascular, reproductive and immune systems, inflammation and 
cell growth. In addition, vitamin D helps genes encode proteins to regulate differentiation and 
cell proliferation (M. Holick, 2004, 2006; Institute of Medicine, 2010; NHMRC, 2012; Prentice, 
Goldberg, & Schoenmakers, 2008; Whiting & Calvo, 2005). The epidemiological evidence 
indicates that there is a relationship between low levels of vitamin D and many other diseases, 
including cancer, diabetes, autoimmune disease, cardiovascular disease, schizophrenia, and 
depression (Holick, 2007; Prentice et al., 2008; Reichrath, 2008). Moreover, an insufficient level 
of vitamin D has an impact on fetal and pubertal growth and places the elderly at greater risk for 
acquiring chronic degenerative diseases (Prentice et al., 2008).  
   Vitamin D and immunologic function. As mentioned in the section on vitamin D 
metabolism, the immune system cells can make the active 1,25(OH)2D3 form, which binds to 
VDR-RXR. Once VDR-RXR link to 1,25(OH)2D3, they bind to response elements (VDRE) in the 
nucleus to function in the immune system (Veldhoen & Brucklacher-Waldert, 2012). The active 
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form then functions on several types of immune cells. In dendritic cells (DCs), 1,25(OH)2D3 acts 
to decrease production of maturation in IL-12, IL-6, and IL-23. The effect of B cells and 
antibody-secreting cells is decreasing proliferation as well as IgG, IgM, and plasma cell 
differentiation. Moreover, inhabitation of T cell stimulation results in response by Th1and Th17 
cells and enhances Th2 and Treg activity (Aranow, 2011; Veldhoen & Brucklacher-Waldert, 
2012). Table 2.6 Important Markers of Inflammation and their Functions. 
Vitamin D receptor polymorphisms and diseases. The vitamin D receptor (VDR) gene, a 
member of the NR1|1 nuclear receptor family, has biological functions on vitamin D3 (Moore et 
al., 2006; Szpirer et al., 1991). VDR hormones, heterodimer, and retinoid-x receptors bind with 
specific vitamin D-response elements (VDRE) on DNA and initiate the transcriptional pre-
initiation complex with other nuclear proteins. This VDR gene causes important effects on 
metabolism, affecting calcium, immune function, and gene activation (Valdivielso & Fernandez, 
2006). A polymorphism of the vitamin D receptor (VDR) gene changes in at least 1% of the 
population. The changes exist in non-coding parts, and they effect the expression degree of the 
gene and the protein levels (Valdivielso & Fernandez, 2006). The polymorphism (genetic 
variants) is associated with susceptibility of some diseases (Simmons, Mullighan, Welsh, Jewell, 
& Unit, 2000). 
 Recent evidence has linked VDR polymorphisms with cancer, nephrolithiasis, diabetes, 
UC, CD, and other diseases. In CD, there is a relationship between CD susceptibility and VDR 
gene; this gene influences BMD as well (Simmons et al., 2000; Todhunter et al., 2005). However, 
conflicting results have been reported regarding the association between VDR and cancer, bone 
biology, blood pressure, diabetes, and autoimmune disorders such as hepatitis, CD, Graves’ 
disease, and multiple sclerosis. In CD, the relationship between Tag1, Apa1, and Fokl 
polymorphisms and the disease has been reported. Indeed, several factors such as diet and 
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latitude influence the VDR (Simmons et al., 2000; Valdivielso & Fernandez, 2006). 
 Vitamin D, chronic and autoimmune diseases. A number of studies have demonstrated 
that patients with autoimmune disease have a low level of vitamin D. The dose of vitamin D 
supplementation that is required to decrease PTH in autoimmune diseases is different in each 
condition (Romagnoli, Pepe, Piemonte, Cipriani, & Minisola, 2013). In a chronic disease, 
researchers suggested that people with higher BMI have lower vitamin D levels, but fat content 
itself is a stronger factor than BMI in inverse relationship with serum 25(OH)D concentration 
(Vimaleswaran et al., 2013). The Endocrine Society guidelines recommend that obese people 
take vitamin D supplements two or three times higher than healthy people do (M. Holick et al., 
2011). Other studies found that 4,000 to 10,000 IU/d of vitamin D supplementation had a 
significant effect on glycemic indices (Belenchia, Tosh, Hillman, & Peterson, 2013; Nagpal, 
Pande, & Bhartia, 2009).  
Moreover, a low level of serum vitamin D was found in patients with multiple sclerosis 
due to low dietary vitamin D intake and indoor activities in fall and winter (Cantorna, 2006; 
Weinstock-Guttman et al., 2012). A low risk of rheumatoid arthritis in older women aged above 
55 years old was associated with high doses of vitamin D intake (Merlino et al., 2004). A daily 
intake of vitamin D supplementation (2,000 IU) had protective impact on risk of developing 
diseases related to vitamin D deficiency in children. Research found that 400 IU/d of vitamin D 
intake may decrease the risk of rheumatoid arthritis and multiple sclerosis by 40% (M. Holick, 
2005; Whiting & Calvo, 2005).  
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Table 2.7 Important Markers of Inflammation and their Functions. 
 
Markers of 
inflammation 
Immune 
cells 
Nature Function 
Th1 T cells 
Adaptive 
immune response 
Develop intracellular bacterial or 
virus infection 
Th2 T cells 
Adaptive 
immune response 
 Antibody-mediated against 
parasites, asthma, allergy, 
bacteria 
 Eosinophil activation 
 Several macrophage functions 
inhabitation 
Th17 T cells 
Adaptive 
immune response 
Inflammation (bacteria, fungi) and 
injury in the skin and GI tract 
Treg T cells 
Adaptive 
immune response 
 Regulation immune response 
 Maintaining immune tolerance 
 Preventing autoimmune 
diseases 
IL-6 
mononuclear, 
phagocytes 
dendritic 
cells 
T cells 
Anti-
inflammatory 
cytokine 
Induction the acute phase protein 
response 
IL-12 
Monocytes, 
macrophages 
dendritic 
cells 
B cells 
Pro-
inflammatory 
cytokine 
Enhancing interferon-ᵧ , IL-2 and 
TNF-α from T cells and NK cells 
IL-23 
macrophages 
dendritic 
cells 
Anti-
inflammatory 
cytokine 
regulation Th17 proliferation and 
function 
 Note. Adapted from (Iwakura & Ishigame, 2006; Romagnani, 1999; R. J. Simpson, Hammacher, 
Smith, Matthews, & Ward, 1997; Stockinger & Veldhoen, 2007; Vignali, Collison, & Workman, 
2008; Wolf, Sieburth, & Sypek, 1994). 
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2.2.5 Assessment of Vitamin D Status   
According to the U.S. Institute of Medicine (2010), a plasma concentration of 25-
hydroxyvitamin D is considered the best biomarker to measure vitamin D status; this represents 
the sum of vitamin D in dietary intake (diet and supplements) and cutaneous synthesis. 
Conversely, the biological active form of calcitriol 1,25(OH)2D is not considered a reliable 
marker to assess vitamin D status because it is under homeostatic control and has a short half-life 
(Hollis, 2005, 2007). Plasma PTH concentration has been reported as a functional index of 
vitamin D status because of the inverse relation between 25(OH)D and PTH. When insufficient 
levels of vitamin D exist, PTH secretion is elevated because of poor calcium absorption or low 
dietary calcium intake. The level of PTH concentration depends on many factors, including 
demographics, dietary Ca, kidney function, and drug use, so the PTH level varies widely among 
individuals, and making it difficult to define the normal level of PTH (Institute of Medicine, 
2010; Prentice et al., 2008). 
The most recent update of vitamin D dietary intake assessment from the Institute of 
Medicine was in 2011. Subclinical deficiency is associated with concentrations of 30–50 nmol/L 
(12–20 ng/mL), and vitamin D deficiency is considered when the concentration is below 30 
nmol/L (< 12 ng/mL). Some findings suggested that a concentration of 25(OH)D ≤ 80 nmol/L 
(32 ng/mL) is an insufficient vitamin D level; a plateau in parathyroid hormone (PTH) 
concentration is observed at 80 nmol/L (M. F. Holick, 2005; Mullin & Dobs, 2007). An optimal 
concentration of serum 25-dihydroxyvitamin D3 is indicated as above 50 nmol/L.  
Hypervitaminosis D can occurs when taking a daily vitamin D supplementation above 
10,000 IU. Adverse effects are associated with serum concentrations >125 nmol/L (>50 ng/mL; 
Institute of Medicine, 2010). Vitamin D is considered potentially toxic when serum 25(OH)D3 
levels exceed 500 nmol/L (200 µg/L; Institute of Medicine, 2010; Vieth, 2006 ; Jones, 2008). The 
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main consequence of vitamin D toxicity is hypercalcemia, which can cause over calcification on 
kidney, bones, heart and soft tissues (Dionne, Abitbol, & Flynn, 2012). In addition, constipation, 
loss of appetite, fatigue, vomiting, muscle weakness and dehydration are symptoms of 
hypervitaminosis D (Cusano, Thys-Jacobs, & Bilezikian, 2011; Vieth, 1999, 2007). Table 2.8 
presents serum 25 (OH)D concentrations and health. 
Table 2.8 Serum 25-Hydroxyvitamin D [25(OH) D] Concentrations and Health 
 
 
 
 
 
Note. Adapted from “Critique of the considerations for establishing the tolerable upper intake 
level for vitamin D: critical need for revision upwards” by Vieth , 2006, The journal of nutrition, 
136(4), 1117-1122 and “Food and Nutrition Board, Dietary Reference Intakes for Calcium and 
Vitamin D” by Institute of Medicine, 2010, National Academy Press. 
2.2.6 Recommendations of Vitamin D Intake  
The Food and Nutrition Board (FNB) at the Institute of Medicine has set dietary reference 
intake (DRI) values for daily vitamin D intake for different age groups to ensure adequate 
calcium metabolism and healthy bones. The Institute of Medicine (2010) stated that the intake of 
vitamin D above the standard of recommended dietary allowance (RDA) has no extra health 
benefits. The RDAs for vitamin D with minimal sunlight exposure are expressed in international 
units (IUs) and micrograms (mcgs) while 40 IU is equal to 1 mcg. The RDA, estimate average 
requirements (EAR), and tolerable upper intake level (UL) of vitamin D are provided in Table 
Vitamin D status 
Range 
Units (nmol/L) or (ng/mL) 
Vitamin D deficient <30 nmol/L <12 ng/mL 
Subclinical deficiency 30–50 nmol/L 12–20 ng/mL 
Optimal level >50 nmol/L 20 ng/mL 
Toxicity >125 nmol/L >50 ng/mL 
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2.9. Toxicity is considered more than 10,000 IU/day (Institute of Medicine, 2010). A review 
conducted in 2014 examined changes in serum vitamin D with oral vitamin D supplementations 
in healthy people. The researchers summarized studies with the amount of vitamin D 
supplements and changes in the serum (Jarrett, Ducasa, Buller, & Berwick, 2014). The lowest 
change was found in people who were treated with 200 IU/d vitamin D3 for a year—baseline 37.4 
and after 46.4 nmol/L (change in serum level 8.9 nmol/Lo; Al-Shaar, Mneimneh, Nabulsi, 
Maalouf, & Fuleihan, 2014). The highest change was noted with people who were taking 10,000 
IU/d for 20 weeks—baseline 65.6 and after 225 nmol/L (change in serum level 159.4 nmol/L; 
Heaney, Davies, Chen, Holick, & Janet Barger-Lux, 2003).  
Table 2.9 Dietary Reference Intakes (DRIs) Values for Vitamin D  
Note. Reprinted from “Food and Nutrition Board, Dietary Reference Intakes for Calcium and 
Vitamin D” by Institute of Medicine, 2010, National Academy Press. 
Age group 
Recommended 
Dietary 
Allowance (RDA) 
per day 
Estimated 
Average 
Requirement 
(EAR) per day 
Tolerable Upper 
Intake Level (UL) 
per day 
Infants 0-6 months 400 IU  (10 mcg) * - 1000 IU (25 mcg) 
Infants 7-12 months 400 IU  (10 mcg) * - 1500 IU (38 mcg) 
Children 1-3 years 600 IU (15 mcg) 400 IU (10 mcg) 2500 IU (63 mcg) 
Children 4-8 years 600 IU (15 mcg) 400 IU (10 mcg) 3000 IU (75 mcg) 
Children and Adults 
9-70 years 
600 IU (15 mcg) 400 IU (10 mcg) 4000 IU (100 mcg) 
Adults > 70 years 800 IU (20 mcg) 400 IU (10 mcg) 4000 IU (100 mcg) 
Pregnancy/ 
Lactation 
600 IU (15 mcg) 400 IU (10 mcg) 4000 IU (100 mcg) 
*Adequate Intake rather than Recommended Dietary Allowance  
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2.2.7 Vitamin D Deficiency 
2.2.7.1  Epidemiology of vitamin D deficiency in Saudi Arabia. Vitamin D deficiency is 
widespread in children and adults (Tangpricha, Pearce, Chen, & Holick, 2002). There are one 
billion people suffering from vitamin D deficiency or hypovitaminosis in the world (M. Holick, 
2006; Lips et al., 2006). The Middle East, in particular Saudi Arabia, has registered one of the 
highest rates of rickets and hypovitaminosis D worldwide (Baroncelli et al., 2008; El-Hajj 
Fuleihan, 2009; Kimball, Fuleihan, & Vieth, 2008; Lips et al., 2006). Saudi Arabia has a great 
deal of sunlight, but fortified products with vitamin D such as fluid milk, powdered milk, and 
yogurt are limited to specific brands. The amount of vitamin D in fluid milk and yogurt is 40–400 
IU/L, and in powdered milk, it is 65.6 IU/100g–350 IU/100g (Sadat-Ali, Al Elq, Al-Farhan, & 
Sadat, 2013).  
It was found that 80% of adolescent Saudi girls had low serum 25(OH)D levels (below 25 
nmol/L), and a 25(OH)D level of 10 to 30 nmol/L was found in elderly females and female 
university students (Sedrani, Elidrissy, & El Arabi, 1983; Siddiqui & Kamfar, 2007). The 
deficiency was found in 59% of newborn samples at King Khaled University Hospital in Riyadh, 
Saudi Arabia; 87.5% of newborns had levels of vitamin D below 50 nmol/L, which is considered 
insufficient (25–50) and deficient (< 25; Alfaleh et al., 2014). Elsammak et al. (2011) conducted 
a study on healthy young Saudis mean age 30 for male and 31 female (M = 30, F = 31) in the 
eastern region of Saudi Arabia. The researchers found low levels of serum 25(OH)D in both 
males (10.1ng/mL) and females (9.9ng/mL). The prevalence of vitamin D deficiency is extremely 
high despite that more than 90% of the participants had adequate dairy products and that more 
than 65% had enough exposure to sunshine (Elsammak, Al-Wossaibi, Al-Howeish, & Alsaeed, 
2011).  
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Some possible explanations for these low vitamin D levels include an indoor lifestyle, 
avoiding the strong heat of the sun (latitude 15–26°N), lack of awareness, and cosmetic 
preferences (i.e., frightened of getting a darker skin tone from the sun’s rays; Christie & Mason, 
2011; Elsammak, Al-Wosaibi, Al-Howeish, & Alsaeed, 2010; Elsammak et al., 2011; Mithal et 
al., 2009; Siddiqui & Kamfar, 2007). Increasing calcium homeostasis, age, and weight were 
significantly associated with vitamin D deficiency (Alfawaz, Tamim, Alharbi, Aljaser, & 
Tamimi, 2014). Testing for vitamin D among children and women is highly recommended. A 
powerful health policy for vitamin D supplementation and the application of dietary health are 
required to meet people’s needs of vitamin D (Hussain, Alkhenizan, El Shaker, Raef, & Gabr, 
2014). 
2.2.7.2  Epidemiology of vitamin D deficiency in Canada: Vitamin D levels are low in many 
healthy people, especially in winter. Canadian researchers examined healthy men and women at 
the end of the winter season in Calgary, Alberta, which is located in the western part of the 
country and has more hours of sunshine than do other Canadian cities. The researchers found that 
20% of the samples had low serum concentration (< 40 nmol/L), 39% were below 50 nmol/L, 
and most participants (86%) had levels of serum < 80 nmol/L. Serum concentrations were found 
to be even lower in summer, with levels of  9%, 14%, and 68%, respectively. This might be 
related to many people travelling during the summer to countries that are below latitude 42° N 
(Rucker, Allan, Fick, & Hanley, 2002). Likewise, vitamin D levels can differ based on ethnicity. 
Vieth et al. (2001) studied the prevalence of hypovitaminosis in young women (ages 18–35) in 
Toronto and found 21% of Caucasian women, 32% of non-White women and 25% of women 
from Africa had low levels of serum 25(OH)D (< 40 nmol/L; Vieth, Cole, Hawker, Trang, & 
Rubin, 2001).  
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Dr. Whiting and coworkers (2011) evaluated vitamin D status in Canadians ages 6–79 
years to determine whether Canadians met specific DRI recommendations. The researchers 
reported that 25% of these Canadians did not meet their RDA; more than 33% of Canadians did 
not take supplements in the winter and thus did not meet their RDA levels. The highest risk 
groups were found in non-Caucasian Canadians (Whiting, Langlois, Vatanparast, & Greene-
finestone, 2011). Other researchers conducted a study using data from CHMS 2007 to 2009 to 
indicate the prevalence of vitamin D deficiency among Canadian populations. Vitamin D 
deficiency was found in 4% of Canadians, whereas 90% had adequate concentrations (≥ 37.5 
nmol/L) for bone health (Langlois et al., 2010). 
Dr. Vatanparast and others conducted a study in 2010 to evaluate vitamin D intake using 
data from food intakes of Canadians reported in a 2004 Canadian Community Health Survey 
Cycle 2.2 (CCHS 2.2); the sample size was 34,789 persons ages over 1 year. The results 
demonstrated that women in all age groups had lower vitamin D intake than did men; White 
Canadians had a higher intake than Canadian minorities, which were 49% and 31.1%, 
respectively. Foods with the highest sources of vitamin D that were consumed included milk, 
meat, and meat alternatives. Canadian populations consume vitamin D from food less than the 
vitamin D dietary recommendation (Vatanparast, Calvo, Green, & Whiting, 2010). Table 2.10 
Summarize the Main Results from Different Studies on 25(OH)D Status. 
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Table 2.10 Summarize the Main Results from Different Studies on 25(OH)D Status 
City (n) Season 
Vitamin D status 
(nmol/L) 
Reference 
Whole 
Canada 
5306 
all 
season 
67.7 (Langlois et al., 2010) 
Toronto 155 fall 44.9 (Liu et al., 1997) 
Edmonton 36 summer 122 (Overton & Basu, 1999) 
Calgary 188 winter 57.3 (Rucker et al., 2002) 
Quebec 741 winter 64.9 
(Sinotte, Diorio, Bérubé, Pollak, 
& Brisson, 2009) 
 
2.2.8  Consequences of low vitamin D status. Low levels of vitamin D are the result of an 
inadequate dietary intake, limited sun exposure, and other factors. Consequences include a lack 
of intestinal absorption of dietary calcium and phosphors (loss into urine), hyperparathyroidism 
(a low serum phosphor level), reduced bone mineralization, and increased cortical bone loss, 
which might be associated with osteoporosis and hip fractures (Bouillon, R., De Groot, L. J., & 
Jameson, 2001; M. Holick, 2004; Institute of Medicine, 2010; Lips, 2001; Rizzoli & Bonjour, 
2004). Moreover, the risk leads to a softening of the bones known as rickets in children and 
osteomalacia in adults. These diseases are due to impaired bone mineralization and might cause 
muscle weakness, bone pain, and skeletal deformities (Bakhtiyarova, Lesnyak, Kyznesova, 
Blankenstein, & Lips, 2006; Bender, 2003; Holick & Chen, 2008; M. Holick, 2007; R. U. 
Simpson, Thomas, & Arnold, 1985).  
  Vitamin D receptors exist in human skeletal muscle tissue and its deficiency has been 
associated with increased body sway and high incidence of fractures  (Bischoff-Ferrari et al., 
2004; Holick & Chen, 2008; R. U. Simpson et al., 1985; Visser, Deeg, & Lips, 2003). A skeletal 
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mineralization defect might occur in adults as well. The non-mineralized osteoid leads to weak 
structural support and flexibility to the covers of the periosteal surface, which causes joint and 
muscle aches and pains (Al-Ali & Fuleihan, 2000; Malabanan, Turner, & Holick, 1998).  
  Low levels of vitamin D result in many other serious health problems. New evidence has 
shown that a vitamin D deficiency is associated with an increased risk of developing cancers e.g. 
breast and prostate cancer, multiple sclerosis (MS), diabetes, and cardiovascular disease (Davis, 
2008; Hassan et al., 2013; Higgins et al., 2013; Holick, 2005; Munger, Levin, Hollis, Howard, & 
Ascherio, 2006; Pittas et al., 2006). Epidemiological studies reported that individuals who have 
low levels of vitamin D are at greater risk of developing colon cancer (Bostick et al., 1993; 
Garland et al., 1985; Kearney et al., 1996; Martinez et al., 1996). Women who live in areas with 
lower levels of sunlight had low serum 1,25(OH)2D and were at five times greater risk of 
developing breast cancer (Garland, Gorham, & Young, 1990; Gorham, Garland, & Garland, 
1989; Vieth et al., 2007). Dietary vitamin D intake was associated inversely with development of 
MS (Munger et al., 2006). In type 2 diabetes, endothelial function was improved by taking a 
single dose of 100,000 IU vitamin D2 supplementation (Sugden, Davies, Witham, Morris, & 
Struthers, 2008).  
2.2.9 Factors that influence vitamin D status. A number of factors influence vitamin D levels 
and absorption. These factors include environmental factors such as latitude (distance from the 
equator), atmospheric particulate matter, cloud cover, seasons, time of day, and individual factors 
including skin tone (i.e., dark skin), age, use of sunscreens, and clothing (i.e., veils, long sleeves 
or pants; Batieha et al., 2011; Holick, 2008; NHMRC, 2012; Tsiaras & Weinstock, 2011).  
 Environmental factors that influence vitamin D status. Seasonal changes significantly 
affect cholecalciferol production. Vitamin D deficiency is more common during the winter period 
because the UVB radiation is not strong enough to produce adequate vitamin D (Burgaz, 
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Akesson, Oster, Michaëlsson, & Wolk, 2007; Holick, 1996; NHMRC, 2012). Moreover, the solar 
zenith angle (SZA) has a significant impact on UV production. When the sun is most directly 
overhead, the smallest SZAs cause stronger UV radiation. To illustrate, in the winter and fall 
when the sun is closer to the horizon, SZA increases, and the amount of UV radiation that 
spreads across the planet is reduced significantly (Holick, 1995; Kimlin, 2008; Webb & 
Engelsen, 2008). 
According to Burgaz et al. (2007), studies have demonstrated that complete cloud cover 
may decrease UV radiation by 50%, shade reduces UV by 60%, and the angle of the sun, distance 
from the equator, and latitude influence vitamin D production in human skin. Vitamin D3 in 
countries at higher latitudes is not produced during the winter, whereas countries at lower 
latitudes (i.e., below 35°N) have vitamin D3 production that is sufficient for the entire year (e.g., 
the latitude of Canada is 45° N, 75° W), and the latitude of Saudi Arabia is 24° N and 45° E; 
Rehman, Halawani, & Mohandes, 2003; Tsiaras & Weinstock, 2011; Ward, Gaboury, Ladhani, & 
Zlotkin, 2007). In other words, the change of seasons or weather conditions and geographic 
latitude can lead to larger or smaller rates of SZA that affect UV production. Consequently, this 
change causes changes in the production of vitamin D in humans.  
   Individuals and lifestyle factors influence vitamin D status. Aging significantly 
reduces the synthesis of vitamin D in the skin. People younger than age 50 have the ability to 
create and store vitamin D for approximately six months, and it remains usable when there is a 
low production of vitamin D during the winter. Skin thickness, however, decreases linearly in 
humans after age 20. The effectiveness of producing 7-dehydrocholesterol by skin cells decreases 
substantially from 100% to 25% in adults (Holick, 1995, 1996, 2008). Darker skin has a greater 
amount of melanin, which is an efficient protector against absorption of UV radiation, but 
melanin decreases the skin’s ability to produce vitamin D. Darker skin tones are more likely to 
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have a vitamin D deficiency and require approximately five to ten times longer sunlight exposure 
than do other ethnicities (with lighter skin tones) for the same level of absorption (Holick & 
Chen, 2008; Holick, 2008; Institute of Medicine, 2010). Obese people have serum vitamin D 15 
nmol/L lower than do non-obese people with no difference between women and men (Snijder et 
al., 2005).   
Using sunscreen and covering the skin with layers of clothing are also factors that can 
contribute to vitamin D deficiency. Skin synthesizes only a small amount of vitamin D when 
sunscreen with an SPF of eight or higher is applied, and sunscreen dramatically reduces UV 
absorption (Holick, 1994, 1995). According to Holick (1994), wearing layers of clothing in a cold 
climate is a factor that prevents cutaneous cholecalciferol production. In some societies, people 
cover most sun-exposed areas for religious and cultural reasons, and these people are at a greater 
risk than others are of vitamin D deficiency (Batieha et al., 2011; Holick, 1994). A study 
conducted by Guzel et al. (2001) aimed to compare vitamin D status in Turkish veiled and 
unveiled women. The study demonstrated that veiled Turkish women could not synthesize 
sufficient vitamin D in their bodies. The researchers concluded that Turkish women who cover 
their whole body had vitamin D deficiency, and dietary vitamin D supplements were 
recommended (Guzel, Kozanoglu, Guler-Uysal, Soyupak, & Sarpel, 2001).  
Similarly, Mishal (2001) conducted a study in Jordan to evaluate vitamin D status, and the 
effect of different styles of clothing on vitamin D metabolism in healthy young Jordanian 
women. Many women in Jordan cover the entire body for religious reasons (the same is true in 
Saudi Arabia); some cover their hands and faces, whereas others wear Western styles (i.e., do not 
cover up as much). The sunlight exposure in Jordan is adequate in summer but not in the winter. 
There is also a lack of vitamin D fortification products and fish consumption. Vitamin D 
deficiency was found in 83.3% of woman who wore full-coverage clothing during summer and in 
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81.8% in winter. In women who were not fully covered, 54% were vitamin D deficient in 
summer and 77.6% in winter, and finally, for Western dress styles, 30.8% of women were 
vitamin D deficient in summer and 75% in Jordan winter. As a result, covered women are more 
likely to have a vitamin D deficiency than are women who wear Western dress styles; however, 
there was no statistical significance observed between different dress styles (Mishal, 2001).  
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Environmental, individuals and lifestyle factors influencing vitamin D levels. 
2.3 Vitamin D and Crohn’s Disease 
2.3.1 Prevalence of Vitamin D Deficiency in IBD 
There is a link between vitamin D and IBD. Vitamin D deficiency is common in IBD 
patients, especially those with Crohn’s disease, where 18–70% of patients are vitamin D 
deficient, and 45% have metabolic bone disease (de Bruyn et al., 2014; Siffledeen et al., 2005; 
Suibhne, Cox, Healy, O’Morain, & O’Sullivan, 2012a; Vogelsang et al., 1989). In 2008, Leslie et 
al. conducted a Canadian study in Manitoba that found that 88% of IBD patients (56 CD and 45 
UC) had plasma vitamin D below 75 nmol/L. In Wisconsin in the United States, another study 
examined 403 CD and 101 UC patients and found that 11% of IBD patients had vitamin D levels 
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below 10 ng/dL, and 50% were below 30 ng/dL (Ulitsky et al., 2011). Of the 81 CD patients, 
63% were deficient (<50 nmol/L; Suibhne, Cox, Healy, O’Morain, & O’Sullivan, 2012).  
Later, Alkhouri, Hashmi, Baker, Gelfond, and Baker (2013) examined 61 IBD patients 
and found that 62% of IBD patients, compared with 75% of the control group, had low vitamin D 
levels. Another study that was conducted in summer found that 95% of 65 IBD Iranian patients 
were deficient, with vitamin D levels below 30 ng/mL (Hassan et al., 2013). In addition, recent 
study shows vitamin D deficiency was low in CD cases and a healthy control group with no 
significant difference with mean 25(OH)D 51.6nmol/L in CD, and 60.8 nmol/L in controls. The 
study found non-Caucasian, high level of BMI, sun protection, and no holidays in the last year 
were associated significantly with serum vitamin D levels in CD cases (de Bruyn et al., 2014). 
However, another study found that 19% of 70 CD, five UC, and three IBDU were vitamin D 
deficient (< 51 nmol/L; Levin et al., 2011). Similarly, in Boston, Massachusetts, researchers 
examined 1,763 CD and 1,454 UC and reported that 28% of IBD were insufficient (20–30 
ng/mL) and that 32% were deficient (< 20 ng/mL; Ananthakrishnan et al., 2013).  
2.3.2 Serum Vitamin D and Crohn’s Disease 
Serum 25(OH)D concentrations correlate well with disease activity, nutritional status, 
bone mineral density (BMD), and quality of life (Abreu et al., 2004; Harries et al., 1985; Ulitsky 
et al., 2011). Researchers found vitamin D deficiency is associated with high disease activity and 
CDAI scores, severe Crohn’s disease (known as a low level of albumin), and low HRQOL scores 
along with patients who do not take vitamin D supplements and those in an early diagnosis stage. 
Decreasing vitamin D levels is associated with high levels of CRP and ferritin, low nutritional 
status, smoking, insufficient sun exposure, and small bowel involvement (Pappa et al., 2006; 
Suibhne et al., 2012a; Ulitsky et al., 2011). Patients who have active CD disease and have little to 
no sunlight exposure were found to have low serum 25(OH)D levels (Joseph et al., 2009). Ham et 
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al. (2014) concluded that the level of vitamin D increases after treating infliximab in active CD 
patients. In both UC and CD patients, an increased risk of surgery and hospitalization are 
associated with low plasma 25(OH)2 D, and an optimal level of 25(OH)2 reduced the risk of 
surgery in CD patients (Ananthakrishnan et al., 2013). New study found no significant 
association between seasonal vitamin D levels and disease activity (Kini, Young, Herbison, & 
Schultz, 2014). Koutkia, Lu, Chen, and Holick (2001) conducted a case report examining 
treatment of vitamin D deficiency with tanning bed UVB radiation in CD patients. After 4 weeks 
of treatment, PTH decreased by 52%, calcium increased from 7.8 to 8.5mg/dL, and serum 
vitamin D increased significantly from 7 to 32 ng/mL.   
Bone health is one of the main concerns in CD cases. A study reported a significant 
negative correlation exists between vitamin D levels and BMD in CD patients who use 
glucocorticoid. Two independent risk factors were associated with low BMD and osteoporosis, 
high levels of 1,25(OH)2D, and use of glucocorticoid (Abreu et al., 2004). Low BMD is common 
in CD patients with ileostomy and low body mass index (Gupta, Wu, Moore, & Shen, 2014). 
However, another study found that patients who have vitamin D deficiency are not at a higher 
risk of low BMD (Pappa et al., 2006). Low levels of 25(OH)D can cause a reduction in calcium 
absorption that enhances the parathyroid hormone (PTH), which regulates serum calcium and 
phosphate (Abreu et al., 2004; Joseph et al., 2009). Vitamin D and K potentially maintain bone 
health in IBD, whereas several factors may influence bone health (e.g., inflammatory cytokines, 
reduced exposure to sunlight, and steroid use; Iijima, Shinzaki, & Takehara, 2012). 
According to current evidence, the main role of vitamin D in CD patients is to promote 
bone health and to decrease the risk of inflammation and cancer. There is an increased risk of 
cancer, especially colorectal cancer, in CD patients with low vitamin D levels; each 8% reduction 
risk of colorectal cancer was associated with an increase in the level of serum vitamin D by 1-
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ng/mL (Abreu et al., 2004; Ananthakrishnan et al., 2014; Edward D. Gorham et al., 2007; Holick, 
2004; Jørgensen et al., 2010; Van Assche et al., 2010). Moreover, CD patients with a BMI greater 
than or equal to 25 are more likely to have a low level of vitamin D (< 20 ng/mL; Singla et al., 
2014). Appendix 1 table 2.11 presents studies on vitamin D and IBDs including one systematic 
review, three clinical trials, five cohort studies, four case- control studies, three cross-sectional 
studies, and one review of four patients’ medical records. Nine of the studies had focused on 
IBDs and seven studies on CD. The minimum dose of vitamin D was 400/d IU and the maximum 
10,000 IU/d. 
2.3.3 Guidelines of Vitamin D Supplementation in Crohn’s Disease 
 The Institute of Medicine RDA guidelines for healthy people ages 9 to > 70 years, 
including pregnant and lactating women, is 600 IU/day and upper level 4,000 IU/day. Holick et 
al. (2011) recommend a daily vitamin D supplement up to 1,500–2,000 IU in order to achieve 
25(OH)D in plasma ≥ 30 ng/mL in people with low vitamin D levels. The doses should be 
increased by a factor of two to threefold in obese or people who are taking anticonvulsant drugs. 
In addition, CD patients require higher daily vitamin D intake than healthy people do. In case of 
malabsorption syndrome, small bowel involvement, and a BMI > 30, the dosage should be 
multiplied by a factor of 1.5–3. Physicians recommend that CD patients with a vitamin D 
deficiency take oral cholecalciferol up to 50,000 IU once a week for 8 weeks or until patients 
achieve serum 25(OH)D 30–36 ng/mL (Basson, 2013; Garg, Lubel, Sparrow, Holt, & Gibson, 
2012; Holick et al., 2011; Zhou, LeBoff, & Glowacki, 2010). In cases of severe vitamin D 
deficiency, a cholecalciferol supplement up to 300,000 to 600,000 IU is considered safe and 
effective, but monitoring Ca levels is required (Basson, 2013; Binkley et al., 2011; Trang et al., 
1998). Table 2.12 presents vitamin D supplementation guidelines for CD patients. 
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Table 2.12 Vitamin D Supplementation Guidelines for CD Patients.  
Serum vitamin D  
Oral vitamin D3 
supplementation 
(ng/mL) (nmol/L) 
≤3 ≤8.5 5000 IU/day 
4≤ 9 8.6≤23.5 4000 IU/day 
10 ≤15 23.6≤38.4 3000 IU/day 
16≤ 23 38.5≤58.4 2000 IU/day 
24 ≤ 29 58.5≤73.4 1000 IU/day 
30 - 36 73.5-89.9 1500- 2000 IU/day* 
* Maintenance doses should be performed for 3 months, and then 3-6 months adjusting the doses 
until the target is achieved.  
Note. Adapted from “Vitamin D and Crohn's Disease in the Adult Patient: A Review.” by 
Basson, 2013, Journal of parenteral and enteral nutrition, 38(4), 438-458. 
2.3.4 Vitamin D Supplementation in Crohn’s Disease 
High 25(OH)D levels from a high dose of vitamin D supplementation may have health 
benefits that can prevent a relapse of Crohn’s disease (Jørgensen et al., 2010; Miheller et al., 
2009). Several studies sought to achieve an optimal level by comparing different doses of vitamin 
D. In 2014, researchers assessed vitamin D levels in children with CD and examined whether 
vitamin D3 supplementation with 400 to 2,000 IU/d for 6 months reduced the deficiency below 
the cut-off of 20–30 ng/mL. The researchers found that 2,000 IU/d vitamin D3 supplementation 
was elevating plasma 25(OH)D above 30 ng/mL more effectively than 400 IU/d (Wingate et al., 
2014). A recent study sought to maintain optimal vitamin D levels in children with IBD by 
having the children receive 400 IU/d of vitamin D2 versus 2,000 IU/d in winter and spring and 
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1,000 IU/d in summer and fall. It has been noted that a daily vitamin D2 supplementation up to 
2,000 IU was insufficient to maintain the optimal levels in children with IBD (Pappa et al., 2014).  
Researchers conducted a study involving pediatric patients with IBD (5–21 years of age) 
that had them receive either a daily 2,000 IU of vitamin D2, 2,000 IU of vitamin D3, or 50,000 IU 
of vitamin D2 weekly for 6 weeks. The researchers found that 2,000 IU of vitamin D3 and 50,000 
IU of vitamin D2 were raising plasma 25(OH)D and were well tolerated by the patients (Pappa et 
al., 2012). A randomized, placebo-controlled trial conducted by Jorgensen (2010) examined the 
benefits of 1,25(OH)2 D3 therapy. CD patients (n = 108) in remission received both vitamin D3 
(1,200 IU) and calcium (1,200mg/d) or calcium (1,200mg/d; placebo) for a year. After 3 months 
of treatment, oral vitamin D3 increased the levels of 25(OH)D from a mean of 69 to 96 nmol/l. 
Furthermore, the study considered 1,200 IU/D of vitamin D3 as a high dose, but now high doses 
of 2,000 IU/D or more are considered safe without the risk of hypercalcemia (Jørgensen et al., 
2010). 
  Studies also examined the effect of different doses of vitamin D on disease activity. 
Researchers investigated the effect of 1, 25-dihydroxyvitamin D and 25(OH)D on disease activity 
and bone metabolism. The results indicated that CDAI and CRP decreased dramatically after 6 
weeks, but this effect disappeared at the end of the trial (at 12 months). In addition, active 
vitamin D has a significant reduction in bone re-absorption and formation compared with 
25(OH)D (Miheller et al., 2009). Each 100 IU/day of vitamin D intake from diet and supplements 
decreases the risk of CD activity by 7% (Ananthakrishnan et al., 2012). In a small cohort of CD 
patients, vitamin D3 supplementation with up to 5,000 IU/d for 24 weeks significantly elevated 
plasma 25(OH)D3 from 16 ± 10 ng/ml to 45 ± 19 ng/ml, decreased CDAI scores from 230 ± 74 to 
118 ± 66, and improved quality of life scores (Yang et al., 2013b). A study examined the changes 
in monocyte-derived DC (mo-DC) maturation marker expression and cytokine production in CD 
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patients who received calcium 1,200 IU (placebo) or vitamin D3 (1,200 IU) and calcium 
(1,200mg/d) for 26 weeks. Lipopolysaccharide-matured mo-DC decreased the expression and 
cytokine production, including IL-10, IL-6, and IL- 1β (Bartels et al., 2014). Sufficient vitamin D 
levels raise the response of anti-inflammatory cytokine to muscular injury (Barker et al., 2014). 
  Boothe, Lakehomer, Jacob, Scherl, and Bosworth (2011) presented a study at the 
American College of Gastroenterology annual meeting in 2011 that examined whether high doses 
of vitamin D3 in CD patients with vitamin D deficiency led to increased clinical outcomes. 
Patients were randomized to receive either 1,000 IU/d or 10,000 IU/d. After 26 weeks of 
treatment, HBI scores in the group with high vitamin D doses had a significant change compared 
with baseline (3.25 ± 2.2, 4.8 ± 1.7). Vitamin D levels were significant when comparing baseline 
(54.4±22.8) after 26 week (64.2 ± 29.8). The low-dose group had no significant difference. As 
shown above, 10,000 IU/d of vitamin D3 supplementation was an effective treatment for 
improving symptoms of CD (Boothe et al., 2011). 
  Crohn’s patients have lower levels of vitamin, which lead to increased disease activity. 
The previous studies show vitamin D supplementation significantly increases plasma 25(OH)D in 
CD patients, but this depends on vitamin D doses. In addition, vitamin D treatment decreases the 
disease activity levels and improve quality of life scores.  
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CHAPTER 3 
3. METHODOLOGY 
3.1 Study phase I 
3.1.1 Design and Setting 
The phase I study was designed as a double-blind randomized trial of approximately 60 
active patients with Crohn’s disease who are receiving induction therapy. We performed 
randomization and blinding of the samples at the Royal University Hospital, University of 
Saskatchewan. The sample size calculation included patients in Saskatoon, Saskatchewan, 
Canada, and Riyadh, Saudi Arabia. The study was conducted between October 2013 and 
September 2014, and our goal was to recruit 30 patients at each site. The patients were divided in 
three groups to receive different oral doses of vitamin D: Group 1 received vitamin D at 400/d IU 
(EAR level), group 2 received vitamin D at 2,000 IU daily, and group 3 received vitamin D at 
10,000 IU daily. The vitamin D intervention lasted 9 weeks, and data were collected at baseline 
(0), 9 weeks, and at a 2-month follow-up. The inclusion criteria included participants that have 
active Crohn’s disease (define by biomarker indicators) without any bowel damage, 16–40 years 
old.  
Exclusion Criteria: 
1.  Patients in remission. 
2.  Patients who are taking Corticosteroids. 
3.  Patients who have serum creatinine, aspartate aminotransferase (AST), alanine 
transaminase (ALT), parathyroid hormone (PTH), calcium, or alkaline phosphatase 
greater than 1.5 times the upper limit of normal at the screening visit. 
4.  Patients who:  
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a. Are pregnant 
b. Suffer from liver or kidney failure 
c. Are unable to take oral supplements or medicine 
d. Are known to have hypersensitivity to vitamin D or any of its analogues or derivatives 
5. Patients who are suffering from 
a. Hypercalcemia 
b. Malabsorption syndrome 
c. Abnormal sensitivity to the toxic effects of Vitamin D 
d. Hypervitaminosis D 
3.1.2 Data Collection Strategies  
We used several strategies to recruit patients at both sites. We invited participants to 
participate through posters posted at the Royal University Hospital and followed by face-to-face 
or phone communication through the inflammatory bowel disease (IBD) clinic at RUH in 
Saskatoon, SK, Canada and the Internal Medicine Department at King Khalid University 
Hospital in Riyadh, Saudi Arabia (Appendix 9). In Saskatoon, we asked patients who were 
interested in participating in the study to make the first appointment with the research assistant. 
In Riyadh, we recruited participants from an outpatient clinic when they had their follow-up 
appointments with our IBD team members. Prior to the collection of any information or test, the 
patient signed the consent form (Appendix 3). We gave the patients subject codes and randomly 
assigned which level of vitamin D supplementation they would receive. We used the subject 
codes on all data collection forms to maintain anonymity. Only information relevant to Crohn’s 
disease was recorded from participants’ files. We indicated this in the consent form. 
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 We took the participants’ anthropometric measurements, including height and weight, 
laboratory examinations of vitamin D status, and disease activity. Participants completed six 24-
hour dietary recalls; the first three recalls were collected at baseline (first 3 weeks) to assess their 
usual intake, and the other set of recalls were collected at week 9. The other appointments were 
scheduled at 9 weeks and 2 months after baseline data collected. The research project funding 
was from the Saudi Arabian Culture Bureau in Canada. The participants’ names and contact 
information were kept confidential, and only research co-investigators accessed them. Each 
participant had a unique code, which was not identifiable by anyone outside of the research team. 
All data were stored in a lockable filing cabinet in the principle investigator’s office or in a secure 
network file for up to 5 years (Appendixes 4,5,6,7 and 10).  
Table 3.1 Assessment Methods. 
Assessments methods 
Timing 
Baseline 
End of 
Intervention 
Follow-up 
Socio-Demographics questionnaire  - - 
Physical activity questionnaire  - - 
Health Related Quality of Life  -  
Dietary assessment 
24-hour dietary recalls 
  - 
Laboratory test 
(WBC, HGB, Hct, platelet, ferritin, 
vitamin D, hsCRP, fecal 
calprotectin) 
   
Crohn’s disease activity index    
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3.1.3 Pre-study Screening and Baseline Evaluation. 
1.  We screened the potential participants based on inclusion and exclusion criteria.  
2. In addition to collecting socio-demographic data, we measured vitamin D status and 
markers of disease activity as the baseline. 
3. We completed standard lab tests at baseline and at safety monitoring time (at week 5 and 9) 
during the trial treatment periods:  
a. Serum: AST, ALT, BUN, Creatinine, 25-hydroxyvitamin D, albumin, calcium, 
alkaline phosphate, glomerular filtration rate (GFR, calculated value from serum 
creatinine). 
b. Urine: calcium, creatinine, urinalysis for hematuria. 
c. Parathyroid hormone (PTH) levels, electrocardiography (ECG). 
3.1.4 Concomitant medication. During the trial, patients continued to receive their regular 
treatment for Crohn’s disease, which may vary from patient to patient. 
3.1.5 Rescue medication and risk management. Patients visited the IBD clinic where they 
received their treatment. Any issue related to the disease was addressed by the medical team, 
including the co-investigators. No adverse events are reported for vitamin D at the doses set in 
the study. However, we regularly checked the patients for any possibility of hypercalcemia, 
which is the main adverse event relate to vitamin D intake. 
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Table 3.2 Safety Measurements. 
 
3.1.6 Measurements 
3.1.6.1 Demographics and socio-economic status. We collected socio-demographic information 
using a modified version of the socio-economic and demographic questionnaire from Canadian 
Community Health Survey (CCHS) 2008. The questionnaire allowed for comparisons with other 
data sets, including socio-economic information for patients with Crohn’s disease in Canada. We 
used the same questionnaire and income level in Saudi Arabia. We collected information on 
patient’s age and sex, region of origin, education, level of income and income resources, and we 
Measurement Frequency 
Timing 
Baseline 
(Week 1) 
Midpoint 
Intervention 
(Week 5) 
End of 
Intervention 
period (Week 9) 
Calcium 3 times    
Phosphate 3 times    
25(OH)D 3 times     
ALT, AST, BUN levels 3 times    
Magnesium 3 times    
Pregnancy test 1 time  - - 
Creatinine 3 times    
Albumin 3 times    
GFR 3 times    
Urinalysis for 
hematuria 
3 times    
PTH 3 times    
ECG 3 times    
 51 
summarized it in four categories using eighteen questions. Table 3.3 shows that household 
income was defined by total income and number of people residing in the home.  
Table 3.3 Household Income.  
Number of 
people in 
household 
Lowest 
income 
level 
Lower-middle 
income level 
Upper-middle 
income level 
Highest 
income 
1 to 2 < $15,000 $15,000- $29,999 $30,000- $59,999 ≥ $60,000 
3 to 4 < $20,000 $20,000- $39,999 $40,000- $79,999 ≥ $80,000 
5 and more < $30,000 $30,000- $59,999 $60,000- $79,999 ≥ $80,000 
* Household income was defined by total income and number of people residing in the home 
Note. (Statistic of Canada, 2008) “Community Health Survey cycle 2.2 (2004)”.  
 
3.1.6.2 Dietary assessment. Three 24-hour dietary recalls were collected twice from each patient 
at the baseline and at the end of the intervention. The first 24-hour dietary recall obtained a 
patient’s exact food intake, while the average dietary intake from the three 24-hour dietary recalls 
that we collected on different days of the week, each a few days apart, allowed us to estimate the 
patient’s usual intake (Gibson, 2005). We conducted the first 24-hour dietary recall in person on 
the day of measurement, while we administered the following five 24-hour dietary recalls over 
the phone or in-person, based on the patient’s convenience. The 24-hour recall was conducted by 
a nutrition research assistant using the USDA Food Models for Estimating Portions. We used a 
multiple-staged approach for the recalls. First, we asked the patients to report all food and 
beverages consumed in the last 24 hours without interruption. Next, we asked the patients about 
foods they may have forgotten, such as snacks. We then asked the patients for detailed 
information about time, occasion, and portion size, using food models. Then we reviewed the 
recall with the patient to ensure that no food or beverages were forgotten. Finally, we had the 
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patients report any supplements they consumed, with specific brand and amount (Conway, 
Ingwersen, & Moshfegh, 2004; Conway, Ingwersen, Vinyard, & Moshfegh, 2003).  
We entered the information that we gathered into the diet analysis program (Food 
Processor Nutrition and Fitness Software version 10, produced by Esha Research) to obtain each 
patient’s intake of food groups and specific nutrients. This program contains more than 4,000 
Canadian food items, and the nutrient values correspond to the Canadian Nutrient File created by 
Health Canada. If the appropriate food were not in the list, we chose the American food items 
nearest to it in nutrient content. In Saudi Arabia, we broke recipes down to basic foods before we 
entered the data into the food processor. 
 We exported the data to Excel spreadsheets for each participant, and we averaged the 
three recalls to obtain the patient’s usual intake. We examined the results to determine if all of the 
patients in the study met the Eating Well with Canada’s Food Guide recommended servings for 
vegetables and fruits, dark green and orange vegetables, grain products, meat and alternatives, 
and milk and alternatives. We did this by comparing the amount of servings per day to the Eating 
Well with Canada’s Food Guide. The patients’ dietary intakes of energy, calcium, zinc, iron, 
sodium, and vitamins (D, B6, and B12) were analyzed in exactly the same way. We followed a 
similar approach for Saudi Arabian participants. 
We used the Canadian version of the Healthy Eating Index (HEI) to assess the quality of 
the patients’ overall diet. The HEI was originally established by the United States Department of 
Agriculture (USDA), using a score of the sum of 10 dietary components, with a maximum of 
100. Each component of the index has 0 to 10 scores and was adapted according to Eating Well 
with Canada’s Food Guide (CDC, 2010; USDA, 2013). The components are total grain, whole 
fruit, vegetable and fruit, dark green and orange vegetables, meat and alternatives, milk and 
alternatives, saturated and unsaturated fat intake, sodium, and other food. The scoring points for 
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each component are based on age and sex recommendations from Eating Well with Canada’s 
Food Guide (Garriguet, 2009). The HEI assesses the quality of the diet and gives a score 
according to three categories: <50= poor diet, 50–80 = needs improvement, and > 80 = good diet 
(CDC, 2010). 
3.1.6.3 Health status. Anthropometric measurements included height, weight, body mass index 
(BMI), and waist circumference at baseline. We used an electronic scale after calibrated to 
measure patients’ weight in kilograms, and recorded the measurement to the nearest 100 gram for 
weight. We used a stadiometer with a sliding head plate to measure the patients’ height. The 
participants removed their shoes and any bulky clothing and then stepped on the platform and 
stretched their backs as much as possible. We recorded the readings in centimetres to the nearest 
millimetre.  
Body mass index (BMI) is calculated using the height and weight for each patient. BMI is 
identified as weight divided by height squared (kg/m
2
). We assessed the body mass index of each 
patient according to World Health Organization (WHO) classifications: <18.5 underweight, 
18.5–24.9 normal, ≥ 25 overweight, and ≥ 30 obese (WHO, 2014). We evaluated each patient’s 
waist circumference to the closest 0.1 cm with the patient in the standing position, using a steel 
flexible tape around the patient’s abdomen at the highest point (the iliac crest) at minimal 
respiration (Li, Ford, Mokdad, & Cook, 2006). We calculated the waist to height ratio by using 
height and waist circumference. 
We evaluated the patients’ general physical activities by using the Canadian Health 
Measures Survey Cycle 2 Physical Activity Questionnaire, 2011. The questionnaire included six 
questions related to leisure activity and time spent on physical activity at work. It was a recall for 
past 3 months that defines physical activity to be any activity that was done during past 3 months 
(Statistic of Canada, 2012). To determine the patient’s activity level, we calculated the physical 
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activity index by the energy expenditure (EE) for each activity, which is expressed by 
multiplying the average duration of each activity (in hours) expended in leisure time (D), the 
metabolic equivalent value (MET) for each activity (kcal/kg/d), and the number of times the 
individual participated in each activity. We then divided the value by number of days in 3 months 
(91 days). Then we estimated the physical activity index by summing the EE for each activity. 
We categorized individuals based on PAI values: inactive < 1.5 kcal/kg/d, moderately active 1.5 
to <3 kcal/kg/d, and active ≥3 kcal/kg/d (CCHS, 2004).  
We used the Health-Related Quality of Life (HRQOL) or IBD questionnaire from the 
McMaster Industry Liaison office at McMaster University to evaluate the health-related quality 
of life for patients with IBD. This questionnaire is validated and a reliable tool to measure 
HRQOL in adults with IBD. It is a self-administrated version and consists of 32 questions 
classified into four dimensions: bowel, social, systemic, and emotional. This questionnaire is 
recall over the last 2 weeks. A score of 1 indicates the poorest condition and a score of 7 indicates 
the best condition (Flintbox, 2010). 
3.1.6.4 Disease biomarkers and vitamin D levels. We used different indicators to evaluate the 
disease activity in patients with CD. Biomarkers of disease activity include C-reactive protein 
and fecal Calprotectin and inflammation, such as complete blood count and albumin. A 
subjective tool, Crohn’s disease activity index (CDAI) was used to estimate the patient’s disease 
activity. Personnel in the laboratory at each hospital site determined serum vitamin D levels 
measuring 25-hydroxyvitamin D levels. They measured the patients at the beginning of the study, 
after 9 weeks, and 2 months from week 9. We then compared the results to the optimal level that 
is required (Appendix Table 3.4).  
 55 
3.1.7 Data Analysis 
We summarized data in tables at three different points in time. We were unable to conduct 
a descriptive analysis because of the small sample size that we had. We then presented the results 
as a case series.  
3.1.8 Efficacy Variables and Analysis  
1.  Primary outcome: We examined the changes in disease activity in patients in the 
different groups that received three different doses of vitamin D. The disease activity 
indicators are Calprotectin, hsCRP and CDAI.  
2.  Secondary outcomes: nutritional status determined by using 24-hour dietary recall, and 
health-related quality of life, which were determined by inflammatory bowel disease 
questionnaire (IBDQ), respectively. This questionnaire was purchased from the website 
FLINTBOX (Flintbox, 2010). 
3.1.9 Premature Withdrawal/Discontinuation Criteria 
1.  Voluntary withdrawal 
2.  Any indication of potential adverse event due to the intervention 
3.  Major health issues related to Crohn’s disease, such as surgery, which may make 
continuous enrolment in the study challenging 
4.  Pregnant women are excluded from our study. We test for pregnancy at the baseline to 
ensure that none of the female participants were pregnant. If a female participant becomes 
pregnant, she should be withdrawn from the study, as indicated in the consent form. 
3.1.10 Safety Variables and Analysis  
We did not face any adverse events related to vitamin D in the described doses. However, 
to avoid hypercalcemia as the main potential adverse event, in addition to monitoring the relevant 
symptoms, we collected blood vitamin D status, total serum calcium corrected for albumin level, 
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blood urea nitrogen, and creatinine concentrations (renal function) at the baseline, mid-point, and 
end of the intervention week 9. 
3.1.11 Ethics 
We obtained ethics approval from University of Saskatchewan Research Ethics Board 
(Bio# 13-180) in August 2013 and we extended the study to 1 year, with an ethics date of July 
2014. Health Canada approved the therapeutic products directorate in August 2013, and 
Saskatoon Health Region gave university ethics approval in March 2014. The College of 
Medicine at King Saud University and King Khalid University Hospital in Riyadh, Saudi Arabia, 
approved the ethics documents (Bio13-1048) in February 2014. We completed the certificate of 
training biosafety, laboratory safety, and (TCPS 2: CORE) tri-council policy statement “Ethical 
conduct for research involving humans” at the University of Saskatchewan in 2013. (Appendix 8)  
We faced many obstacles in recruiting participants at each site, including a small number 
of initial participants, as well as participants who withdrew, and participants who were missing 
during the follow-up. Over a year, there was a small number of patients (n=11) who participated 
in the study (Saskatoon (n=3) and Riyadh (n=8)). Due to the small sample size, we present the 
results of study phase I as a case series. We decided to conduct a retrospective cohort study called 
study phase II to determine the association of vitamin D and disease activity in patients with CD. 
3.2 Study Phase II 
3.2.1 Design, Study Site, Data Source, and Ethics Approval  
This phase contains a retrospective cohort study of approximately 201 patients with 
Crohn’s disease. We extracted the data from medical charts at the IBD clinic of the Royal 
University Hospital in Saskatoon, Saskatchewan, Canada. The study objective was to determine 
the association between vitamin D status and disease activity in a cohort of patients with CD. The 
biomedical research ethics board (#Bio 14-161) at the University of Saskatchewan and the 
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Saskatoon Health Region approved the ethics documents during the summer of 2014. I completed 
a McMaster Certificate of Completion for completing the tutorial for researchers conducting a 
retrospective review of health records in June 2014.  
3.2.2 Data Collection Strategies 
We requested username and password to access the medical charts at Royal University 
Hospital. We collected the data from July to August 2014 and entered them directly into a 
password-protected Excel spreadsheet. We then stored the data collection file in a university 
network JADE file for Dr. Vatanparast. The data items include age, sex, disease duration, current 
medications and supplements, history of surgery, Harvey-Bradshaw Index (HBI) scores, and 
blood test (e.g. hsCRP and 25(OH)D). The season of measurements was also taken into account. 
I extracted all available data and entered them into the excel spreadsheet, and then divided into 
three different points in time (first visit, midtime visit, last visit). We describe specific details 
about the variables used in Table 3.5. 
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Table 3.5 Variables Used in the Data Analysis. 
 
3.2.3 Statistical Analysis 
We used descriptive statistics to summarize the data as means and standard deviation 
(SD) for continued variables and percentages for categorical variables at three time points. I 
completed the descriptive analysis using SPSS Version 22 (IBM 2014). We conducted a non-
parametric test Kruskal-wallis post hoc to test the significance of variables between time points 
and know which group differ from other. For analytical analysis, we used generalized estimating 
equations (GEE). GEE is a convenient approach to estimate the possible unknown correlation and 
Variable Type Description 
Age Continues At each time points 
Sex Categorical Male , female  
Disease duration Continues Duration of CD from the day of diagnosed 
Times Categorical 
Time 1 = first visit , Time 2= 8 months 
(mean of number of months from the first 
visit), Time 3= last visit 
months Continues Number of months from the first visit 
HBI score 
Continues/ 
Categorical 
1. Remission < 5 
2. Active disease ≥ 5 
History of surgery Categorical Yes , No  
hsCRP level 
Continues/ 
Categorical 
1. low risk <1 
2. Intermediate risk between 1-3 
3. High risk > 3 
25(OH)D level Categorical 
1. Vit D deficient  <29 nmol/L 
2. Vit D insufficient 29-50  nmol/L 
3. Vit D Adequate 51-74  nmol/L 
4. Vit D Optimal >75  nmol/L 
Vitamin D 
supplementation 
Continues Amount of vitamin D doses  
Season Categorical 
1. April to Sep 
2. Oct to Mar 
Corticosteroid drugs use Categorical Yes , No 
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changes between outcomes over time that have an impact on covariates (Liang & Zeger, 1986). 
This test includes all available data (completed and missing data) in an unbalanced design; it is 
more efficient and has a higher power with a smaller sample size or lower number of repeated 
measurements ANOVA (Ma, Mazumdar, & Memtsoudis, 2012). Since the long forms of the data 
were being used, only observations that have missing subjects are lost, not all measurements 
(Twisk, 2013).  
In this current study, the exchangeable correlation matrix between hsCRP, the main factor 
serum vitamin D, and several predictors were evaluated by GEE at three time points of 
measurements. The predictors for HBI score and hsCRP were age, sex, three of the 
measurements, vitamin D level, disease duration, use of corticosteroid, surgery, and season. 
Analytical analyses were conducted by STATA/SE 11; StataCorp and alpha was set at 0.05. We 
used GEE exchangeable correlation matrix with a hsCRP variable using the following model: 
(xtgee hscrp age sex disease_duration i. times surgary i. vitd_cat4 cs season, family(gaussian) 
link(identity) corr(exchangeable) eform). To evaluate the association between vitamin D and HBI 
in presence of other covariates, GEE with logistic regression was used with cut-off HBI score as 
categorical variable using the following model:  (xtgee hbi_2cat age sex disease_duration i. times 
surgary i. vitd_cat4 cs season, family(binomial 1) link(logit) corr(exchangeable) eform).  
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CHAPTER 4 
4 RESULTS 
4.2 Study Phase I (Case Series) 
4.1.1 Subject Characteristics  
We recruited 11 adults from Royal University Hospital in Saskatoon and King Khalid 
University Hospital in Riyadh. We deemed these subjects eligible to participate in the study. Two 
subjects had withdrawn themselves on the first day of the study and thus are not included. One 
further subject had lung cancer and withdrew during the follow-up. Two subjects were missing 
from the follow-up. The following results are presented for nine participants, six from Saudi 
Arabia and three from Saskatoon. Figure 4.1 study design. 
Socio-demographic data are presented for nine patients. Their age was ranged from 19 to 
60 years old, five males and four females. All participants were educated except for one case 
from Saskatoon. Saudis’ participants were Arab and Canadian participants were Caucasian. Case 
5 from Saskatoon had upper-middle income level according to Statistic Canada income 
categories (Statistic of Canada, 2008). Three participants from Saudi had lowest income level and 
one had lower- middle-income category according to Statistic Canada, 2008 Appendix table 4.1 
presented Socio-demographic characteristics.  
In general, among nine participants, four patients had normal weight, three patients were 
underweight, and two were overweight. Physical activity index indicates that eight patients have 
sedentary lifestyle and only one patient was moderately active. Health-related quality of life was 
improved in three patients comparing the score at baseline and at followup. According to Healthy 
Eating Index Canada (HEI), at baseline, six patients had poor diet and three patients needed 
improvement in their diet. At week 9 (end of intervention), four patients had poor diet, four 
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patients needed improvement and one patient missed follow up. Comparing both time points, 
HEI was improved in two patients. Vitamin D status and related information are presented in 
Table 4.2 .Table 4.5 shows intake of food groups and HEI. 
Figure 4.1 Study design 
 
4.1.2 Vitamin D and disease status  
Tables 4.2 and 4.3 provide information on vitamin D status and disease activity 
throughout the study. Among the group who were receiving vitamin D with the dose of 400 
IU/day, two patients had vitamin D deficiency and two patients had vitamin D insufficiency at 
the baseline. Vitamin D levels were improved at week 9, however declined at follow-up. The 
hsCRP levels were decreased in three patients while five patients had increased hsCRP levels at 
week 9 with concurrent changes in other factors such as medication, dietary intake and physical 
activity. In addition, vitamin D deficiency can concurrently be seen with high disease activity 
Study Phase I 
Vitamin D 400 IU/d 
Saskatoon: 1 
Riyadh :3 
withdrew:1 
missing follow up: 1 
analysed: 2 
Vitamin D 2000 IU/d 
Saskatoon:1 
Riyadh:2 
withdrew:1 
missing follow up: 1 
analysed: 1 
Vitamin D 10,000 IU/d 
Saskatoon:1 
Riyadh:3 
withdrew: 0 
missing follow up: 1 
analysed: 3 
Saskatoon 
(n=3) 
Riyadh 
 (n=8) 
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level; however, high level of vitamin D supplementation coincides with decreased hs-CRP level. 
In one case with available Calprotectin level, it decreased significantly from baseline to week 9, 
while vitamin D status increased rapidly from 36.6 to 105.5 nmol/L. There was only one patient 
who received 2000 IU of vitamin D. Her vitamin D level was raised over time while hsCRP level 
decreased in followup. Patients who received 10,000 IU of vitamin D had considerable increase 
in vitamin D levels in week 9, which decreased at followup. However, hsCRP levels were 
slightly increased in week 9 and followup; only one case had decreased hsCRP level at the 
follow-up. Appendix tables 4.7, 4.8, 4.9 and 4.10 present laboratory and safety measurements at 
four time points. Table 4.4 presents Average Dietary Usual Intake of Nutrients Associated with 
IBD at Baseline and Week 9 comparing to RDA 
4.1.3 Case Reports 
4.1.3.1 Case 1. Case 1 was a 60-year-old female with active CD. She was in the diagnosis 
process of hyperthyroidism. No current medication was in place. She was taking a probiotic and 
was assigned to receive 400 IU/d of vitamin D3. We completed baseline measurements during the 
first week of the study and week 9 lab tests with a 2-week delay (week 11). She was overweight 
with moderate physical activity, and her HEI was in the needs improvement category. Her hsCRP 
results were 8.1 mgs/L at baseline and 40.7 mgs/L at week 11, indicating high disease in disease 
activity levels over time. HBI and CDAI were not accurate indicators to estimate the disease 
activity; both indicated inactive disease (remission), and HBI indicated moderate disease at week 
11. Although she was exposed to sunlight 1 to 2 hours daily, she had an insufficient vitamin D 
level (36.6 nmol/L) at baseline. After receiving vitamin D treatment with a dose of 400 IU per 
day, her vitamin D level increased from 36.6 to 105.5 nmol/L. In addition, her vitamin D intake 
from food increased from 122.1 to 4047.2 IU. During her follow-up, Case 1 asked the research 
coordinator if she could withdraw from the study because she was diagnosed with stage IV lung 
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cancer. Due to the lung cancer, the research coordinator advised Case 1 to withdraw from the 
study. 
4.1.3.2 Case 2. Case 2 was a 25-year-old male with active CD. He had a bachelor’s degree, and 
his main source of income was wages at the lowest income level. The disease was located in the 
small bowel (jejunum) and colon (ascending, transverse, descending, and sigmoid). The CD was 
controlled by 5-ASA and Azathioprine. We assigned him to receive 400 IU/d of vitamin D3. We 
completed baseline measurements during the first week of the study, the week 9 lab tests with a 
2-week delay (week 11), and the 2-months follow-up with a 4-month delay (6 months from week 
11). He was an inactive person with a normal BMI, and his HEI was in the poor diet category at 
baseline and then the needs improvement category at week 11. His HRQOL score was 200 at 
baseline and 197 at the follow-up, which indicated good or same level quality of life. His hsCRP 
results were 5.8 mgs/L at baseline, 4.9 mgs/L at week 11, and 0.7 mgs/L at the follow-up, 
indicating a decrease in the disease activity levels over time. HBI and CDAI were not accurate 
indicators to estimate the disease activity. HBI indicated mild disease at baseline and remission at 
the follow-up. Although he was exposed to sunlight 1 to 2 hours daily, he had an insufficient 
vitamin D level (33.0 nmol/L) at baseline. After receiving vitamin D treatment with a dose of 400 
IU per day, his vitamin D level increased from 33.0 to 59.0 nmol/L at week 11. Then his vitamin 
D decreased to 42.5 nmol/L at the follow-up. In addition, his vitamin D level from food improved 
from 30.2 to 58.9 IU.  
4.1.3.3 Case 3. Case 3 was a 21-year-old female with mild to moderate CD. She had a bachelor’s 
degree and the lowest income level. The CD location was in the small bowel and colon 
(ascending, transverse, descending, and rectum). Her doctor placed her on Azathioprine and 
Adalimumab. We assigned her to receive 400 IU/d of vitamin D3. We completed her baseline 
measurements during the first week of the study, the week 9 lab tests at a 2-week delay (week 
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11), and the 2-month follow-up with a 4-month delay (6 months from week 11). She was 
underweight and inactive, and her HEI was in the poor diet category. The HRQOL score 
decreased from 183 at baseline to 152 at follow-up, which indicates a worse quality of life. Her 
hsCRP results increased from 11.6 mgs/L at baseline, 11.8 mgs/L at week 11, and 19.5 mgs/L at 
follow-up. However, her vitamin D level increased from 8.8 to 14.5 nmol/L at week 11 and then 
decreased to 9.8 nmol/L at the follow-up. Vitamin D from food increased from 22.1 to 92.5 IU. 
She was exposed to sunlight for less than 30 minutes daily.  
4.1.3.4 Case 4. Case 4 was a 19-year-old female high school student. She was taking 
Azathioprine drugs and had a perianal fistula. We assigned her to receive 400 IU/d of vitamin D3. 
We completed her baseline measurements and week 9 lab test on time. She was underweight with 
inactive physical activity, and her HEI was in the poor diet category. The hsCRP results were 
10.1 mgs/L at baseline and 8.5 mgs/L at week 9, indicating low disease activity levels over time. 
She was exposed to sunlight < 30 minutes daily, and she had deficient vitamin D levels (12.8 
nmol/L) at baseline. After receiving vitamin D treatment with a dose of 400 IU per day, her 
vitamin D level increased from 12.8 to 36.9 nmol/L. The research coordinator tried to keep in 
touch with Case 4 but she was lost during the follow-up.  
4.1.3.5 Case 5. Case 5 was a 32-year-old female. Her highest grade of education was below grade 
8, her main source of income was wages, and she was in the upper middle-income level. The CD 
location was in the small bowel (terminal ileum and ileocecal valve) and colon (cecum, 
ascending, transverse, descending, and sigmoid). Her doctor placed her on Budesonide, and she 
was taking multivitamins. We assigned her to receive 2000 IU/d of vitamin D3. We completed 
her baseline measurements during the first week of the study, the week 9 lab tests with a 5-week 
delay (week 14), and the 2-month follow-up. She was inactive and overweight, and her HEI was 
in the needs improvement category. The HRQOL score improved from 178 at baseline to 191 at 
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follow-up, which indicates a better quality of life. Her hsCRP results decreased from 12.4 mgs/L 
at baseline, 4.6 mgs/L at week 14, and 0.7 mgs/L at the follow-up. In addition, her vitamin D 
level steady increased from 63.0 to 73.0 nmol/L at week 14 and 89.0 nmol/L at the follow-up. 
Vitamin D from food decreased from 988.6 to 829.4 IU. She was exposed to sunlight for 2 to 3 
hours daily and used sunscreen sometimes. Her Calprotectin measurement levels were 1.99 mg at 
baseline and 1.37 mg at follow-up, which indicated that the inflammation decreased. 
4.1.3.6 Case 6. Case 6 was a 35-year-old male with mild active CD in the small bowel (terminal 
ileum and ileocecal valve) and colon (cecum, ascending, transverse, descending, sigmoid). He 
was treated with Azathioprine and then Budesonide. We assigned him to receive 10,000 IU/d of 
vitamin D3. We completed baseline measurements during the first week and week 9 with a 4-
week delay (week 13). His weight was normal, he had inactive physical activity, and his HEI was 
in the poor diet category at baseline and the needs improvement category at week 14. His hsCRP 
results were 4 mgs/L at baseline and 5.7 mgs/L at week 9, indicating high disease activity levels 
over time. He was exposed to sunlight for 3 to 4 hours daily, and he had deficient vitamin D 
levels (18.6 nmol/L) at baseline. After he received vitamin D treatment with a dose of 10,000 IU 
per day, his vitamin D level increased from 18.6 to 78.0 nmol/L. His vitamin D from food 
improved from 137.4 to 187.2 at week 13. The research coordinator tried to communicate with 
him several times but he was lost during the follow-up.  
4.1.3.7 Case 7. Case 7 was a 25-year-old male with active CD in the small bowel (terminal 
ileum) with perianal abscess. His income was based on wages, and he was in the lowest income 
category. He was an educated person with bachelor’s degree. The CD was treated with 
Infliximab. We assigned him to receive 10,000 IU/d of vitamin D3. We completed his baseline in 
the first week and week 9 lab tests with 1-week delay (week 10) and the 2-month follow-up with 
a 4-month delay (6 months from week 10). He was an inactive person with a normal BMI. His 
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HEI indicated that his diet was in the poor diet category. His HRQOL score improved from 159 
to 188 at the follow-up, which indicates a better quality of life. C-reactive protein levels remained 
the same: 1.2 mgs/L at baseline, 1.2 mgs/L at week 10, and 1.4 mgs/L at follow-up. He lost his 
vitamin D supplements (2 weeks with no vitamin D), and then he asked the research coordinator 
if he could have another bottle. He had vitamin D deficiency (27.3 nmol/L) at the baseline, and 
his vitamin D level increased significantly to 164.9 nmol/L at week 10. Then his vitamin D 
decreased to 120 nmol/L at the follow-up. In addition, his vitamin D level from food improved 
from 46.2 to 78.5 IU. 
4.1.3.8 Case 8. Case 8 was a 28-year-old male with active CD in the small bowel and colon 
(sigmoid, rectum). He was an educated person with a bachelor’s degree, his main income was 
wages, and he was in the lower middle-income level. His doctor prescribed Azathioprine and 
Adalimumab and he was taking multivitamins. He received 10,000 IU/d of vitamin D3. We 
completed his baseline in the first week and week 9 lab tests with a 6-week delay (week 15), and 
the 2-month follow-up with a 2-week delay. He was an inactive person with a normal BMI. The 
HEI indicated that his diet was in the poor diet category. His HRQOL score decreased from 218 
to 203 at follow-up, which indicated a worse quality of life. C-reactive protein levels were 0.53 
mgs/L at baseline and 0.9 mgs/L at week 15, and this increased significantly to 19.8 mgs/L at the 
follow-up. He had an optimal vitamin D level (87.6 nmol/L) at baseline and his vitamin D level 
increased significantly to 138.1 nmol/L at week 15. At the follow-up, vitamin D decreased to 
88.0 nmol/L. His vitamin D level from food was 53.1 IU at baseline and 45.7 IU at week 15. 
Case 8 was exposed to sunlight for less than 30 minutes daily, and sometimes he used sunscreen 
to protect his skin from the strong sunlight. 
4.1.3.9 Case 9. Case 9 was a 24-year-old male with active CD in the small bowel and terminal 
ileum. His income level was upper middle-income level, his income was based on wages, and he 
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was an educated person with a bachelor’s degree. He was treated with Azathioprine. He received 
a high dose of vitamin D3 10,000 IU/d. We completed week 9 measurements on time and follow-
up measurements with a 47-day delay. He was an underweight and inactive person, and his HEI 
showed that his diet was in the poor diet category. Quality of life increased from 161 to 206 at 
follow-up, which indicates a better quality of life. C-reactive protein levels were 12.9 mgs/L at 
baseline, increased in week 9 to 22.8 mgs/L, then decreased significantly to 5.9 mgs/L at follow-
up. He had an optimal vitamin D level (77.9 nmol/L) at baseline and 88.4 nmol/L at week 9. 
During the follow-up, vitamin D decreased to 67.6 nmol/L. His vitamin D level from food was 
59.9 IU at baseline and 123.5 IU at week 9. Case 9 was exposed to sunlight from 1 to less than 2 
hours daily. 
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Table 4.2 Vitamin D Status as 25-hydroxyvitamin D levels and Related Info. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 
Supplement 
use 
Exposure 
to 
sunlight 
Use of 
sunscreen 
Vitamin D 
treatment 
group 
(IU) 
Baseline Week 9 Follow-up 
25(OH)D 
(nmol/L) 
25(OH)D 
(nmol/L) 
25(OH)D 
(nmol/L) 
Case 1 No 1 to < 2 h always 400 36.6 105.5 - 
Case 2 No 1 to < 2 h rarely 400 33.0 59.0 42.5 
Case 3 No <30 min never 400 8.8 14.5 9.8 
Case 4 No <30 min never 400 12.8 36.9 - 
Case 5 multivitamin 2 to < 3 h sometimes 2000 63.0 73.1 89.0 
Case 6 No 3 to < 4 h rarely 10,000 18.6 78.1 - 
Case 7 No None sometimes 10,000 27.3 164.9 120 
Case 8 multivitamin <30 min sometimes 10,000 87.6 138.1 88.1 
Case 9 No 1 to < 2 h sometimes 10,000 77.9 88.42 67.6 
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Table 4.3 Disease Activity Lab Measurements and Indicators throughout the Study. 
 
 
* HBI (Harvey-Bradshaw Index), CDAI (Crohn’s disease activity index), HRQOL (Health-related quality of life).  
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Case 1 0 41 145 8.1 6.39 8 76.6 40.7 1.3 - - - - - 
Case 2 6 88.2 200 5.8 - 3 67.6 4.9 - 3 111.9 197 0.7 - 
Case 3 8 111.2 183 11.6 - 5 73.2 11.8 - 2 82.2 152 19.5 - 
Case 4 0 101.4 190 10.1 - 3 102.4 8.5 - - - - - - 
Case 5 2 130 178 12.4 1.99 3 130 4.6 - 0 50 191 0.7 1.4 
Case 6 7 89.2 153 4 2.47 2 47 5.7 - - - - - - 
Case 7 2 61.2 159 1.2 - 2 49.2 1.2 - 2 61.2 188 1.4 - 
Case 8 1 50 218 0.5 - 0 50 0.9 - 1 69.1 203 19.8 - 
Case 9 2 39 161 12.9 - 11 39.5 22.8 - 2 39.5 206 5.9 - 
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Table 4.4 Average Dietary Usual Intake of Nutrients Associated with IBD at Baseline and Week 9 comparing to RDA 
 
Case Ca (mg) 
(1000)
** 
Fe (mg) Zinc 
(mg) 
Na(mg)
 
(1500)
*
 
Vit D
**
 
(600IU) 
Vit C 
(mg) 
Vit E 
(mg) 
(15)
**
 
Vit B6 
(mg) 
(1.3)
**
 
Vit 
B12(mcg) 
(2.4)
**
 
Sat 
fats 
(g) 
Unsat 
fats 
(g) 
Calories 
 Baseline (RDA or AI)  
Week 9 
Case 1 612.4 6.6 (8) 5.9 (8) 1753.6(1300) 122.1 57.6 (75) 2.9 1.3 (1.5) 2.8 11.7 7.9 1042.4 
1607.7 9.4 7.3 2222.9 4047.2 56.5 3.8 1.5 2.3 13.5 14.4 1458.5 
Case 2 420.8 11.0 (8) 5.6 (11) 2204.8 30.2 69.1 (90) 1.9 0.6 1.9 29.0 13.3 1708.7 
441.3 6.9 7.5 1135.0 58.9 86.9 2.0 1.1 1.8 10.9 9.8 1401.7 
Case 3 431.6 10.6 (8) 8.8 (8) 2047.7 22.1 0.7 (75) 54.7 1.9 1.0 18.1 22.8 1776.3 
344.2 8.0 6.4 3216.0 92.5 55.9 1.0 0.8 3.0 20.1 18.2 1644.1 
Case 4 496.9 10.7(18) 5.0 (8) 2091.8 75.0 14.7 (75) 2.2 0.9 1.9 19.9 9.6 1168.6 
Case 5 1550.0 21.0(18) 10.7 (8) 2163.3 988.6 150.9 (75) 8.6 3.6 13.1 33.0 16.3 1964.5 
969.7 16.2 10.5 1406.6 829.4 85.5 12.1 3.9 6.3 17.3 15.6 1504.8 
Case 6 998.7 12.7 (8) 6.8 (11) 3927.3 137.4 120.8 (90) 1.8 1.2 2.1 31.9 7.5 1812.1 
796.0 26.7 11.9 3097.5 187.2 6.5 0.8 1.7 4.1 16.4 8.3 1612.0 
Case 7 239.9 10.3 (8) 12.9(11) 2072.5 46.2 79.3 (90) 3.7 1.1 3.9 21.7 22.1 2231.6 
453.3 6.3 8.6 1183.2 78.5 10.1 1.6 1.1 3.0 18.2 16.1 1850.5 
Case 8 246.9 7.4 (8) 7.9 (11) 1116.1 53.1 40.7 (90) 3.7 1.3 1.4 18.3 13.4 941.1 
375.0 7.9 3.9 2124.7 45.7 47.7 10.3 1.2 0.9 14.7 18.1 1797.9 
Case 9 351.9 7.1 (8) 5.4 (11) 1482.4 59.9 4.2 (90) 1.2 1.0 0.9 12.7 9.3 1306.9 
500.5 7.0 3.6 2942.8 123.5 7.4 0.9 0.6 1.5 11.3 4.7 1104.2 
*Average dietary usual intake was derived from the average of 24 hours dietary recalls. *Adequate intake (AI) **RDA 
* Nutrients usual intake was comparing with RDA for healthy people from the Institute of Medicine.
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4.2 Study Phase II (Retrospective Cohort) 
4.2.1 Descriptive Analysis  
We present the descriptive results for the retrospective data for (n=201) patients with 
Crohn’s disease at Royal University Hospital, Saskatoon, SK. Canada. Table 4.11 and 4.12 
summarize the descriptive characteristics for the retrospective data. 
4.2.1.1 Socioeconomic, demographic, disease duration, and surgery and corticosteroids. 
Table 4.11 shows Sex distribution was 42.3% male and 58.7% female with mean age of 
40.2±15.2 y, 40.8±15.2 y and 41.5±15.1 y at three time-points (time 1, time 2, and time 3). The 
number of months from the first visit was 8.2±5.5 month for the second visit and 15.3±6.6 month 
for the third visit. Mean of CD duration at the first visit was 9.7 years. History of surgery was 
reported in 35.8%, 37.3% and 39.4% at three time-points respectively. Only 19.4% patients were 
placed on corticosteroids in the first visit and 14.3% in the last visit.  
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 Table 4.11 Descriptive Characteristics for the Retrospective Cohort Data Socioeconomic 
Demographic, Disease Duration, Surgery and Corticosteroids Variables 
 
 
*Age and number of months from the first visit presented as mean ± SD 
  
Variables Time 1 Time 2 Time 3 
Age (y)  (n=201) 40.2±15.2 40.8±15.2 41.5±15.1 
Sex 
Male 
Female 
(n=201) 
83 (41.3) 
118 (58.7) 
(n=201)  
83 (41.3) 
118 (58.7) 
(n=201)  
83 (41.3) 
118 (58.7) 
Number of months from the 
first visit (months) 
        - 8.2±5.5 15.3±6.6 
History of surgery 
Yes 
No 
(n=201) 
72 (35.8) 
129 (64.2) 
(n=201) 
75(37.3) 
126 (62.7) 
(n= 180) 
71 (39.4) 
109 (60.6) 
Disease duration (y) 
(n=162) 
9.7±9.6 
(n=162) 
10.5 ±9.6 
(n=139) 
11.2±9.8 
Corticosteroids  
Not using corticosteroids 
Using corticosteroids 
(n=196)  
158 (80.6) 
38 (19.4) 
(n=196)  
162 (82.6) 
34 (17.3) 
(n=175)  
150 (85.7) 
25 (14.3) 
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4.2.1.2 Vitamin D status. The mean serum vitamin D level was significantly different between 
time1 and time 3 (p= .04). At the baseline measurement, the mean 25-hydroxy vitamin D was 
58.2±30.0 nmol/L: twenty-six percent of the patients had optimal levels, 30% had adequate 
vitamin D, 26% had insufficient levels, and 18% of the patients had a deficient vitamin D status. 
Vitamin D doses were reported in 48 patients, with a mean of 1629.1±1190.7 IU, and most of 
them were taking a daily vitamin D supplements up to 1,000 IU as a minimum dose. One 
hundred and sixteen patients had their serum vitamin D measured between April to September, 
and eighty-six patients had their measurement between October to March.  
 At the midpoint measurement ( time 2), the mean serum vitamin D status was 60.1±31.2 
nmol/L: Thirty-one point three percent had optimal levels, 31.3% patients had insufficient levels, 
22.1% patients had adequate levels, and 15.2% of patients were vitamin D deficient. One hundred 
and seven patients were having their measurements between October to March.  
During the final visit, 66 patients had vitamin D results with the mean of 74.5±42.6 
nmol/L: Forty-three point nine percent of patients had optimal levels of vitamin D, 24.2% 
patients had adequate levels, 18.1% patients had insufficient vitamin D levels, and 13.6% patients 
had vitamin D deficiency. Vitamin D supplements were used by only 47 patients (28.0 %) with 
the mean intake of 2085.1±1501.1 IU. Most patients had their last visit (114 from 168 CD 
patients) between April to September. 
4.2.1.3 Disease biomarkers (CRP) and HBI scores. The mean of the hsCRP test varied 
significantly between time 1 and time 3 (p=.001). During the first visit, 192 patients had serum 
hsCRP with a mean of 13.0± 22.3 mgs/L, and 55.7% of them had high levels of hsCRP. Among 
patients who reported their HBI scores (n=187); 3.2% had a sever disease, 31% were mild 
disease, 33.1% had a moderate disease and 32.1% were in remission. During the second visit, 
48.2% of patients had very high levels of hsCRP, 30.2% had moderate level and 21.5% had low 
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levels of hsCRP. The mean of the hsCRP levels decreased significantly (p=.001) from the first 
visit to the third visit, 13.0± 22.3 mgs/L to 7.2±15.4 mgs/L, respectively. Of the patients tested, 
38.6% had high levels of hsCRP at Time 3. Close to half of patients (n=35 from 67 patients) were 
in remission based on their HBI score. Table 4.12 shows descriptive characteristics for the 
retrospective cohort data for vitamin d status, dosage and disease activity variables. 
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Table 4.12 Descriptive Characteristics for the Retrospective Cohort Data for Vitamin D Status, 
Dosage and Disease Activity Variables 
 
  
Variables Time 1 Time 2 Time 3 
Serum 25(OH)D status 
 ( nmol/L) 
(n= 116) 
58.2± 29.9 
(n= 118) 
60.1± 31.2 
(n= 66) 
74.5± 42.6 
Vitamin D categories 
Deficient 
Insufficient 
Adequate 
Optimal 
(n=116)  
21 (18) 
30 (26) 
35 (30) 
30 (26) 
(n=118)  
18 (15.2) 
37 (31.3) 
26 (22.1) 
37 (31.3) 
(n=66)  
9 (13.6) 
12 (18.1) 
16 (24.2) 
29 (43.9) 
Vitamin D doses (IU) 
(n= 48) 
1629.1±1190.7 
(n= 56) 
2095.3±1860.1 
(n= 47) 
2085.1±1501.2 
hsCRP ( mgs/L) 
(n= 192) 
13.0± 22.3 
(n= 195) 
11.2± 28.9 
(n= 158) 
7.2± 15.4 
hsCRP  categories 
Low risk 
Intermediate risk 
High risk 
(n=192)  
35 (18.2) 
50 (26) 
107 (55.7) 
(n=195)  
42 (21.5) 
59 (30.2) 
94 (48.2) 
(n=158)  
49 (31) 
48 (30.3) 
61 (38.6) 
HBI score 
(n=187) 
7.0±4.4 
(n=90) 
6.3±4.8 
(n=67) 
6.0±5.2 
HBI score categories 
Remission 
Mild disease 
Moderate disease 
Severe disease 
(n= 187)  
61 (32.6) 
58 (31) 
62 (33.1) 
6 (3.2) 
(n= 90)  
40 (44.4) 
17 (18.8) 
29 (32.2) 
4 (4.4) 
(n=67)  
35 (52.2) 
10 (14.9) 
18 (26.8) 
4 (5.9) 
Season 
April to September 
October to March 
(n=201)  
115 (57.2) 
86 (42.8) 
(n=201)  
94 (46.8) 
107 (53.2) 
(n=168)  
114 (67.8) 
54 (32.1) 
  
76 
4.2.2 Results from Statistical Modeling 
4.2.2.1 High sensitivity C-reactive protein (hsCRP). Table 4.13 shows the estimates of the 
model parameters with 95% confidence intervals along with results of the tests for their statistical 
significance. Out of eight predictor variables included in the model, only three predictors showed 
statistically significant association with hsCRP level. These statistically significant predictors of 
hsCRP level were Corticosteroids, time of measurement, and vitamin D categories. Age, sex, 
disease duration, season, and surgery did not show a statistically significant effect (P > .05) on 
hsCRP level. 
The estimated coefficient for Corticosteroids is Coef. = 7.2 with a 95% confidence 
interval (1.0, 13.5). Time of visit also showed a significant association with hsCRP. In the last 
visit, patients showed a significantly lower mean hsCRP level compared to first visit (Coef. = -
9.2, p =.013). However, no significant difference in hsCRP level was found between the first visit 
and the second visit, which was measured approximately 8 months after the first visit. Vitamin D 
status also showed a significant association with hsCRP level. Vitamin D status was included in 
the model as a categorical variable: deficient (reference) insufficient, adequate and optimal 
levels. All the three categories showed significantly lower mean hsCRP level compared to 
deficient vitamin D category (p <.05). The insufficient vitamin D category had a Coef. = 12.8 
units lower, while the adequate vitamin category had a Coef. =7.8 units, and the optimal vitamin 
D category had a Coef. = 9.8 units of hsCRP level lower compared to the deficient vitamin D 
category. In summary, the deficient vitamin D category had a significantly higher hsCRP level 
than all of the other three categories of vitamin D status. 
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Table 4.13 Factors Associated with hsCRP Levels among Crohn’s Disease Patients 
 
hs-CRP continues variable 
Coefficient 
(Coef.) 
95% Confidence 
Interval 
*
P-value 
Age (y) -0.1 (-0.3, 0.1) 0.449 
Sex -4.5 (-11.4, 2.3) 0.194 
Disease duration (y) 0.2 (-0.1, 0.6) 0.185 
Corticosteroids 7.2 (1.0, 13.5) 0.023 
Season 3.7 (-0.6, 8.1) 0.092 
Surgery 0.1 (-7.8, 8.2) 0.968 
Times 
Time 2 
           Time 3 
 
-2.7 
-9.2 
 
(-7.2, 1.6) 
(-15.1, -3.4) 
 
0.224 
0.002 
Vitamin D categories 
Insufficient 
Adequate 
Optimal 
 
-12.8 
-7.8 
-9.8 
 
(-19.8, -5.8) 
(-14.9, -0.7) 
(-17.6, -2.0) 
 
0.000 
0.031 
0.013 
*P value was determined using GEE test. P<0.05 was considered to be significant.  
 
4.2.2.2 Harvey-Bradshaw Index indicator category (HBI). GEE, binary logistic regression 
was used to explore possible association between selected predictor variables and likelihood of 
active disease (cut-off ≥ 5 score). Table 4.14 shows the estimates of odds ratio for each predictor, 
along with results of the test for their significance. Three predictor variables—(i) use of 
corticosteroids, (ii) time of visit and (iii) vitamin D status—had a significant effect on the odds of 
active disease.  
The use of corticosteroids had an odds ratio estimate of 5.5. Time of visit was 
significantly associated with active disease. The second visit, 8 months after the first visit, had an 
odds ratio of 0.4. This means that the odds of having an active disease during the second visit 
were 58% lower than odds at the first visit. This odds ratio is found to be statistically significant 
  
78 
(OR = 0.4, p = .025). The last visit had an odds ratio of 0.2. This means that odds of having 
active disease during the last visit were 71% lower than odds at the first visit (OR = 0.2, p = 
.014). 
Vitamin D status also associated with disease activity. However, only insufficient 
category was significantly associated with HBI. The insufficient category had an odds ratio 
estimate of 3.4. For those with vitamin D insufficiency, the odds of having active disease was 3.4 
times higher than the reference group (vitamin D deficient) while the vitamin deficient 
participants had high hsCRP. Adequate and optimal vitamin D status did not report any 
significant difference in the odds of having an active disease compared to deficient vitamin D 
status. This indicates the importance of using more objective measure of disease activity in CD 
patients. 
To summarize, statistical analysis of data about high sensitivity C- reactive protein test 
and HBI categories indicated that the use of corticosteroids, time of visit, and vitamin D status 
had significant influence on the outcome variables (hsCRP level and HBI Category). 
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Table 4.14 Factors Associated with HBI Scores among Crohn’s Disease Patients 
 
HBI with 2 Categories 
Odds Ratio 
(OR) 
95% Confidence 
Interval 
*
P-value 
Age 0.9 (0.9, 1.0) 0.778 
Sex 0.7 (0.3, 1.6) 0.505 
Disease duration 1.0 (0.9, 1.0) 0.910 
Corticosteroids 5.5 (2.1, 14.3) 0.000 
Season 0.9 (0.4, 1.9) 0.916 
Surgery 0.6 (0.2, 1.6) 0.398 
Times 
Time 2 
           Time 3 
 
0.4 
0.2 
 
(0.2, 0.8) 
(0.1, 0.7) 
 
0.025 
0.014 
Vitamin D categories 
Insufficient 
Adequate 
Optimal 
 
3.4 
1.0 
2.7 
 
(1.0, 10.8) 
(0.3, 2.9) 
(0.9, 8.2) 
 
0.034 
0.919 
0.072 
*P value were determined using GEE logistic regression test. P<0.05 were considered to be 
significant.  
- HBI scores with two cut- off categories (0= < 5 remission and 1= ≥5 active disease).   
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CHAPTER 5 
5. DISCUSSION 
When this study was designed, there was one unpublished study conducted in the USA to 
examine the effect of a daily high dose 10,000 IU of vitamin D3 on Crohn’s disease patients. To 
our knowledge, there are only a few published studies that have measured vitamin D levels in CD 
patients in Canada and Saudi Arabia. There have been no clinical trials in Saudi Arabia that 
explore the relationship between CD and high dose of vitamin D supplementation. We used 
different studies to address the research question. Thus the main objectives of this thesis were, 
first to determine the effect of vitamin D supplementation on disease activity in Crohn’s disease 
patients in Canada and Saudi Arabia. Along with vitamin D, quality of life, socio-demographic 
and physical activity, vitamin D status, disease biomarkers, and dietary assessment as major 
determinants of health were examined. Secondly, the association between vitamin D status and 
disease activity in a cohort of CD patients in Saskatoon, Canada was investigated. This study 
examined the main outcome disease activity (hs-CRP and HBI) with the main factor “vitamin D 
status” and other potential predictors such as disease duration, using corticosteroids, surgery, age, 
sex and diet. All of these factors are discussed in detailed below.  
5.1 Vitamin D status, Supplementation 
It was hypothesized that patients who are suffering from Crohn’s disease are at risk of 
vitamin D deficiency. In both studies, we reported high rates of vitamin D deficiency/ 
insufficiency among active CD patients; the prevalence of vitamin D deficiency increased during 
the winter season. Most phase I cases had vitamin D deficiency/ insufficiency at baseline 
measurements. The mean of serum vitamin D concentration in our cohort was 58.2 nmol/L at 
first visit. Phase II study found a 44% of  a cohort of CD patients had serum vitamin D below 50 
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nmol/L. Our resulst are in agreement with other studies indicating vitamin D deficiency are more 
common among IBD patients than general population (Gaidos, Sultan, Dahl, & Valentine, 2011). 
Studies have shown a 62% of IBD patients had vitamin D deficiency and 88% of IBD patients 
(56 CD and 45 UC) had plasma vitamin D below 75 nmol/L (Alkhouri et al., 2013; Leslie et al., 
2008a). Comparing active CD patients with those in clinical remission, active disease patients 
had lower serum vitamin D concentrations (Ham et al., 2014; Jørgensen et al., 2013).  
It was hypothesized that providing vitamin D supplementation in doses higher than the 
RDA (> 600 IU/d) reduces the disease activity in Crohn’s disease cases. The results of Phase 1 
study are not conclusive. While the disease activity indicators were decreased in three cases, six 
cases had increased disease activity levels perhaps due to other factors such as surgery and 
disease complications. A study shows a daily vitamin D3 supplement up to 400 IU did not 
significantly increase vitamin D status in participants with CD. Vitamin D3 supplementation up to 
2,000 IU/d for 6 months elevated plasma 25(OH)D above 30 ng/mL more effectively than 400 
IU/d, but both achieved the cutoff of 20 ng/mL at 6 months (Wingate et al., 2014). A study shows 
a daily vitamin D2 supplementation up to 2,000 IU for 6 weeks was insufficient to maintain the 
optimal levels in children and adolescents with IBD, while 2000 IU/day of vitamin D3 and 50,000 
IU/week were did (Pappa et al., 2014).  
Boothe et al., (2011) found the doses of 10,000 IU had significant results in improving 
serum vitamin D when comparing 8 week (54.4±22.8) and after 26 week of treatment (64.2 ± 
29.8) than 1000 IU/d. In our cohort, vitamin D levels improved significantly (p=.005) from 
baseline to the last visit (over 15 months) with decreasing the disease activity level hs-CRP 
significantly. A significant increase in vitamin D concentrations over 15 months was found in our 
CD cases who were receiving vitamin D supplement with mean intake of 1629 IU/d. In Phase I 
(case series), all our cases who were receiving 10,000 IU/d showed increased vitamin D 
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concentrations at week 9 (end of intervention) then declined at the follow-up. We observed 
different results from vitamin D supplementations and disease activity levels, and this limit us to 
draw an overall conclusion in Phase I study. 
5.2 C- reactive protein, Disease activity index, and Health related quality of life 
 
High sensitivity C-reactive protein was significantly associated with vitamin D levels 
among CD patients. Active Crohn’s patients, based on endoscopy results, had high levels of 
hsCRP and vitamin D plasma below the optimal concentrations (< 75 nmol/L). All Phase I cases 
had hs-CRP levels above of 1 mgs/L at baseline. Only three cases showed decreased hsCRP 
levels after taking vitamin D supplement for 9 weeks. Phase II study have been shown vitamin D 
concentration was significantly associated with hsCRP level compared with deficient vitamin D 
category (p <.05). The disease activity indicator (hsCRP) decreased significantly over 15 months 
(p=0.001), while vitamin D concentration increased significantly (p= 0.04) in our cohort. In some 
cases in Phase I study, we found patients who were taking vitamin D supplement had increased 
vitamin D levels and improved their disease activity by decreasing hsCRP levels at 9 weeks. The 
hsCRP levels were increased in some cases perhaps because of other factors such as  cancer and 
surgery. Use of corticosteroids had a positive association with hsCRP levels in our cohort (p= 
0.023, Coef. 7.2). Steroids prescribed for short term to reduce the inflammation, however the risk 
factor for long term corticosteroid use including decrease calcium absorption and vitamin D 
metabolism are contribute to develop osteoporosis (Buckley, Leib, Cartularo, Vacek, & Cooper, 
1996; De Sevaux, Hoitsma, Corstens, & Wetzels, 2002). In addition, all vitamin D categories 
(deficient as reference category) have shown a negative association with hsCRP levels. A study 
found oral vitamin D3 supplementation up to 1200 IU/d for three months significantly increased 
vitamin D levels from a mean of 69 to 96 nmol/L and insignificantly decreased the disease 
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activity from 29% to 13% (p=0.06) (Jørgensen et al., 2010). Researchers show inactive CD 
patients who were treated with 0.25 μg alfacalcidiol (1,25(OH)2D3) for 6 weeks had significant 
reduction in disease activity plasma CRP concentrations of mean 15.8 ±23.57 mmol/L versus 
7.81± 3.91 mmol/L (Miheller et al., 2009).  
Harvey-Bradshaw Index and Crohn’s Disease Activity Index were the only indicators to 
subjectively estimate the disease activity in our Phase I and HBI in Phase II study. In our cohort, 
the HBI scores show a significant association (p<0.05) with insufficient vitamin D levels only. 
Clinically, we found 18.2% of CD cases had active disease at baseline comparing to 32.6% were 
in remission according to HBI score. An inverse relationship was found from HBI and CDAI 
comparing to clinical biomarker (hsCRP). The CDAI did not correlate with ileocolonic 
inflammation; Crohn’s patients who were in remission (defined by a CDAI score less than 150 
points) had active disease (colonic inflammation) by endoscopy and vice versa (Modigliani et al., 
1990). Only 38 patients out of 131 were in clinical and endoscopic remission (Modigliani et al., 
1990). The heavily weighted symptoms in CDAI and HBI such as general well-being, abdominal 
pain and diarrhea were not considered as specific biomarkers of intestinal inflammation 
(Modigliani et al., 1990). In both studies, we found the results on hsCRP as the outcome variable 
were more interpretable than the subjective tools. 
Disease duration and surgery did not reach statistical significance with hsCRP levels and 
HBI scores. A study indicated CRP levels during a relapse were not significantly associated with 
surgeries and duration of disease (Koelewijn, Schwartz, Samsom, & Oldenburg, 2008). However, 
the HBI score was positively associated with use of corticosteroids (p=0.000, OR= 5.5) and 
insufficient vitamin D category only (p=0.034, OR= 3.4) in our cohort. Using oral corticosteroids 
was more prevalent to patients who were vitamin D deficient (<25 nmol/L) comparing to normal 
levels group (> 50 nmol/L) (Chatu et al., 2013). In addition, use of corticosteroids drugs to 
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achieve remission for active disease were more effective than defined-formula diets (Messori et 
al., 1996).  
Health-Related Quality of Life was used to quantify the degree of the impact of vitamin D 
supplementation in our cases. The HRQOL scores were improved in some cases after receiving 
supplementation for two months. Quality of life correlated with disease activity in CD, but it was 
influenced by other factors such as disease severity, corticosteroid use, smoking and surgery in 
the past three months (Blondel-Kucharski et al., 2001). 
5.3 Dietary pattern, Healthy eating index, BMI and physical activity 
In Phase I study, most of our cases had inadequate intake of vitamins including vitamins 
D, C and E. Important minerals including calcium, iron and zinc were below the RDA levels for 
healthy people. Moreover, all our cases had poor diet or needs improvement in their diet 
according to HEI. Poor dietary intakes cause malnutrition and micronutrients deficiencies 
especially those nutrients related to bone health and anemia, are more common in IBD 
(O’Sullivan & O’Morain, 2006). Vitamins and minerals deficiencies should be prevented by 
advising patients to consume food containing vitamins and minerals or supplements to avoid 
series of related health consequences (Goh & Morain, 2003; O’Sullivan & O’Morain, 2006).  
Enteral nutrition is recommended as a primary therapy for CD (when the small intestine is 
affected), which controls the inflammation and helps to reach remission (Lucendo, 2009).  
BMI is affected by food intake and physical activity. In Phase I, we found only three 
cases were underweight and two were overweight according to BMI categories. Most patients (8 
out of 9) had sedentary activity levels. As CD patients were at risk of malnutrition due to loss of 
appetite, medication side effects or malabsorption of nutrients (CCFC, 2001). In addition, 
intestinal inflammation interferes with food absorption, which leads to a weight classification of 
underweight BMI category (CCFC, 2001). A recent study found 40% of CD outpatients had 
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BMI ≥ 25 kg/m2 and this was significantly associated with several factors including older age and 
lower level of physical activity (Nic Suibhne et al., 2013).  
5.4 Socio-economic and demographics 
In Phase I study, participants had different household income levels including upper-
middle, lower- middle and lowest income levels. All our cases except one from Saskatoon were 
educated. Due to the small sample size, no statistical analysis could be performed to examine the 
socio-economic and demographics variables associated with CD. A study was done using  the 
population-based University of Manitoba IBD Database, showed IBD cases were not higher 
socioeconomic status compared to general population (Bernstein et al., 2001).  
6. Challenges and limitations 
One limitation of Phase I study is a small sample size. Participant’s recruitment was 9 
months in Riyadh and one year in Saskatoon, and we recruited small number of participants. 
Most participants were not newly diagnosed and they had a history of surgery, which is one of 
our exclusion criteria. Some participants were living outside of the city and they were not able to 
come each visit, which lead to missing follow-up. Some patients did not adhere to the 
instructions to take vitamin D on a daily basis. In addition, some patients did not want to be 
blinded in the study and others resisting to be in the treatment groups with lowers doses. Another 
limitation is recall bias from the questionnaires that we provided (PAC and HRQOL). In addition, 
calprotectin measurement was not available at King Khaled University Hospital, and it was 
difficult to manage it in other laboratory outside the hospital. Laboratory tests were not done at 
the same time points of measurements. All these limitations affect our phase I results.  
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The main limitation in Phase II study was the retrospective nature of the data that limited 
us to only available information in patients’ charts with relatively frequent missing data. We used 
GEE method to overcome the challenge with missing data considering that they were missing 
completely at random.  
7. Recommendation for future research and practice 
Vitamin D status of CD cases should be assessed regularly, and recommendation for 
vitamin D supplement intake should be provided accordingly. The role of vitamin D in 
autoimmune diseases and the possibility of higher requirements to vitamin D in CD patients 
warrant further researches with higher doses of vitamin D. Large randomized clinical trials are 
required to understand the impact of vitamin D supplements especially higher doses what is 
recommended to general population, such as 4000 IU and 10,000 IU/d, in CD patients in different 
ethnicities and environmental factors. 
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Table 2.11 Studies on Vitamin D and IBDs 
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25(OH) D 
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IU/d or more 
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CRP 
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IU/d (2wk)-  
taking 5,000 
IU/d to 
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IBDQ 
BMD 
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recalls, 
IL-10,IL-17 
PTH 
Ca 
albumin 
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TNF-α 
 
24 weeks supplementation with up to 
5,000 IU/d vitamin D3 effectively raised 
serum 25(OH)D3 and reduced CDAI 
scores in a small cohort of CD suggesting 
that restoration of normal vitamin D serum 
levels may be useful in the management of 
patients with mild-moderate Crohn's 
disease. 
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Higher predicted plasma levels of 25(OH) 
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There is no association between Vit D 
deficiency and disease activity in 
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supplements 
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Vit D supplementation as an adjunctive 
treatment, may help in controlling colitis, 
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vit D in treating IBD. 
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2,000 IU/d of vit D3 and 50,000 IU vit D2 
weekly for 6 wk are superior to 2,000 IU 
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tolerated among children and adolescents 
with IBD. The change in serum PTH 
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Supplementation with 10,000 IU/d of Vit 
D3 may been effective adjunctive therapy 
for ameliorating symptoms in CD. 
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CD 
Ireland 
- Serum 
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Serum IL-10 
TNF-alpha 
Circulating levels of IL-10, but not TNF-
alpha, were significantly lower in CD 
patients with inadequate serum 25(OH) D. 
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- VDR - 
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(Diagnose -
location) 
 
No significant association between any of 
the polymorphisms and risk of IBD for 
either heterozygotes or rare allele 
homozygotes. No significant differences 
in our results when analyzed by disease 
subtype (CD or UC) or by sex 
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of 15.5 y) 
101[UC] (age 42.4Y) 
(disease duration 10.9 y) 
US 
- Plasma 
25(OH) D 
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HRQOL 
Vitamin B12, 
folate, iron, 
albumin 
Vit D deficiency is common in IBD and is 
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HRQOL and greater disease activity in 
CD 
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- No 
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diagnosis of 
UC or CD 
DBP adds to the list of potential genes that 
contribute to the complex genetic etiology 
of IBD, and further emphasizes the 
association between vit D homeostasis and 
intestinal inflammation 
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Oral supplementation with 1,200 IE vit D3 
significantly increased serum vit D levels 
and insignificantly reduced the risk of 
relapse from 29% to 13%, (p= 0.06) 
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aVD has a more prominent short-term 
beneficial effect on bone metabolism and 
disease activity in CD compared with 
pVD. 
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( m=24-f=10)                
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India 
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Ca, 
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ca phosphate 
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Metabolic bone disease is a significant 
problem in patients with Crohn’s disease. 
The main pathophysiological mechanisms 
involved include impaired absorption of 
calcium and vitamin D, treatment with 
steroids and the effect of the chronic 
inflammatory process on bone. 
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ages 8 to 22y 
US 
0
2
, 
2
0
0
3
 -
 0
1
,2
0
0
5
 
Serum 
25(OH)D 
Vit D 
supplements 
PTH 
 
Serum Ca 
LSBMD 
BMI 
VitD deficiency is highly prevalent among 
pediatric patients with IBD. Factors 
predisposing to the problem include 
having a dark-skin complexion, winter 
season, lack of VitD supplementation, 
early stage of disease, more severe 
disease, and upper GI tract involvement in 
patients with CD. 
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138 patients with CD 
(M=75,F=63),mean age 
37.7y 
29 with UC 
(M=17,F=12) mean age 
38.1y 
US 0
1
,2
0
0
2
- 
0
8
,2
0
0
2
 
Serum 
25(OH)D 
1,25(OH)
2D 
- 
Serum iPTH 
 
fractional 
urinary ca 
excretion 
 
LSBMD -
nondominant 
proximal 
femur 
-Elevated 1,25(OH)2D is more common in 
CD than previously appreciated and is 
independently associated with low bone 
mineral density 
-Normal 25(OH)D and elevated 
1,25(OH)2D is in contrast with previous 
studies demonstrating low 25(OH)D and 
secondary hyperparathyroidism in patients 
with CD 
S
il
v
en
n
o
in
en
,1
9
9
6
 
C
as
e–
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o
n
tr
o
l 
IBD cases N=150  
(M=79- F=71) age 40.0 
Controls N=73 (M=35- 
F=38) age 40.8 
Finland 
- Serum 
25(OH)D 
VD 
supplementat
ion and 
dietary 
intake 
serum Ca, P, 
iPTH 
 
Blood 
leukocytes 
Patients with IBD have lower serum levels 
of 25(OH)D than healthy controls, but 
similar serum PTH concentrations and 
vitamin D intake. Vitamin D intake, and 
the serum levels of 25(OH)D and PTH are 
not associated with BMD, and 
malabsorption is unlikely to be a major 
factor in the aetiology of bone loss in 
unselected IBD patients. 
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Table 3.4 Measured Biomarkers for Inflammation and Disease Activity 
Biomarkers 
Type of 
test 
Range 
Study sites 
Saskatoon Riyadh 
hsCRP
1
 
Blood 
test 
a. Low risk: less than 1.0 mg/L 
b. Average risk: 1.0 to 3.0 mg/L 
c. High risk: above 3.0 mg/L 
√ √ 
Albumin
1
 
Blood 
sample 
Normal range: 
  3.4 - 5.4 grams per deciliter 
(g/dL) (medlineplus, 2013). 
√ √ 
WBC 
2 
 
Blood 
sample 
Normal range: 
4,500 to 10,000 cells/mcL  √ √ 
Fecal 
calprotectin 
 
Stool 
test 
a. -Standard range (10-600 μg/g 
or 0.01-0.6 mg)) optimal 
range for differentiating IBD 
from IBS. 
b. -Extended range (30-1800 
μg/g or 0.03-1.8 mg) 
advantageous in mentoring 
mucosal inflammation& 
disease activity.  
in research 
only 
- 
CDAI 
 
Tool 
a. >150 indicates active disease 
a. < 150 indicates a remission 
√ 
√ 
(in 
research 
only) 
PCDAI Tool 
 
a. ≤ 10 inactive disease 
b. 11-30 mild disease 
b. ≥ 30 moderate-to-severe 
disease 
√ 
(in research 
only) 
√ 
(in 
research 
only) 
1
Routinely checked in study site(s)  
2
Note: 
 cells/mcL = cells per microliter 
Note. Adopted from (ALPCO, 2014; Institute of Medicine, 2010; MedlinePlus, 2012, 2013)
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PRINCIPAL INVESTIGATOR:  
Hassanali Vatanparast, Associate Professor, College of Pharmacy and Nutrition, University of 
Saskatchewan 
 
SUB-INVESTIGATORS:  
Dr. Jennifer Jones, Assistant Professor of Medicine, University of Saskatchewan 
Dr. Hani Jawa, Assistant Professor of Medicine, King Abdulaziz University 
Dr. Wael El-matary, Head, Section of Pediatric Gastroenterology, Department of Pediatrics, 
Associate Professor of Pediatrics, Faculty of Medicine, University of Manitoba 
 
STUDENT RESEARCHER: 
Dania Alrefai, Nutrition M.Sc. candidate, College of Pharmacy and Nutrition, University of 
Saskatchewan. 
 
SPONSORS 
University of Saskatchewan; Saudi Arabian Cultural Bureau in Ottawa 
 
CONTACT PHONE NUMBER: 306-966-6341, vatan.h@usask.ca 
 
 
INTRODUCTION 
You are invited to take part in this research study because you are recently diagnosed 
with Crohn’s disease. There have been reports on the positive impact of vitamin D in controlling 
disease activity in autoimmune diseases such as Crohn’s disease. The knowledge of the 
scientific community on the impact of vitamin D on Crohn’s disease is very limited.  Our research 
team designed this study as a MSc Thesis Project to evaluate the intake of high safe dose of 
vitamin D (10,000 IU/d) in disease activity. Mrs. Dania Alrefai will be conducting this study under 
direct supervision of Dr. Hassanali Vatanparast and members of the Advisory Committee. 
It is up to you to decide whether or not you wish to take part. If you wish to participate, 
you will be asked to sign this form. If you do decide to take part in this study, you are still free to 
withdraw at any time and without giving any reasons for your decision. If you do not wish to 
participate, you will not lose the benefit of any medical care to which you are entitled or are 
presently receiving. It will not affect your relationship with any of the investigators and 
researchers. Your family physician will be informed of your involvement in the study. Please take 
time to read the following information carefully. You can ask the researcher to explain any words 
or information that you do not clearly understand. You may ask as many questions as you need. 
Please feel free to discuss this with your family, friends or family physician before you decide. 
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WHO IS CONDUCTING THE STUDY?  
The study is being conducted by Mrs. Dania Alrefai, Dr. Hassanali Vatanparast, 
Dr.Jennifer Jones from the University of Saskatchewan, Dr. Hani Jawa from King Abdulaziz 
University and Dr. Wael El-matary from University of Manitoba. Along with in kind contributions 
from Royal University Hospital at the University of Saskatchewan, King Abdulaziz Hospital in 
Jeddah, Saudi Arabia, and Eruo-pharm Company, Saudi Arabian Cultural Bureau will partly 
cover the costs of this study. However, neither the institution nor any of the investigators or staff 
will receive any direct financial benefit from conducting this study. 
 
WHY IS THIS STUDY BEING DONE? 
This study is being done because only a few published studies measured Vitamin D 
levels in Crohn’s disease patients in Saudi Arabia and Canada. The majority of studies on 
Crohn’s disease and Vitamin D used regular dose of vitamin D supplementation. To our 
knowledge, there is only one unpublished study which has been conducted in the United States 
to determine the effect of high doses of Vitamin D (1000 and 10,000 IU/d) on Crohn’s disease.  
As of yet, there has been no clinical trial in Saudi Arabia or Canada that explores the 
relationship between Crohn’s disease and of Vitamin D supplements in safe doses higher than 
regular dose of 400 IU/d.  
 
WHO CAN PARTICIPATE IN THE STUDY? 
You are eligible to participate in this study if you are over 16 years of age and have been 
recently (≤2 years) diagnosed with an active Crohn’s disease. Patients in remission or the 
duration of disease of more than 2 years, pregnancy, liver or kidney failure, and inability to take 
oral supplements or medicine will not be eligible to participate in this study. 
 
Notice to women of child-bearing age:  
 The effect of high doses of vitamin D on the fetus may be harmful.  
 If you are pregnant or are a nursing mother you may not participate in this study. 
 If you are able to have children and are sexually active you must agree to not become 
pregnant during the study and must agree to use acceptable methods of birth control 
until 30 days after the last dose of study drug.  The study doctor will discuss these 
methods with you.  
 If you believe you have become pregnant, you must inform your study doctor 
immediately and you will be withdrawn from the study. Your study doctor will continue to 
monitor the pregnancy to termination or delivery. The newborn infant will be monitored 
for at least 30 days after birth. 
 
WHAT DOES THE STUDY INVOLVE? 
This pilot study is a double-blind randomized control trial. After the initial screening on 
your disease activity and other indicators of health, you will be assigned to one of the study 
arms where you receive vitamin D in an assigned dose. Vitamin D supplements will be provided 
to you at two time points at the beginning of the study and at week four, when you return the 
empty bottle. Along with completing some questionnaires, your blood and fecal samples will be 
taken in three time points, at the beginning of the study, at week 9 (end of supplementation) and 
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week 15 (follow up). In addition to your regular visits with your physician, a study personnel will 
be in communication with you throughout the study to hear from you any concerns or changes in 
disease/health status related to Crohn’s disease. 
 
During the study period, you will take vitamin D supplements for 9 weeks. We will record 
available information related to your disease from your file.  In addition to collecting some limited 
socio-demographic information, we will assess your dietary intake and physical activity using 
questionnaires. We will also measure your height and weight. Further, laboratory examinations 
to assess your disease status will include CBC, WCC, Vitamin D and Crohn’s disease activity 
index.  These laboratory tests will be conducted at the beginning of study, week 9 and after 2 
months follow up. 
 
WHAT ARE THE BENEFITS OF PARTICIPATING IN THIS STUDY?  
By enrolling in this study, you will receive free examination and advanced measurements on 
your disease status as well as free supplementation for a period of 9 weeks. Further, a full report 
on your health status will be provided to you through your family physician upon completion of 
our study.  It is hoped the information gained from this study can be used to benefit patients with 
Crohn’s disease. 
 
ARE THERE POSSIBLE RISKS AND DISCOMFORTS? 
If you choose to participate in this study, no known risks have been reported on Vitamin D intake 
of 10,000 IU/d according to the Food and Nutrition Board (FNB) at the Institute of Medicine 
where recommendations on nutrient intake is set. We will monitor your health status throughout 
the study to prevent any unlikely event. 1 
 
You may have early symptoms of hypercalcemia (high level of calcium in the blood) which can 
include:  
 
 Weakness 
 Fatigue 
 Somnolence 
 Headache 
 Dry mouth  
 
 Metallic taste 
 Nausea 
 Vomiting 
 Vertigo 
 
 Tinnitus 
 Ataxia 
 Hypotonia  
 Anorexia 
May have more serious manifestations which can include:  
 
 Nephrocalcinosis 
 Renal dysfunction 
 Calcification 
 Osteoporosis in adults  
 Impaired growth in children 
 Seizures 
                                                        
1Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 
2010. 
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WHAT IF NEW INFORMATION BECOMES AVAILABLE THAT MAY AFFECT MY DECISION 
TO PARTICIPATE? 
During the course of this study, new information that may affect your willingness to continue to 
participate will be provided to you by the researcher.  
 
WHAT HAPPENS IF I DECIDE TO WITHDRAW? 
Your participation in this research is voluntary. You may withdraw from this study at any time. 
You do not have to provide a reason. There will be no penalty or loss of benefits if you choose to 
withdraw. Your future medical care will not be affected. If you choose to enter the study and then 
decide to withdraw later, all data collected about you during your enrolment will be retained for 
analysis.  
 
WILL I BE INFORMED OF THE RESULTS OF THE STUDY? 
The results of the study will be available to participants on September 2014 from Dania Alrefai 
and Hassanali Vatanparast. The results will be presented in a Master’s thesis, and may also be 
presented at conference presentations and published in journal articles. However, the results 
cannot be traced back to the individual participants. Following completion of the study, the 
research findings should be used as scientific evidence on the impact of Vitamin D on disease 
activity at Crohn’s disease. This study will not contribute to any commercialization ventures. 
 
WHAT WILL THE STUDY COST ME? 
You will not be charged for any research-related procedures. You will not be paid for 
participating in this study. You will not receive any compensation, or financial benefits for being 
in this study, or as a result of data obtained from research conducted under this study.  
 
WHAT HAPPENS IF SOMETHING GOES WRONG?  
In the unlikely event of any adverse event related to the study occurs, you should seek 
immediate care and, as soon as possible, by notifying us through the contact information in 
consent form. Necessary medical treatment will be made available at no cost for you.  By signing 
this document, you do not waive any of your legal rights should you need to seek compensation 
for damages which arise. 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
In Saskatchewan, the Health Information Protection Act (HIPA) defines how the privacy of your 
personal health information must be maintained so that your privacy will be respected. 
 
The study data will be stored securely (in a locked cabinet contained within a locked office under 
the supervision of the PI) by the study team for a length of time for a maximum of five years post 
publication. Your name will not be attached to any information, nor mentioned in any study 
report, nor be made available to anyone except /for the research team.  Confidentiality will be 
attained by use of a unique numeric identification number. Your data with be combined with data 
from other participants in aggregated form so that no individual identity is disclosed.  However, 
research records and medical records identifying you may be inspected in the presence of the 
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Investigator and/or the University of Saskatchewan Research Ethics Board for the purpose of 
monitoring and verifying the integrity of the research data. Scientific presentations or 
publications will not disclose individual identity. 
 
WHO DO I CONTACT IF I HAVE QUESTIONS ABOUT THE STUDY? 
If you have any questions or desire further information about this study before or during 
participation, you can contact Dr. Hassan Vatanparast at 306-966-6341. If you have any 
concerns about your rights as a research participant and/or your experiences while participating 
in this study, contact the Chair of the University of Saskatchewan Research Ethics Board, at 
306-966-2975 (out of town calls 1-888-966-2975). The Research Ethics Board is a group of 
individuals (scientists, physicians, ethicists, lawyers and members of the community) that 
provide an independent review of human research studies. This study has been reviewed and 
approved on ethical grounds by the University of Saskatchewan Research Ethics Board.  
 
In case of emergency you can call Dr. Hassan Vatanparast at ………… any time.
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CONSENT TO PARTICIPATE 
 
Study Title: The impact of vitamin D on disease activity in Crohn’s disease 
 
 
o I have read (or someone has read to me) the information in this consent form. 
o I understand the purpose and procedures and the possible risks and benefits of the 
study.  
o I was given sufficient time to think about it. 
o I had the opportunity to ask questions and have received satisfactory answers. 
o I understand that I am free to withdraw from this study at any time for any reason and the 
decision to stop taking part will not affect my future relationships. 
o I give permission to the use and disclosure of my de-identified information collected for 
the research purposes described in this form. 
o I understand that by signing this document I do not waive any of my legal rights. 
o I will be given a signed copy of this consent form. 
 
 
I agree to participate in this study: 
 
 
          
Printed Name of Adult Study Participant         
 
 
Signature of Adult Study Participant       Date    
 
          
Printed Name of Person Explaining Consent Form     
 
             
8.1 Signature of Person Explaining Consent Form     
 Date  
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CONSENT FORM 
 
 
 
رارقإ جذومن 
 
 
 
The impact of vitamin D on disease activity in Crohn’s disease. 
 
 
Principal  Investigator: 
Dr. Abdelrahman Aljebreen 
 
:سيئرلا ثحابلا 
نيربجلا نمحرلادبع .د 
 
Co-Investigator(s): 
Dr. Othman Alharbi  
Dr. Majid Almadi 
Dr. Nahla Azzam 
 
Student: 
Dania Alrefai 
 
:كراشملا ثحابلا 
يبرحلا نامثع .د  
 يضاملا دجام .د 
  مازع ةلهن د 
 
يعافرلا ايناد :هبلاطلا 
You are being asked to participate voluntarily in a 
Research Study. If you decide to take part in this study, 
please sign this consent form and return it. 
 
نمو   امكنثو   نذوقفاورانذو ا ثرانا واندو نذه يوةكرانمو كنموجرن
ي قرإنيه يج إ نذق مرانا انىل نعققم رانم كنمجرتنمر ب 
 
ن
STUDY PURPOSE: To study the impact of vitamin D 
on disease activity in Crohn’s disease in Saudi Arabian 
patients. 
STUDY PLAN: 
This pilot study is a double-blind randomized control 
trial. The duration of study is 9 weeks and 2 months 
follow up later.  
If you decide to Participate in this study.  
 You will be assigned to one of the study arms 
(400IU, 2000IU, 10,000IU Vitamin D) where you 
receive vitamin D in an assigned dose and you 
will not know which group you will be assign. 
 Vitamin D supplements will be provided to you at 
two time points at the beginning of the study and 
at week five, when you return the empty bottle. 
 Along with filling out some questionnaires e.x 
socio-demographic, physical activity and health 
related quality of life, your blood and fecal 
samples would be taken in three time points, at the 
beginning of the study, at week 9 and week 15. 
:ةساردلا نم فدهلانن
ثيثاتنرثأنتلاكككن ق نقكيندنىل ن يوةنن روكراندو نىوضركران
ني راننمنيعي نكنءادننن رهند نذكلككرانذقبرعرانذيدمعسرا. 
ن
:ثحبلا هطخ 
 هدمل  هيئاوشع هبرجت هساردلا هذه٩  نيرهش و عيباسا
.هعباتملل نيرخا 
يف لاح كلوبق ةكراشملل: 
  فوس يتلا تاعومجملا نم هدحاو يف لجست فوس
 ( د نيماتيف تلامكم ذخأت٤٠٠  ،هيلود هدحو٢٠٠٠ 
 وا هيلود هدحو١٠،٠٠٠  يا ملع نود )هيلود هدحو
نوكت فوس هعومجم 
  يف ( نيترم د نيماتيف تلامكم كئاطعإب موقن فوس
 عاجرا دنع سماخلا عوبسلآا يف و هساردلا هيادب
.)ىلولآا هبلعلا 
  هلاحلا نع تانايبتسلإا ضعب هئبعتب موقت فوس
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 htiw evah uoy taht stisiv raluger ot noitidda nI  
 no eb lliw lanosrep yduts a ,naicisyhp ruoy
 raeh ot yduts eht thguoht uoy htiw noitacinummoc
 ni segnahc ro snrecnoc yna uoy morf
 .esaesid s’nhorC ot etaler sutats htlaeh/esaesid
 
حاله الصحيه. الاجتماعيه و النشاط الرياضي و ال
مرات خلال مده الدراسه ( في  ٣اخد عينه من الدم 
 الآسبوع الآول، الآسبوع التاسع، و نهايه الدراسه)
سوف يقوم الباحث بالتواصل معك و اخباره في حاله  
 وجود اي تغييرات صحيه مصاحبه للمرض
ن 
 tifeneb ton yam yduts siht fo tluser ehT  :STIFENEB
 eht lliw s'doG htiw erutuf eht ni tub ,yltcerid uoy
 .deriuqca egdelwonk eht morf tifeneb lliw stneitap
 
إننالا  فيدةنكونناو انارث ا وذنالاستفادة المرجوة من الدراسة: 
قووثنلانتعوومدن لقوومنكويكوورةن ركووننقووثنتكوومننر  ووي  ناوو انارواوو ن
نتأثقراتن لىنكعيرجذناركرضىنالآخرين.
 siht ni etapicitrap ot esoohc uoy fI :TCEFFE EDIS
 detroper neeb evah tceffe edis ro sksir nwonk on ,yduts
 eht ot gnidrocca d/UI 000,01 fo ekatni D nimatiV no
 fo etutitsnI eht ta )BNF( draoB noitirtuN dna dooF
 si ekatni tneirtun no snoitadnemmocer erehw enicideM
 tes
 
اذانا دتناركةي ههن دناروا ،نرقسنا يكنايننالجانبية:الآثار 
خطر نا  نا را نجينوقه نرلجر يت نارك ثكه ن د نا ا نارث ا هن
    ينر مصقيتنك ظكهنارغ اءن نار غ يهن دنكعهثنارطب.
 eb lliw ereht ,etapicitrap ot esufer uoy fI :LASUFER
 yduts eht evael nac uoY .stifeneb fo ssol ro ytlanep on
 eht ot secneuqesnoc evitagen yna tuohtiw egats yna ta
 eviecer lliw uoy erac fo level
 
إذا ن  ضت ناركةي هذ ن د نا اننعدم الرغبة في المشاركة:
.نارث ا ذن إنمنرننت عر نلأينجزاءنأ ن  ثاننرلكزايينارعلاجقذ
نتس طقعناننتغيد نارث ا هن دناين قتنبث نناين ماقب.
 yduts siht ni noitapicitrap ruoY :YTILATNEDIFNOC
 hcraeser siht fo stluser ehT .laitnedifnoc tpek eb lliw
 eb reven lliw ytitnedi ruoy ,revewoh ,dehsilbup eb yam
   .delaever
 
إن نكي ه م ن د نا ا نارث ا ذ ن  كمن ن دننسرية المعلومات:
لأغرا نأهيديكقذننغييذنارسريذ.نقثني مننةرنار  ي  نا ا ناروا 
ن ركننرنني مناركةفن ننامي من دنأينحيلنكننالأحمال.
ن 
 noitamrofni eht dnatsrednu ylluf I :LAVORPPA
 .mrof tnesnoc eht dna
ا  م وت ناركعلمكيت ن د نا ا نار كمذج, نر انالموافقة بالمشاركة: 
أ ا قنبيركةي هذن دنا ا نارث ا ذ. نهكي نأن دنلانأكينعنكننا  خثامن
ارعق يتنارك اصلن لقهينكننا انارث ا ذنبأننتس خثمن دند ا يتن
نكس  ولقذنكننقولنارويحفقن.
ر ث نتمنكرحنا ا نار كمذجنرلك ورعنبما طذ نأحث نارويحفقننقولن لبن
 ار مققعنك ه.
ن
 
 
 
 
 
 
 
 
 
 521
 
 
 
ن
 neeb sah ypoc A .yliratnulov dna yleerf ngis I
 .em ot nevig
 
وقععد يععط إعطععائي ن عع ة مععن أوقععأ أنععا بمحععت إراديععي وحريتععي 
 الإقرار.
 :etaicossA ro rotagitsevnI
 
 أسط الباحث أو من ينوب عنه:
 :erutangiS
 :etaD
 
  :emaN tneitaP
 
 :erutangiS
 :etaD
 
 :emaN ssentiW
 
 :erutangiS
 :etaD
 
 
 التوقيأ:
 التاريخ:
 
 أسط المريت:
 
 التوقيأ:
 التاريخ: 
 
 أسط الشاهد:
 
 التوقيأ:
 التاريخ:
 ,snoitseuq ro snrecnoc rehtruf yna evah uoy fI
 .000 # peelB( idamlA dijaM .rD tcatnoc nac uoy
 )000 # .txE
 لايصععا أ كعنعد الرغبععة فععي أس استف ععار  عن هععمك الدراسععة يم نعع
 .000. يحويلة 000على يليفون رقط الماضي  ماجد بالدكتور
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Baseline Visit 1 
 
__ __/ __ __/ __ __ __ __            
(dd/mm/yyyy) 
 
 Appendix 4: Baseline form 
 
 
 
 
 
First Name:      Last name:  
Home address:                              Phone number:    
     
Date of Birth: __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)         
 
 Age: ________________                        
 
Sex:              Male    Female    
  
Household type (ie. mother only, father only, both parents):  
 
Total number of individuals in the household: 
Number of children in household:  
 
Socio-demographic characteristics (SDC) 
 
1. Indicate your migration status: 
 Immigrant (permanent resident) 
 Refugee (permanent resident) 
 Canadian Citizen 
 Student or worker (temporary resident) 
 Non status (unrecognized immigrant)  
 
2. In what country you born?  
 
3. What date did you (participant) first come to (Canada/ Saudi Arabia) (MM/DD/YY) 
(must be < 5 years)?  If the participant was born in Canada, indicate when family arrived. 
_____________________________ 
 
4. People living in (Canada/ Saudi Arabia) come from many different cultural and racial 
backgrounds. Are you:  
 White 
 Chinese 
 South 
Asian (e.g., 
East Indian, 
Pakistani, Sri 
Lankan)  
 Black 
 Latin 
 American 
 Southeast 
Asian (e.g., 
Cambodian, 
Indonesian, 
Laotian, 
Vietnamese, 
Burmese) 
 Filipino 
 Arab 
 West Asian 
(e.g., Afghan, 
Iranian) 
 Japanese 
 Korean
SOCIO-DEMOGRAPHICS 
1  
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Baseline Visit 1 
 
__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 
5. What languages do you speak (list all, including English)?  
 
 
 
6. What language do you speak most often at home?  
 
7. What is the language that you first learned at home? 
8. Can you still…? 
 Speak and understand your first language 
 Only understand your first language 
 Neither speak nor understand your first language 
 
Education (EDU) 
9. What is your (participant’s) highest grade of elementary school completed in your 
home country?  
 
10. Father’s education in home country: 
 <Grade 8 
 <Grade 12 
 High school diploma 
 Some University 
 University degree-Indicate highest 
degree____________________________________ 
 Trade/other education-Indicate 
certification__________________________________ 
 Refuse to answer 
 
11. Father’s education in (Canada/ Saudi Arabia): 
 High school diploma 
 Some University 
 University degree-Indicate highest 
degree____________________________________ 
 Trade/other education-Indicate 
certification__________________________________ 
 Refuse to answer 
 
12. Mother’s education in home country: 
 <Grade 8 
 <Grade 12 
 High school diploma 
 Some University 
 University degree-Indicate highest 
degree____________________________________ 
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Baseline Visit 1 
 
__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 Trade/other education-Indicate 
certification__________________________________ 
 Refuse to answer 
 
13. Mother’s education in (Canada/ Saudi Arabia): 
 High school diploma 
 Some University 
 University degree-Indicate highest 
degree____________________________________ 
 Trade/other education-Indicate 
certification__________________________________ 
 Refuse to answer 
 
Income (INC) 
Although many health expenses are covered by health insurance, there is still a 
relationship between health and income. Please be assured that, like all other 
information you have provided, these answers will be kept strictly confidential. 
 
14.  What is your best estimate of the total income, before taxes and deductions, of all 
household members from all sources in the past 12 months? If participant has been 
in (Canada/ Saudi Arabia) less than 12 months, indicate average per month and 
multiply by 12.  __________________ 
 Refuse to answer 
 
15.  Thinking about the total income for all household members, from which of the 
following sources did your household receive any income in the past 12 months? If 
participant has been in (Canada/ Saudi Arabia) less than 12 months, indicate 
sources of income since arrival in (Canada/ Saudi Arabia). 
 
 Wages and salaries 
 Income from self-employment 
 Dividends and interest (e.g. bonds, savings)  
 Worker’s compensation 
 Retirement pensions, superannuation and annuities 
 Old age security and guaranteed income supplement 
 Provincial or municipal social assistance or welfare 
 Child tax benefit 
 Child support 
 Alimony, other (e.g., rental income, scholarship) 
 Refuse to answer 
 
16. What was the main source of income? 
 Wages and salaries 
 Income from self-employment 
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Baseline Visit 1 
 
__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
  Dividends and interest (e.g. bonds, savings)  
 Worker’s compensation 
 Retirement pensions, superannuation and annuities 
 Old age security and guaranteed income supplement 
 Provincial or municipal social assistance or welfare 
 Child tax benefit 
 Child support 
 Alimony, other (e.g., rental income, scholarships)  
 Refuse to answer  
 
17. Can you estimate in which of the following groups your household income falls? 
Was the total household income from all sources: 
 
 less than $5,000  
        $5,000 to less than $10,000 
 $10,000 to less than $15,000  
 $15,000 to less than $20,000  
 $20,000 to less than $25,000  
 $25,000 to less than $30,000 
 $30,000 to less than $40,000  
 $40,000 to less than $50,000 
 $50,000 to less than $60,000 
 $60,000 to less than $80,000 
 $80,000 to less than $100,000  
 $100,000 or more 
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Baseline Visit 1 
 
__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 
 
 
 
1) Past History 
Diagnosis: CD     UC   IC (Indeterminent colitis)  
 
Date of initial diagnosis __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)          
 
Date of onset of symptoms __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)         
 
Date of initial colonoscopy __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)         
 
IBD Phenotype 
Disease Location for Crohn’s Disease (check all that apply)  
Grey boxes- minimum location to define extent. Non-shaded- prospective data or not in 
chart  
                                             
 At Diagnosis At Enrollment                  Date 
(dd/mm/yyyy)          
Upper GI  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Small Bowel  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Jejunum  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Terminal Ileum  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Ileocecal Valve  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Colon  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Cecum  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Ascending  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
DISEASE RELATED INFORMATION 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Transverse  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Descending  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Sigmoid  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Rectum  Bowel+, inflam + 
 Bowel+, inflam - 
 Bowel- or unknown 
 Bowel+, inflam +:      
 Bowel+, inflam - :      
 Bowel- or unknown 
Confirmation of Disease Location (check all that apply):      
              (dd/mm/yyyy)              
 clinical chart note:  Date of Confirmation   __ __/ __ __/ __ __ __ __  
 endoscopy: Date of Confirmation    __ __/ __ __/ __ __ __ __         
 radiology: Date of Confirmation    __ __/ __ __/ __ __ __ __  
 operative: Date of Confirmation    __ __/ __ __/ __ __ __ __  
 histopathology: Date of Confirmation    __ __/ __ __/ __ __ __ __         
 other (comment box): Date of Confirmation     __ __/ __ __/ __ __ __ __           
 
Disease Behavior for Crohn’s Disease (check all that apply)  
Grey boxes- minimum data to define behavior. Non-shaded- prospective data or not in 
chart  
 At Diagnosis       Date 
(dd/mm/yyyy)          
At Enrollment              Date 
(dd/mm/yyyy)          
Inflammatory  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
aFibrostenosis  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
Penetrating  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
b Internal fistula 
(not perianal) 
 Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
Abd. 
inflammatory 
mass 
 Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
Abdominal 
abscess 
 Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
The impact of Vitamin D on disease activity in Crohn’s disease 
 
Subject ID:     
   
                           Site #                                     Screening #                             Initials  
 
132 
 
 
Baseline Visit 1 
 
__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Other   
aIf fibrostenosis is checked, (check all that apply): ileal, colonic, other (comment) 
 
b If Internal fistula is checked, then(check all that apply): entero-enteric, entero-
cutaneous, peri-stomal fistula, entero-vesical, entero-vaginal, other (comment box) 
 
If yes to entero-enteric 
 ileal-ileal  
 ileo-colonic 
 gastro-colic 
 colo-colic 
 
If yes to enterocutaneous,  
 enterocutaneous confirmed 
 peristomal 
 
 
 
Confirmation of Disease Behavior (check all that apply): 
                 
      (dd/mm/yyyy)  
 clinical chart note:  Date of Confirmation __ __/ __ __/ __ __ __ __          
 endoscopy: Date of Confirmation   __ __/ __ __/ __ __ __ __          
 radiology: Date of Confirmation   __ __/ __ __/ __ __ __ __         
 operative: Date of Confirmation   __ __/ __ __/ __ __ __ __         
 histopathology: Date of Confirmation  __ __/ __ __/ __ __ __ __         
 other (comment box): Date of Confirmation    __ __/ __ __/ __ __ __ __          
 
Perianal Disease for Crohn’s Disease (check all that apply)   
Grey boxes- minimum data to define behavior. Non-shaded- prospective data or not in 
chart  
 At Diagnosis      Date 
(dd/mm/yyyy)          
At Enrollment           Date 
(dd/mm/yyyy)          
Perianal Fistula  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Perianal Abscess  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
Anal ulceration  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
Anal stenosis  Yes 
 No  
 Unknown 
 Yes 
 No  
 Unknown 
Confirmation of Perianal Disease (check all that apply): 
 
                        (dd/mm/yyyy) 
 clinical chart note:  Date of Confirmation __ __/ __ __/ __ __ __ __          
 endoscopy: Date of Confirmation   __ __/ __ __/ __ __ __ __          
 radiology: Date of Confirmation   __ __/ __ __/ __ __ __ __          
 operative: Date of Confirmation   __ __/ __ __/ __ __ __ __          
 histopathology: Date of Confirmation   __ __/ __ __/ __ __ __ __          
 other (comment box): Date of Confirmation    __ __/ __ __/ __ __ __ __          
 
Evidence of granuloma on histopathology at any time  
 Yes    No  Unknown 
If YES then: __ __/ __ __/ __ __ __ __         dd/mm/yyyy 
 
 
Hospitalization for IBD Flares:  
 Yes    No  Unknown 
If YES then: 
Number of Hospital Admissions:     1 
             2 
          > 2 
           unknown 
  
Date of First Hospital Admission: __ __/ __ __/ __ __ __ __      (dd/mm/yyyy) 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Crohn’s Disease Past Medication 
Medication Dose Route Frequenc
y 
   Start Date    End Date 
5-ASA 
 
     
6MP  
 
     
 Azathioprine 
 
     
Prednisone 
 
     
Budesonide 
 
     
Methotrexate      
Cyclosporine      
Infliximab      
Adalimumab      
 
List of:  
Supplements  1. __________________________________ 
   2. __________________________________ 
   3. __________________________________ 
 
Probiotics  1. __________________________________ 
   2. __________________________________ 
   3. __________________________________ 
 
Herbal  1. __________________________________ 
   2. __________________________________ 
   3. __________________________________ 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Surgical History 
 
 Appendectomy            Yes             No   
 
Others _____________________________________________ 
 
Has a resection been performed? 
 
Yes    No   
 
 
                If yes, please record Crohn’s disease surgical history below. 
 
Site of Resection: 
 
 
1. 
 
Date: 
 
2. 
 
Date: 
 
3. 
 
Date: 
 
4.  
 
Date: 
 
 
Crohn’s Disease Medication Presently 
Medication Dose Route Frequenc
y 
   Start 
Date 
   End 
Date 
5-ASA 
 
     
6MP  
 
     
 Azathioprine 
 
     
Prednisone 
 
     
Budesonide 
 
     
Methotrexate      
Cyclosporine      
Infliximab      
Adalimumab      
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 Extra-Intestinal Manifestations:        
Joint: Arthralgia   Yes             No   Date __ __/ __ __/ 
__ __ __ __          
  Arthirits    Yes             No   Date __ __/ 
__ __/ __ __ __ __          
  
 
Eyes: Uveitis    Yes             No   Date __ __/ 
__ __/ __ __ __ __          
   Episcleritis   Yes             No   Date __ __/ __ __/ 
__ __ __ __          
   
 
Skin:  Erythema Nodosum  Yes             No   Date __ __/ __ __/ 
__ __ __ __          
   Pyoderma Gangrenosum Yes             No   Date __ __/ __ __/ 
__ __ __ __          
 
 
Mucocutaneous: Oral Apthous ulcers  Yes            No   Date __ __/ 
__ __/ __ __ __ __          
 
Family History IBD-Associated Conditions: 
PSC:  
Parent Yes             No    
  Sibling  Yes             No   
 Children Yes             No   
 Second degree Yes             No   
 
 
Psoriatic Arthritis:  
Parent Yes             No   
  Sibling  Yes             No   
 Children Yes             No   
 Second degree Yes             No   
 
 
Asthma:  
Parent Yes             No   
  Sibling  Yes             No   
 Children Yes             No   
 Second degree Yes             No   
 
 
Eczema: 
 Parent Yes             No   
  Sibling  Yes             No   
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 Children Yes             No   
 Second degree Yes             No   
 
 
Colon Cancer:  
Parents  Yes             No   
  Sibling  Yes             No   
 Children Yes             No   
 Second degree Yes             No   
 
aternal smoking during pregnancy:  Yes             No     Don’t know   
 
 
 
 
 
Date of Assessment: __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)        
 
High _________ cm     Weight ________ kg     BMI ________   Blood Pressure 
_______     Not done 
 
Waist circumference:  
 
 
1. Have you done any of the following in the past 3 months, that is, date three 
months ago) to yesterday? 
 
 Walking for exercise 
 Gardening or yard work 
 Swimming 
 Bicycling 
 Popular or social dance 
 Home exercises 
 Ice hockey 
 Ice skating 
 In-line skating or rollerblading 
 Jogging or running  
 Golfing 
 Exercise class or aerobics 
 Downhill skiing or snowboarding 
 Bowling 
 Baseball or softball 
ANTHROPOMETRICS EXAMINATION 
 
PHYSICAL ACTIVITY 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 Tennis 
 Weigh-training 
 Fishing 
 Volleyball 
 Basketball 
 Soccer 
 Any other_______________________ 
 No physical activity 
 
2. In the past 3 months, did you do any other physical activity for leisure? 
 Yes______________________________ 
 No  
 
3. In the past 3 months, how many times did you participate in identified activity? 
 
4. About how much time did you spend on each occasion? 
 1 to 15 minutes 
 16 to 30 minutes 
 31 to 60 minutes 
 More than one hour 
Next, some questions about the amount of time spent in the past 3 months on physical 
activity at work, while doing daily chores around the hours, or doing errands, but not 
leisure time activity. 
 
5. In a typical week in the past 3 months, how many hours did you usually spend 
walking to work or to school or while doing errands? 
 None 
 Less than 1 hour 
 From 1 to 5 hours 
 From 6 to 10 hours 
 From 11 to 20 hours 
 More than 20 hours 
 
6. In a typical week in the past 3 months, how many hours did you usually spend 
bicycing to work or to school or while doing errands? 
 None 
 Less than 1 hour 
 From 1 to 5 hours 
 From 6 to 10 hours 
 From 11 to 20 hours 
 More than 20 hours 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
7. Thinking back over the past 3 months, which of the following best describes your 
usual daily activities or work habits? 
 Usually sit during the day and don’t walk around very much 
 Stand or walk quite a lot during the day but don’t have to carry or lift things very 
often 
 Usually lift or carry light leads, or have to climb stairs or hills often 
 Do heavy work or carry very heavy loads 
 
Sun Exposure (SEB) 
The next two questions are about your exposure to the sun since you have been in 
Canada.  For these questions, think about a typical weekend or day off from school in 
the summer months. 
 
1. About how much time each day do you spend in the sun between 11 am and 4 
pm? 
 None 
 Less than 30 minutes 
 30 to 59 minutes 
 1 hour to less than 2 hours 
 2 hours to less than 3 hours 
 3 hours to less than 4 hours 
 4 hours to less than 5 hours 
 5 hours 
 
2. In the summer months, on a typical weekend or day off from school, when you are 
in the sun for 30 minutes or more, how often do you use sunscreen? 
 Always 
 Often 
 Sometimes 
 Rarely 
 Never 
 
Vitamin D: 
 
 1.  Are you taking Vitamin D supplements on a regular daily basis?    
 Yes  
 No 
 
If yes, please indicate the amount? 
 600 IU/d 
 1000 IU/d 
 2000 IU/d 
 Other….………… 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 
 
 
 
 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)        
 
  Lab Test 
 
Concentration (units) 
WBC 
 
 
Hg 
 
 
Hct 
 
 
Platelets 
 
 
Ferritin 
 
 
Vitamin D 
 
 
Serological Biomarkers 
hsCRP 
 
 
Fecal Biomarkers 
Calprotectin 
 
 
 
Safety measurments 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)       
 
Lab Tests Concentration (units) 
Calcium 
 
Phosphate 
 
25(OH)D 
 
ALT, AST, BUN levels 
 
Magnesium 
 
Pregnancy test 
 
LABORATORY TESTS – Screening Visit 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Creatinine 
 
GFR  
Urinalysis for hematuria  
PTH  
Albumin  
 
MEASURES OF DISEASE ACTIVITY 
 
 
Harvey-Bradshaw Index for Crohn’s Disease 
 
A. General Wellbeing 0=Very Well 
      1=Slightly below par 
      2=Poor 
      3=Very poor 
      4=Terrible 
 
B. Abdominal Pain  0=None 
      1=Mild 
      2=Moderate 
      3=Severe 
 
C. # Liquid Stools/Day 
 
D. Abdominal Mass  0=None 
      1=Dubious 
      2=Definite 
      3=Definite and tenderness 
 
E. Complications  1=Arthralgia 
      1=Erythema Nodosum 
      1=Aphthous Ulcers 
      1=Pyoderma Gangrenosum 
      1=Anal Fissure 
      1=New Fistula 
      1=Abscess 
 
 
     Total Score= ______________ 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 
 
 
 
 Number of liquid or very soft stools 
 
 
 
                                                                                                        =  
 
 
 
 
 
               X2 = 
                 
SUBTOTAL 
 
 
 Abdominal pain  (0=none; 1=mild, 2=moderate, 3=severe) 
 
 
 
                                                                                                         = 
 
 
 
 
 
               X5 = 
                 
 
 
 
 General well-being (0=generally well; 1-slightly under par; 2=poor; 3-very poor; 4-terrible) 
 
 
 
                                                                                                         = 
 
 
 
 
 
               X7 = 
                 
 
 
 
   
 Number of 6 listed categories patient now has (tick all that apply) 
     Arthritis/Arthralgia        Iritis/Uveitis         Anal Fissure, Fistula or 
Abscess 
      Other fistula            Fever > 37.8 C during previous week                       
      Erythema Nodosum, Pyoderma Gangrenosum/Aphthous Stomatitis  
                                                                        Total number of 
categories 
 
 
 
              X20 
= 
                 
 
 
 
 Taking Lomotil/opiates for diarrhea (tick appropriate and report total) 
 
      Yes (30)                          No (0)         
                                            
 
 
                       
 
 
 
 Abdominal Mass (tick appropriate and report total) 
      None (0)              Questionable (20)           Definite (50) 
 
 
 
 Hematocrit (Please enter hematocrit value and calculate) 
 
Male                 (47 – (minus)                               %) x 6           
 
 
Female            (42 – (minus)                                %) x 6     
 
 
= 
 
= 
                        
 
 
 
 Body weight  
 
           Body weight                                                       kg 
                               ( 1 -                                       ) X 100     
=    
        Standard weight                                                        kg 
 
    Tick appropriate box 
Please add (underweight) 
               
                          
 
Or subtract (overweight) 
 
                         
 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 Total 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 Total 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 
Total 
Total 
 
 
2 CROHN’S DISEASE ACTIVITY INDEX 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 (Please add all subtotals) CDAI TOTAL  
 
 
 
 
 
Smoking Status: 
  
- Ever smoked regularly, at least 1 cigarette/day for 3 or more months?        Yes          
No    
 
- Currently smoke at least 1 cigarette / day  Yes          No     
 
  - Current extent of smoking:  -1 to 5 cigarettes / month   
-1 to 5 cigarettes / week    
- < 1/2 pack (10 cigarettes)  / day  
- 1/2 to 1 pack (20 cigs) / day   
- > 1 pack / day     
 
How many years have you smoked at least 1 cigarette / day? -
__________________________ 
 
 
Do you currently reside with anyone who smokes inside the home? Yes          No    
 
Regular Medications: 
 
List all medications that you take on a regular basis: 
  
Supplements  1. __________________________________ 
   2. __________________________________ 
   3. __________________________________ 
 
Probiotics  1. __________________________________ 
   2. __________________________________ 
   3. __________________________________ 
 
Herbal  1. __________________________________ 
   2. __________________________________ 
   3. __________________________________ 
 
 
NSAID Use:   Never    
 
RISK FACTORS  
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
Previously regular  
 
Current regular   
 
Have you been on antibiotics for 3 or more times in the past year?  
 
Yes          No        Don’t know    
 
Infections: 
 
Ever diagnosed with Chicken pox?  Yes         No        Don’t know    
  
Ever diagnosed with measles?   Yes          No        Don’t know    
     
Ever diagnosed with shingles?   Yes          No        Don’t know    
    
Ever diagnosed with food poisoning?  Yes          No        Don’t know    
    
Ever diagnosed with gastroenteritis?  Yes          No        Don’t know    
     
Ever diagnosed with recurrent ear infections? Yes     No       Don’t know    
     
Immunizations: 
 
Received all childhood pneumococcal immunizations? Yes      No     Don’t know   
 
 
Received all childhood meningicoccal immunizations? Yes          No       Don’t know   
 
 
Received all childhood varicella immunizations? Yes          No       Don’t 
know    
 
Received all childhood Hepatitis B immunizations?  Yes          No       
Don’t know    
 
Received all Hepatitis A immunizations? Yes          No       Don’t know    
 
Received teenage pertussis booster (teenager)? Yes          No       Don’t 
know    
 
Received all HPV immunizations?  Yes          No       Don’t know    
 
Neonatal Breastfeeding: 
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__ __/ __ __/ __ __ __ 
__            
(dd/mm/yyyy) 
 
 
 
Were you breastfed as a baby exclusively or nearly exclusively for longer than 4 
months?  
Yes          No       Don’t know    
Family History: 
 
            First-degree relative with Ulcerative Colitis:   
 
 Mother       Father          Brother          Sister      Son              
Daughter   
  
         First-degree relative with Crohn’s Disease:  
 
Mother     Father     Brother     Sister       Son       
Daughter    
 
Farm Exposure: 
 
Have you ever lived on a farm?  
 
During what years (i.e., 1990 to 1995) did you reside on a farm?
 _________________________  
 
What type of farm did you reside on?  
   
-Dairy cattle   
-Beef cattle   
-Pigs    
-Chicken/poultry  
-Grain/wheat only 
-Other _________________ 
Well Water: 
 
Has your main source of water ever been well water? Yes          No    
 
During what years (i.e. 1990 to 1995) was well water your main source of water? 
 
Unpasteurized Milk: 
 
Have you ever routinely drunk unpasteurized milk? Yes          No    
 
  
During what years (i.e. 1990 to 1995) did you routinely drink unpasteurized milk? 
_____________ 
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__ __/ __ __/ __ __ __ 
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(dd/mm/yyyy) 
 
 
 
Household Exposures: 
 
How many people lived with you (including yourself)? 
 
At age 1        5        16         25        30  
 
How many bathrooms did you have in your home? 
 
At age 1       5        16        25        30  
 
Which pets did you have in your home?   
 Cat 
 Dog   
 Bird 
 Turtle   
 Rabbit   
 None   
 Other ___________________ 
 
At age 1        5        16        25       30       current 
 
Single Child:           Yes          No    
 
First Born:           Yes          No    
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First 24- dietary Hour Recall  
    
Time Food Items 
Type & 
Preparation 
Amount 
Brand Name 
or Where 
Bought 
Morning     
     
     
     
     
     
Mid-
morning 
    
     
     
Noon 
Meal 
    
     
     
     
     
     
     
     
Midday     
     
     
DIETARY ASSESSMENT 
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Evening 
Meal 
    
     
     
     
     
     
     
     
Before 
Bed 
    
     
     
     
 
Was this intake usual? Circle one: 
 
 Yes  
 No 
If No, explain why not___________________________________ 
 
Any vitamin / mineral intake during this time?  
 
 Yes 
if Yes, list names:  
 
 No 
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Second 24- dietary Hour Recall  
    
Time Food Items 
Type & 
Preparation 
Amount 
Brand Name or 
Where Bought 
Morning     
     
     
     
     
     
Mid-
morning 
    
     
     
Noon 
Meal 
    
     
     
     
     
     
     
     
Midday     
     
     
     
Evening 
Meal 
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__ __/ __ __/ __ __ __ 
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Before 
Bed 
    
     
     
     
 
Was this intake usual? Circle one: 
 
 Yes  
 No 
If No, explain why not___________________________________ 
 
Any vitamin / mineral intake during this time?  
 
 Yes 
if Yes, list names:  
 
 No 
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Third  24- dietary Hour Recall  
    
Time Food Items 
Type & 
Preparation 
Amount 
Brand Name or 
Where Bought 
Morning     
     
     
     
     
     
Mid-
morning 
    
     
     
Noon 
Meal 
    
     
     
     
     
     
     
     
Midday     
     
     
     
Evening 
Meal 
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Before 
Bed 
    
     
     
     
 
Was this intake usual? Circle one: 
 
 Yes  
 No 
If No, explain why not___________________________________ 
 
Any vitamin / mineral intake during this time?  
 
 Yes 
if Yes, list names:  
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1. How frequent have your bowel movements been during the last two weeks?  
 
 Bowel movements as or more frequent than they have ever been 
 Extremely frequent 
 Very frequent 
 Moderate increase in frequency of bowel movements 
 Some increase in frequency of bowel movements 
 Slight increase in frequency of bowel movements 
 Normal, no increase in frequency of bowel movements 
2. How often has the feeling of fatigue or of being tired and worn out been a problem for you during the 
last 2 weeks? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
3. How often during the last 2 weeks have you felt frustrated, impatient, or restless?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
4. How often during the last 2 weeks have you been unable to attend school or do your work because of 
your bowel problem?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
5. How much of the time during the last 2 weeks have your bowel movements been loose? 
 All of the time 
 Most of the time 
 A good bit of the time 
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  Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
6. How much energy have you had during the last 2 weeks?  
 No energy at all 
 Very little energy 
 A little energy 
 Some energy 
 A moderate amount of energy 
 A lot of energy 
 Full of energy 
7. How often during the last 2 weeks did you feel worried about the possibility of needing to have surgery 
because of your bowel problem? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
8. How often during the last 2 weeks have you had to delay or cancel a social engagement 
because of your bowel problem?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
9. How often during the last 2 weeks have you been troubled by cramps in your abdomen? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
10. How often during the last 2 weeks have you felt generally unwell?  
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
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  None of the time 
11. How often during the last 2 weeks have you been troubled because of fear of not finding a washroom?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
12. How much difficulty have you had, as a result of your bowel problems, doing leisure or sports 
activities you would have liked to have done during the last 2 weeks? please choose an option from 
 A great deal of difficulty; activities made impossible 
 A lot of difficulty 
 A fair bit of difficulty 
 Some difficulty 
 A little difficulty 
 Hardly any difficulty 
 No difficulty; the bowel problems did not limit sports or leisure activities 
13. How often during the last 2 weeks have you been troubled by pain in the abdomen? Please choose an 
option from 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
14. How often during the last 2 weeks have you had problems getting a good night's sleep, or been 
troubled by waking up during the night? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
15. How often during the last 2 weeks have you felt depressed or discouraged?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
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16. How often during the last 2 weeks have you had to avoid attending events where there was no washroom 
close at hand?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
17. Overall, in the last 2 weeks, how much of a problem have you had with passing large 
amounts of gas?  
 A major problem 
 A big problem 
 A significant problem 
 Some trouble 
 A little trouble 
 Hardly any trouble 
 No trouble 
18. Overall, in the last 2 weeks, how much a problem have you had maintaining or getting to, the weight 
you would like to be at.  
 A major problem 
 A big problem 
 A significant problem 
 Some trouble 
 A little trouble 
 Hardly any trouble 
 No trouble 
19. Many patients with bowel problems often have worries and anxieties related to their illness. these 
include worries about getting cancer, worries about never feeling any better, and worries about having a 
relapse. in general, how often during the last 2 weeks have you felt worried or anxious?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
20. How much of the time during the last 2 weeks have you been troubled by a feeling of abdominal 
bloating?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
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  Hardly any of the time 
 None of the time 
21. How often during the last 2 weeks have you felt relaxed and free of tension?  
 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 Almost all of the time 
 All of the time 
22. How much of the time during the last 2 weeks have you had a problem with rectal bleeding with your 
bowel movements?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
23. How much of the time during the last 2 weeks have you felt embarrassed as a result of your bowel 
problem?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
24. How much of the time during the last 2 weeks have you been troubled by a feeling of having to go to 
the bathroom even though your bowels were empty?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
25. How much of the time during the last 2 weeks have you felt tearful or upset?   
 
 All of the time 
 Most of the time 
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  A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
26. How much of the time during the last 2 weeks have you been troubled by accidental soiling of your 
underpants?   
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
27. How much of the time during the last 2 weeks have you felt angry as a result of your bowel problem?   
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
28.To what extent has your bowel problem limited sexual activity during the last 2 weeks? 
  
 1 no sex as a result of bowel disease 
 2 major limitation as a result of bowel disease 
 3 moderate limitation as a result of bowel disease 
 4 some limitation as a result of bowel disease 
 5 a little limitation as a result of bowel disease 
 6 hardly any limitation as a result of bowel disease 
 7 no limitation as a result of bowel disease 
29. How much of the time during the last 2 weeks have you been troubled by nausea or feeling sick to 
your stomach?   
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
30. How much of the time during the last 2 weeks have you felt irritable?   
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 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
31. How often during the past 2 weeks have you felt a lack of understanding from others? 
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
32. How satisfied, happy, or pleased have you been with your personal life during the past 2 weeks?  
 Very dissatisfied, unhappy most of the time 
 Generally dissatisfied, unhappy 
 Somewhat dissatisfied, unhappy 
 Generally satisfied, pleased 
 Satisfied most of the time, happy 
 Very satisfied most of the time, happy 
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Appendix 5: Week 5 form 
First Name:      Last name:  
Home address:                              Phone number:    
     
Date of Birth: __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)         
 
 Age: ________________                        
 
Sex:              Male    Female    
 
 
 
 
 
 
Safety measurements 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)       
 
Lab Tests Concentration (units) 
Calcium 
 
Phosphate 
 
25(OH)D 
 
ALT, AST, BUN levels 
 
Magnesium 
 
Pregnancy test 
 
Creatinine 
 
GFR  
Urinalysis for hematuria  
PTH  
Albumin  
 
3 LABORATORY TESTS  
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 Appendix 6: Week 9 form 
First Name:      Last name:  
Home address:                              Phone number:    
     
Date of Birth: __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)         
 
 Age: ________________                        
 
Sex:              Male    Female    
  
 
 
 
 
 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)        
 
  Lab Test 
 
Concentration (units) 
WBC 
 
 
Hg 
 
 
Hct 
 
 
Platelets 
 
 
Ferritin 
 
 
Vitamin D 
 
 
Serological Biomarkers 
hsCRP 
 
 
Fecal Biomarkers 
Calprotectin 
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 Safety measurements 
 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)       
 
Lab Tests Concentration (units) 
Calcium 
 
Phosphate 
 
25(OH)D 
 
ALT, AST, BUN levels 
 
Magnesium 
 
Pregnancy test 
 
Creatinine 
 
GFR  
Urinalysis for hematuria  
PTH  
Albumin  
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 MEASURES OF DISEASE ACTIVITY 
 
Harvey-Bradshaw Index for Crohn’s Disease 
 
F. General Wellbeing  0=Very Well 
      1=Slightly below par 
      2=Poor 
      3=Very poor 
      4=Terrible 
 
G. Abdominal Pain  0=None 
      1=Mild 
      2=Moderate 
      3=Severe 
 
H. # Liquid Stools/Day 
 
I. Abdominal Mass  0=None 
      1=Dubious 
      2=Definite 
      3=Definite and tenderness 
 
J. Complications  1=Arthralgia 
      1=Erythema Nodosum 
      1=Aphthous Ulcers 
      1=Pyoderma Gangrenosum 
      1=Anal Fissure 
      1=New Fistula 
      1=Abscess 
 
 
     Total Score= ______________ 
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 Number of liquid or very soft stools 
 
 
 
                                                                                                        =  
 
 
 
 
 
               X2 = 
                 
SUBTOTAL 
 
 Abdominal pain  (0=none; 1=mild, 2=moderate, 3=severe) 
 
 
 
                                                                                                         = 
 
 
 
 
 
               X5 = 
                 
 
 
 
 General well-being (0=generally well; 1-slightly under par; 2=poor; 3-very poor; 4-terrible) 
 
 
 
                                                                                                         = 
 
 
 
 
 
               X7 = 
                 
 
 
 
   
 Number of 6 listed categories patient now has (tick all that apply) 
     Arthritis/Arthralgia        Iritis/Uveitis         Anal Fissure, Fistula or 
Abscess 
      Other fistula            Fever > 37.8 C during previous week                       
      Erythema Nodosum, Pyoderma Gangrenosum/Aphthous Stomatitis  
                                                                        Total number of 
categories 
 
 
 
              X20 
= 
                 
 
 
 
 Taking Lomotil/opiates for diarrhea (tick appropriate and report total) 
 
      Yes (30)                          No (0)                                             
 
 
                       
 
 
 
 Abdominal Mass (tick appropriate and report total) 
 
      None (0)              Questionable (20)           Definite (50) 
 
 
 
 
 
 Hematocrit (Please enter hematocrit value and calculate) 
 
Male                 (47 – (minus)                               %) x 6           
 
 
Female            (42 – (minus)                                %) x 6       
 
 
 
= 
 
                  = 
 
 
 
 Body weight  
  
         Body weight                                                kg 
                                 ( 1 -                                     ) X 100     
= 
        Standard weight                                                       kg 
 
    Tick appropriate box 
Please add (underweight) 
               
                          
 
Or subtract (overweight) 
 
                         
 
 
 (Please add all subtotals) CDAI TOTAL  
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 Total 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 Total 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 
Total 
Total 
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First 24- dietary Hour Recall  
    
Time Food Items 
Type & 
Preparation 
Amount 
Brand Name or Where 
Bought 
Morning     
     
     
     
     
     
Mid-
morning 
    
     
     
Noon 
Meal 
    
     
     
     
     
     
     
     
Midday     
     
     
     
DIETARY ASSESSMENT 
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 Evening 
Meal 
    
     
     
     
     
     
     
     
Before 
Bed 
    
     
     
     
 
Was this intake usual? Circle one: 
 
 Yes  
 No 
If No, explain why not___________________________________ 
 
Any vitamin / mineral intake during this time?  
 
 Yes 
if Yes, list names:  
 
 No 
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 Second 24- dietary Hour Recall  
    
Time Food Items 
Type & 
Preparation 
Amount 
Brand Name or Where 
Bought 
Morning     
     
     
     
     
     
Mid-
morning 
    
     
     
Noon 
Meal 
    
     
     
     
     
     
     
     
Midday     
     
     
     
Evening 
Meal 
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Before 
Bed 
    
     
     
     
 
Was this intake usual? Circle one: 
 
 Yes  
 No 
If No, explain why not___________________________________ 
 
Any vitamin / mineral intake during this time?  
 
 Yes 
if Yes, list names:  
 
 No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The impact of Vitamin D on disease activity in Crohn’s disease 
 
Subject ID:     
   
                           Site #                                     Screening #                             Initials  
169 
 
 
Week 9 Visit 3 
 
__ __/ __ __/ __ __ __ __            
(dd/mm/yyyy) 
 
 Third  24- dietary Hour Recall  
    
Time Food Items 
Type & 
Preparation 
Amount 
Brand Name or Where 
Bought 
Morning     
     
     
     
     
     
Mid-
morning 
    
     
     
Noon 
Meal 
    
     
     
     
     
     
     
     
Midday     
     
     
     
Evening 
Meal 
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Before 
Bed 
    
     
     
     
 
Was this intake usual? Circle one: 
 
 Yes  
 No 
If No, explain why not___________________________________ 
 
Any vitamin / mineral intake during this time?  
 
 Yes 
if Yes, list names:  
 
 No 
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__ __/ __ __/ __ __ __ __            
(dd/mm/yyyy) 
 
 
Appendix 7: Follow-up form 
 
First Name:      Last name:  
Home address:                              Phone number:    
     
Date of Birth: __ __/ __ __/ __ __ __ __ (dd/mm/yyyy)         
 
 Age: ________________                        
 
Sex:              Male    Female    
 
 
 
 
 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)        
 
  Lab Test 
 
Concentration (units) 
WBC 
 
 
Hg 
 
 
Hct 
 
 
Platelets 
 
 
Ferritin 
 
 
Vitamin D 
 
 
Serological Biomarkers 
hsCRP 
 
 
Fecal Biomarkers 
Calprotectin 
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Follow-up Visit 4 
 
__ __/ __ __/ __ __ __ __            
(dd/mm/yyyy) 
 
 
 
Safety measurments 
 
__ __/ __ __/ __ __ __ __ (dd/mm/yyyy)       
 
Lab Tests Concentration (units) 
Calcium 
 
Phosphate 
 
25(OH)D 
 
ALT, AST, BUN levels 
 
Magnesium 
 
Pregnancy test 
 
Creatinine 
 
GFR  
Urinalysis for hematuria  
PTH  
Albumin  
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MEASURES OF DISEASE ACTIVITY 
 
Harvey-Bradshaw Index for Crohn’s Disease 
 
K. General Wellbeing  0=Very Well 
      1=Slightly below par 
      2=Poor 
      3=Very poor 
      4=Terrible 
 
L. Abdominal Pain  0=None 
      1=Mild 
      2=Moderate 
      3=Severe 
 
M. # Liquid Stools/Day 
 
N. Abdominal Mass  0=None 
      1=Dubious 
      2=Definite 
      3=Definite and tenderness 
 
O. Complications  1=Arthralgia 
      1=Erythema Nodosum 
      1=Aphthous Ulcers 
      1=Pyoderma Gangrenosum 
      1=Anal Fissure 
      1=New Fistula 
      1=Abscess 
 
 
     Total Score= ______________ 
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 Number of liquid or very soft stools 
 
 
 
                                                                                                        =  
 
 
 
 
 
               X2 = 
                 
SUBTOTAL 
 
 
 Abdominal pain  (0=none; 1=mild, 2=moderate, 3=severe) 
 
 
 
                                                                                                         = 
 
 
 
 
 
               X5 = 
                 
 
 
 
 General well-being (0=generally well; 1-slightly under par; 2=poor; 3-very poor; 4-terrible) 
 
 
 
                                                                                                         = 
 
 
 
 
 
               X7 = 
                 
 
 
 
   
 Number of 6 listed categories patient now has (tick all that apply) 
     Arthritis/Arthralgia        Iritis/Uveitis         Anal Fissure, Fistula or 
Abscess 
      Other fistula            Fever > 37.8 C during previous week                       
      Erythema Nodosum, Pyoderma Gangrenosum/Aphthous Stomatitis  
                                                                        Total number of 
categories 
 
 
 
              X20 
= 
                 
 
 
 
 Taking Lomotil/opiates for diarrhea (tick appropriate and report total) 
 
      Yes (30)                          No (0)                                              
 
 
                       
 
 
 
 Abdominal Mass (tick appropriate and report total) 
 
      None (0)              Questionable (20)           Definite (50) 
 
 
 
 
 
 Hematocrit (Please enter hematocrit value and calculate) 
 
Male                 (47 – (minus)                               %) x 6           
 
 
Female            (42 – (minus)                                %) x 6       
 
 
= 
 
 
                        
 
 
 
 Body weight  
 
           Body weight                                                       kg 
                                ( 1 -                                         ) X 100     
=    
        Standard weight                                                        kg 
 
    Tick appropriate box 
Please add (underweight) 
               
                          
 
Or subtract (overweight) 
 
                         
 
 
 
 (Please add all subtotals) CDAI TOTAl     
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 Total 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 Total 
Day 1 Day 2 Day 3 Day 5 Day 6 Day 7 Day 4 
Total 
Total 
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1. How frequent have your bowel movements been during the last two weeks?  
 
 Bowel movements as or more frequent than they have ever been 
 Extremely frequent 
 Very frequent 
 Moderate increase in frequency of bowel movements 
 Some increase in frequency of bowel movements 
 Slight increase in frequency of bowel movements 
 Normal, no increase in frequency of bowel movements 
2. How often has the feeling of fatigue or of being tired and worn out been a problem for you during the 
last 2 weeks? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
3. How often during the last 2 weeks have you felt frustrated, impatient, or restless?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
4. How often during the last 2 weeks have you been unable to attend school or do your work because of 
your bowel problem?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
5. How much of the time during the last 2 weeks have your bowel movements been loose? 
 All of the time 
 Most of the time 
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 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
6. How much energy have you had during the last 2 weeks?  
 No energy at all 
 Very little energy 
 A little energy 
 Some energy 
 A moderate amount of energy 
 A lot of energy 
 Full of energy 
7. How often during the last 2 weeks did you feel worried about the possibility of needing to have surgery 
because of your bowel problem? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
8. How often during the last 2 weeks have you had to delay or cancel a social engagement 
because of your bowel problem?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
9. How often during the last 2 weeks have you been troubled by cramps in your abdomen? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
10. How often during the last 2 weeks have you felt generally unwell?  
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
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 Hardly any of the time 
 None of the time 
11. How often during the last 2 weeks have you been troubled because of fear of not finding a washroom?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
12. How much difficulty have you had, as a result of your bowel problems, doing leisure or sports 
activities you would have liked to have done during the last 2 weeks? please choose an option from 
 A great deal of difficulty; activities made impossible 
 A lot of difficulty 
 A fair bit of difficulty 
 Some difficulty 
 A little difficulty 
 Hardly any difficulty 
 No difficulty; the bowel problems did not limit sports or leisure activities 
13. How often during the last 2 weeks have you been troubled by pain in the abdomen? Please choose an 
option from 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
14. How often during the last 2 weeks have you had problems getting a good night's sleep, or been 
troubled by waking up during the night? 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
15. How often during the last 2 weeks have you felt depressed or discouraged?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
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 None of the time 
16. How often during the last 2 weeks have you had to avoid attending events where there was no washroom 
close at hand?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
17. Overall, in the last 2 weeks, how much of a problem have you had with passing large 
amounts of gas?  
 A major problem 
 A big problem 
 A significant problem 
 Some trouble 
 A little trouble 
 Hardly any trouble 
 No trouble 
18. Overall, in the last 2 weeks, how much a problem have you had maintaining or getting to, the weight 
you would like to be at.  
 A major problem 
 A big problem 
 A significant problem 
 Some trouble 
 A little trouble 
 Hardly any trouble 
 No trouble 
19. Many patients with bowel problems often have worries and anxieties related to their illness. these 
include worries about getting cancer, worries about never feeling any better, and worries about having a 
relapse. in general, how often during the last 2 weeks have you felt worried or anxious?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
20. How much of the time during the last 2 weeks have you been troubled by a feeling of abdominal 
bloating?  
 
 All of the time 
 Most of the time 
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 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
21. How often during the last 2 weeks have you felt relaxed and free of tension?  
 
 None of the time 
 A little of the time 
 Some of the time 
 A good bit of the time 
 Most of the time 
 Almost all of the time 
 All of the time 
22. How much of the time during the last 2 weeks have you had a problem with rectal bleeding with your 
bowel movements?  
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
23. How much of the time during the last 2 weeks have you felt embarrassed as a result of your bowel 
problem?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
24. How much of the time during the last 2 weeks have you been troubled by a feeling of having to go to 
the bathroom even though your bowels were empty?  
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
25. How much of the time during the last 2 weeks have you felt tearful or upset?   
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 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
26. How much of the time during the last 2 weeks have you been troubled by accidental soiling of your 
underpants?   
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
27. How much of the time during the last 2 weeks have you felt angry as a result of your bowel problem?   
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
28.To what extent has your bowel problem limited sexual activity during the last 2 weeks? 
  
 1 no sex as a result of bowel disease 
 2 major limitation as a result of bowel disease 
 3 moderate limitation as a result of bowel disease 
 4 some limitation as a result of bowel disease 
 5 a little limitation as a result of bowel disease 
 6 hardly any limitation as a result of bowel disease 
 7 no limitation as a result of bowel disease 
29. How much of the time during the last 2 weeks have you been troubled by nausea or feeling sick to 
your stomach?   
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
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 None of the time 
30. How much of the time during the last 2 weeks have you felt irritable?   
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
31. How often during the past 2 weeks have you felt a lack of understanding from others? 
 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
32. How satisfied, happy, or pleased have you been with your personal life during the past 2 weeks?  
 Very dissatisfied, unhappy most of the time 
 Generally dissatisfied, unhappy 
 Somewhat dissatisfied, unhappy 
 Generally satisfied, pleased 
 Satisfied most of the time, happy 
 Very satisfied most of the time, happy 
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Table 4.1 Socio –Demographics characteristics 
 
 
Case Location Age Sex BMI 
no. of 
individual 
living at 
home 
no. of 
children 
living at 
home 
languages 
Highest 
grade of 
education 
Total income (per 
year) 
Case 1 
(withdrew) 
Saskatoon 60 F 25.3 - - 
English, 
French 
- - 
Case 2 Riyadh 25 M 22.9 10 2 Arabic Bachelor $25,000 to < $30,000 
Case 3 Riyadh 21 F 17.9 7 0 Arabic Bachelor $20,000 to < $25,000 
Case 4 
(Missing follow up) 
Riyadh 19 F 16.9 8 6 
Arabic, 
English 
High 
school 
- 
Case 5 Saskatoon 32 F 29 3 1 English < Grad 8 $60,000 to < $80,000 
Case 6 
(Missing follow up) 
Saskatoon 35 M 23.4 - - English - - 
Case 7 Riyadh 25 M 22.8 11 4 Arabic Bachelor $20,000 to < $25,000 
Case 8 Riyadh 28 M 23 4 2 Arabic Bachelor $30,000 to < $40,000 
Case 9 Riyadh 24 M 18.3 - - 
Arabic, 
English 
Bachelor $60,000 to < $80,000 
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Table 4.5 Food Groups Dietary Usual Intake and Healthy Eating Index Indicators 
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Case 
1 
65.1 61.6 2.0 1.3 2.3 0.3 3.3 1.7 1.8 15.6 2.3 0.4 3.8 0.9 4.1 1.7 2.0 27.5 
Case 
2 
28.5 55.5 1.3 0.5 5.3 0 2.2 0.3 0.2 34.5 2.0 0.5 5.9 0 2.5 0.6 0 12.3 
Case 
3 
40.6 34.0 1.4 0.6 6.0 0 0.7 0.1 0 40.8 2.2 0.6 3.4 0 0.8 0 0 47.9 
Case 
4 
30.3 - 1.6 0.6 5.1 0 0.2 0 0 34.5 - - - - - - - - 
Case 
5 
69.4 73.5 1.4 2.9 5.2 2.2 6.0 0.8 3.8 15.3 2.0 1.8 3.8 0.8 4.3 0.6 2.6 15.9 
Case 
6 
37.7 57.0 1.2 1.7 5.3 1.0 4.3 1.0 1.3 33.6 1.3 1.4 8.2 6.1 0.9 0 0.3 9.4 
Case 
7 
50.3 36.5 4.6 0.1 3.0 0 1.8 0.1 0 16.9 1.9 0.8 3.2 0 0.8 0 0 38.9 
Case 
8 
48.2 41.1 3.6 0.2 4.4 0.3 1.9 0.2 0 7.9 2.5 0.6 3.8 0 1.3 0 0 34.0 
Case 
9 
39.8 35.6 2.3 0.4 4.3 1.5 0.3 0 0 33.3 1.3 1.1 3.8 0 0.9 0.2 0.1 29.4 
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Table 4.6 Disease Related Information Data 
Case 
Disease location 
at enrolment 
Disease 
behavior at 
enrolment 
Perianal 
disease 
at 
enrolment 
Past 
medication/ 
supplements 
Current 
medication 
S
u
rg
ic
a
l 
h
is
to
ry
 Family History 
IBD-Associated 
Conditions 
Extra-
intestinal-
manifications 
Case 1 - - - Probiotic None No 
Sibling (PSC), 
parent (eczema), 
second degree 
( colon cancer) 
None 
Case 2 
++small bowel (Jejunum), 
++ colon (ascending, 
transverse, descending, 
sigmoid) 
- none 
5-ASA 
Azathioprine 
5-ASA 
Azathioprine 
No 
Sibling 
( Eczema) 
None 
Case 3 
++small bowel , ++ colon 
(ascending, transverse, 
descending,rectum) 
Inflammatory none Azathioprine 
Azathioprine 
Adalimumab 
No none None 
Case 4 - 
Inflammatory 
Penetrating 
Perianal 
Fistula 
Azathioprine Azathioprine No none None 
Case 5 
*++small bowel (terminal 
lleum, ileocecal valve), +– 
colon (cecum, ascending, 
transverse, descending, 
sigmoid) 
Inflammatory none multivitamin 
Budesonide 
Infliximab 
No 
Second degree 
(Eczema, colon 
cancer) 
None 
  
 
 
 
 
1
9
7
 
* Bowel+, inflam +, Bowel+, inflam –, Bowel– or unknown 
  
Case 6 
++small bowel (terminal 
lleum, ileocecal valve), +– 
colon (cecum, ascending, 
transverse, descending, 
sigmoid) 
- - Azathioprine Budesonide 
il
eu
m
 
Parent, sibling 
(asthma),  sibling,  
children ( 
eczema) 
None 
Case 7 
–Small bowel (terminal 
lleum) 
Inflammatory 
Perianal 
Abscess 
5-ASA 
Infliximab 
Infliximab No none None 
Case 8 
++small bowel , ++ colon 
( sigmoid, rectum) 
Inflammatory none Azathioprine 
Azathioprine 
Adalimumab 
No none None 
Case 9 
+– small bowel, ++ 
terminal lleum 
Inflammatory none Azathioprine Azathioprine No none None 
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Table 4.7 Laboratory and Safety Measurements at Baseline 
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Case 1 6.8 127 38.4 341 35 2.3 1.2 14 13 7.8 0.7 57 - 0 4.3 37 
Case 2 4.3 146 42.9 311 65.4 2.2 - 38 21 - 0.8 71 - 0 5.3 42.4 
Case 3 4.5 126 37.3 315 19.1 2.1 - 26 14 - 0.8 49 - 0 16.8 38 
Case 4 11.4 101 31.3 385 35.1 2.2 - 25 11 - 0.8 47 - 0 - 33 
Case 5 10.9 115 34.7 300 - 2.2 1.0 18 14 2.8 - 66 106 10 3.2 33 
Case 6 6.1 147 42.3 356 122 - - 10 21 4.9 - 76 114 - - - 
Case 7 6.9 162 48.7 192 190.2 2.1 - 44 26 - 0.8 93 - 0 1 36 
Case 8 6.6 145 42.1 228 134.9 2.2 - 49 26 - 0.8 81 - - 2.9 43 
Case 9 9.3 155 44.9 262 74.6 2.2 - 31 21 - 0.8 63 - 0 7.8 36 
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Table 4.8 Laboratory and Safety Measurements at Week 5 
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Case 1 2.4 1.5 22 20 8.1 0.6 50 101 0 2.4 29 
Case 2 2.3 - 26 19 - 0.8 65 - 0 5.3 41 
Case 3 2.1 - 27 13 - 0.8 49 - 0 6.9 36 
Case 4 2.2 - 24 7 - 0.8 55 - 0 17.2 33 
Case 5 2.1 1.1 11 13 3.4 0.7 65 108 0 4.7 30 
Case 6 2.3 1.1 13 21 4.1 0.7 73 116 10 - 37 
Case 7 2.2 - 41 22 - 0.9 80 - 0 1.4 39 
Case 8 2.2 - 49 26 - 0.8 81 - - 3.8 43 
Case 9 2.3 - 27 22 - 0.8 65 - 0 8 42 
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Table 4.9 Laboratory and Safety Measurements at Week 9 
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Case 1 10.0 132 41.1 388 145 2.6 1.5 41 55 6.6 0.6 46 104 10 2 34 
Case 2 7.9 138 40.4 295 73.8 2.2 - 30 20 - 0.8 65 - 0 5.6 44 
Case 3 5.1 117 35.5 372 21.4 2.1 - 25 12 - 0.8 65 - 0 15.8 34 
Case 4 12.8 107 33.1 340 35.1 2.2 - 26 10 - 0.8 67 - 0 17.2 35 
Case 5 11.1 118 36.6 340 - 2.1 1 9 12 2.7 0.7 64 110 0 3.6 29 
Case 6 5.9 156 44 310 87 2.2 0.9 10 18 5.4 0.8 84 105 0 2.2 33 
Case 7 8.7 163 47.6 279 228.7 2.2 - 79 91 - 0.8 83 - 0 1.4 37 
Case 8 8.2 156 45.8 217 134.9 2.2 - 53 29 - 0.8 91 - 0 3.8 41 
Case 9 6.5 156 45.2 279 76.0 2.3 - 27 20 - 0.8 71 - 0 8 39 
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Table 4.10 Laboratory and Safety Measurements at Follow-up 
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Case 1 - - - - - - - - - - - - - - - - 
Case 2 4.2 126 36.9 312 81.0 2.3 1.0 28 19 - 1 70 - 0 6.4 40 
Case 3 5.5 105 32.6 11.9 9.8 2.1 1.2 30 14 - 0.9 60 - 0 26.8 32 
Case 4 - - - - - - - - - - - - - - - - 
Case 5 6.6 117 35.3 267 55 2.1 1.2 17 - 3.4 0.8 68 102 10 4 33 
Case 6 - - - - - - - - - - - - - - - - 
Case 7 8.8 163 47.6 300 200 2.3 1 79 91 - 0.8 70 - 0 1.4 37 
Case 8 8.1 154 45.3 231 192.5 2.2 1.1 37 - - 0.8 90 - 0 3.5 42 
Case 9 6.9 167 47.4 272 104 2.3 1.3 25 17 - 0.8 71 - 0 3.1 38 
 
